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Abstract
The gammaherpesvirus subfamily has long been the study of intensive investigation
owing to the association between infection and development of lymphoproliferative
disease. Well-known members of the Gammaherpesvirinae include Epstein-Barr virus
(EBV) and Kaposi's Sarcoma-associated herpesvirus (KSHV). Common properties of
gammaherpesviruses include a narrow host range of infection and limited productive
growth in vitro, and these factors make the study of acute infection problematic.
Murine gammaherpesvirus-68 (MHV-68) is able to undergo lytic replication in a
range of cell types in vitro and can infect inbred strains of mice. These properties
make MHV-68 an excellent model for the study of gammaherpesvirus pathogenesis.
Herpesviruses have been indicated in development of diseases in the lung, including
pneumonia and idiopathic pulmonary fibrosis. MHV-68 allows investigation of
gammaherpesvirus infection of and persistence in the lung - following intranasal
inoculation the virus establishes a life-long infection in this organ, with virus
persisting in epithelial cells and/or B cells. Identification of key viral genes required
for persistence may allow for development of vaccination and/or treatment strategies.
Using real-time PCR the long-term viral load in the lungs was reduced following the
deletion of key genes from the viral genome. Genes identified are the thymidine
kinase gene, previously shown to play a role during acute infection of the lung and
ORF73, a homologue of the KSHV LANA-1 gene. Initial data also suggests that the
ORF72 and Mil genes, both involved in reactivation from latency, may play a role in
maintaining viral load at late time pomts post-infection.
In vivo investigation of the Ml gene of MHV-68 has demonstrated a potential role in
control of viral reactivation from latency in the spleen. A novel MHV-68 mutant,
MIA, lacking 1171 bp of the Ml ORF, was used to study the role of Ml in
pathogenesis. Initial data suggests that in vivo infection with MIA results in increased
viral titres during acute infection of the lung, indicating a potential role in control of
initial infection. The major role of Ml appears to be during acute phase latency in the
spleen, with the MIA virus failing to drive splenomegaly and establishing latency at
lower levels. Despite the presence of fewer latently infected splenocytes, MIA
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reactivates at significantly higher levels, indicating that a function of Ml is to control
viral reactivation from latency.
A viral mutant (M4Inl) was created that carries a stop codon inserted at genome co¬
ordinate 8386 in the region between the M3 and M4 genes. The mutation is thought to
be in an untranscribed region of the genome, potentially in the promoter region of the
M3 or M4 genes. Studies demonstrated that the virus is attenuated following infection
of both wild-type and IFNyR " mice with respect to lung pathology scores. The
lethality of M4Inl in juvenile IFNyR." mice is reduced compared with wild-type
MHV-68 infection. Despite the location of the mutation within potential promoter
regions, M4Inl transcribes both M3 and M4 at wild type levels in vitro, and in vivo in
the spleen. This evidence suggests an apparently untranscribed region of the MHV-68
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The large and ever-increasing herpesvirus family consists of at least 130 viruses, the
hosts of which cover a range from oysters to elephants. Between these two extremes
lie the herpesviruses that infect humans, fish, birds and many other species. The long
co-evolution of herpesviruses with their hosts has produced a family of viruses well
adapted to persist in their natural host for a lifetime without (in the majority of cases)
overt signs of disease.
Members of the herpesvirus family have four important properties in common:
1. The genome encodes a large range of enzymes involved in nucleic acid
metabolism (e.g. dUTPase), DNA synthesis (e.g. DNA polymerase) and
processing of proteins (e.g. protein kinase).
2. Viral DNA synthesis and capsid assembly occurs in the nucleus.
3. Production of infectious progeny is accompanied by the destruction of the infected
cell.
4. They are able to undergo a latent infection in their natural host, a process that
requires the formation of closed circular viral genomes and the expression of only
a small subset of viral genes (Roizman & Pellet, 2001).
It is this last characteristic that allows the persistence of herpesviruses for the lifetime
of a host. The ability of the virus to remain in a quiescent state allows avoidance of
the host immune system, and periodic reactivation from latency allows production of
infectious virions for transmission to new hosts.
1.1.1 Classification of Herpesviruses
Current classification has the herpesviruses defined as the family Herpesviridae, with
three subfamilies contained within this group: the Alphaherpesvirinae, the
Betaherpesvirinae, and the Gammaherpesvirinae. Historically, membership of the
herpesvirus family was assigned based on virion morphology; subfamilies were
designated according to biological characteristics. The onset of genome sequencing
has allowed refinement of subfamily classification, and is now the primary approach
for phylogenetic studies (McGeoch et al., 2006).
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The Herpesviridae Study Group of the International Committee on Taxonomy of
Viruses is currently considering revision of the above classifications; investigations of
a number of piscine and amphibian herpesviruses have suggested these would be
better characterised by assignment to a new family, the Alloherpesviridae. The single
invertebrate herpesvirus will be given its own family, the Malacoherpesviridae, and
all herpesvirus families will further fall into the order Herpesvirales (McGeoch et al.,
2006). However, as these proposals have yet to be accepted, discussions will be
limited to the traditional three herpesvirus subfamilies, the alpha-, beta- and
gammaherpesviruses.
1.1.1.1 Alphaherpesviruses
The members of the Alphaherpesvirinae are characterised by their ability to establish
latency predominantly in sensory ganglia Other properties include a variable host
range, relatively short reproductive cycle and rapid spread in culture. This subfamily
includes the genera Simplexvirus (e.g. herpes simplex virus [HSV]-l and -2);
Varicellovirus (e.g. varicella zoster virus [VZV]), Mardivirus (e.g. Marek's disease
virus, which unusually is latent in T cells), and Infectious laryngeotracheitis-like
virus.
1.1.1.2 Betaherpesviruses
The site of latency for the betaherpesviruses is predominantly the mononuclear cells
(Mocarski & Courcelle, 2001), but infection can persist in secretory glands,
lymphoreticular cells, kidneys and other tissues. Infection is further characterised by
the enlargement of infected cells, a process known as cytomegalia. In culture the
reproductive cycle is long, and the time to produce cytopathic effects is long. This is
not the case in vivo, where viral load can double in less than 2 days (Emery et al.,
1999). This subfamily contains the genera Cytomegalovirus (e.g. human
cytomegalovirus, HCMV), Muromegalovirus (MCMV) and Roseolovirus (human
herpesvirus-7, HHV-7).
1.1.1.3 Gammaherpesviruses
The gammaherpesvirus subfamily shows an extremely narrow host range, with
infection often limited to the family or order of the natural host. In vitro viruses
replicate in lymphoblastoid cells, and some can undergo lytic replication in epithelial
3
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and fibroblast cell lines. Latency usually (but not exclusively) occurs in B and T cells,
and in vivo virus is frequently detected in lymphoid tissue. This subfamily is further
divided into the Lymphocryptoviruses (e.g. EBV) and Rhadinoviruses (e.g. Kaposi's
sarcoma associated herpesvirus [KSHV], herpesvirus saimiri [HVS] and murine
gammaherpesvirus [MHV-68J).
1.1.2 Herpesvirus Structure
The herpesvirus virion consists of several different layers. The virion core is covered
by the capsid, which in turn is covered by the tegument, which is finally covered by
the envelope.
The core consists of the viral double stranded DNA. This is surrounded by the capsid,
an icosadeltahedral structure made up of 162 capsomeres. The capsid is linked to the
envelope by the tegument. This is an amorphous layer of varying thickness containing
a number of viral proteins - in the case of HSV-1 more than 15 proteins are associated
with this structure (Metteleiter et al., 2002a). The viral envelope appears to be derived
from patches of altered cellular membranes containing viral proteins and
glycoproteins. The overall size of the herpesvirions varies from 120 to 300 nm, with
the variation due to variability in tegument thickness and the state of the envelope -
damaged envelopes appear much larger than intact virions (Roizman & Pellet, 2001).
1.1.3 Herpesvirus Genomes
The herpesvirus genomes range in size from approximately 120 kb for VZV to 250 kb
for HCMV. Individual herpesviruses also show up to 10 kb variation within the
species owing to polymorphisms in terminal and internal repeat copy numbers. Total
G+C composition of herpesviruses varies from as little as 32% for canine herpesvirus-
1 to 75% for cercopithecine herpesvirus-1 (HV simiae). G+C composition can be
homogeneous across the genome, as seen for HSV-1; or largely localised to reiterated
sequences of high G+C content at the ends of the genome, with unique regions of low
G+C content (e.g. the genome of ateline herpesvirus-2).
The sequence arrangements of the herpesviruses can be categorised into one of 6
groups depending on the presence and localisation of repeat regions (see figure 1.1).
These genomes contain between 70 and 200 open reading frames (ORFs), with








Us /s / \
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Figure 1.1 Herpesvirus genome arrangements. Herpesvirus genome arrangements fall into
one of the 6 categories (A-F) shown above. Class A (e.g. channel catfish virus) has both left and right
long terminal repeats (LTRs). Class B (e.g. Herpesvirus Saimiri) have reiterated terminal repeat
sequences (TRs). Class C (e.g. EBV) have four internal repeat sequences (IR1-IR4) within the unique
region of the genome, as well as reiterated terminal repeat sequences. Class D (e.g. VZV) have a
single LTR which is found in an inverted orientation within the unique region of the genome. Class E
(e.g. HSV) consist of two elements: one terminus contains n copies of sequence a next to sequence b.
The other terminus has one directly repeated a sequence next to sequence c. The terminal ab and ac
sequences are inserted in an inverted orientation (b'a^c') separating the unique regions into U, and
Us domains. Class F (e.g. tuapia herpesvirus) has no identified repeat regions. Adapted from
Roizman & Pellet, 2001
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product of which is a truncated version of the larger gene (e.g. HSV Ul26 and
Ul26.5), and genes expressed from entirely antisense sequence (e.g. HSV-1 yi34.5
and ORFs P and O). Introns are relatively infrequent in herpesvirus genes, although
most will contain a limited number of spliced genes. Most genes contain a promoter
region of between 50 and 200 bp lying upstream of a TATA box. Transcription
initiation sites are normally 20-25 bp downstream of the TATA box, and this is
followed by a 5' non-translated leader sequence of 30-300 bp. At the start of the ORF
is a translation initiation codon, followed by 10-30 bp of 3' non-translated sequence,
and finally a polyA signal. Transcription is carried out by the host RNA polymerase
II.
In addition many herpesvirus genomes contain non-coding RNA molecules, such as
the EBERs of EBV and the vtRNAs of MHV-68. The recent discovery of microRNAs
(Pfeffer et al., 2004; Pfeffer et al., 2005) increases the number of identified non-
coding RNAs.
Herpesvirus genes can be broadly divided into two classes: those essential for growth
in culture (including genes encoding the proteins of DNA replication and the virion
structural proteins), and non-essential genes which may have a more significant effect
on replication in vivo. These non-essential genes may be involved in evasion of the
host immune response, establishment of latency, or alteration of the cellular
environment to improve conditions for replication or latency.
Approximately 26 "core" genes are conserved across the alpha-, beta- and
gammaherpesvirus subfamilies. These genes are contained within seven core gene
blocks, with between 2 and 12 genes in a block. Within the blocks gene order and
polarity are conserved, and within the subfamilies block arrangement is usually
conserved. The core genes include virion structural genes, nucleotide metabolism
genes, DNA replication genes, and genes with regulatory roles. Within the
subfamilies there are further conserved genes. The alphaherpesviruses share latency-
associated genes and glycoprotein D, while betaherpesviruses all have a block of 14
genes not found in the other subfamilies. Gammaherpesviruses have shared
homologues of cellular genes, along with ORFs encoding proteins required to
maintain latent genomes in cycling cells (Roizman & Pellet, 2001).
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1.1.4 Herpesvirus Life Cycle
The majority of research has focused on the replication of herpes simplex virus, and
as such most of the mechanisms of replication discussed below relate to this virus.
Where possible examples are given from other members of the herpesvirus family.
1.1.4.1 Attachment
Virion glycoproteins are involved in the initial attachment of the virus to the target
cell. In the case of HSV these glycoproteins target glycosaminoglycan (GAG) chains
of cell surface proteoglycans. The virion glycoproteins gB and gC are involved in this
binding process, targeting the host heparan sulfate proteoglycan. Loss of gC reduces
HSV infectivity but does not abolish it completely, indicating the attachment step is
not an absolute requirement for infection (Herold et al., 1991). Loss of both gB and
gC substantially reduces binding and also prevents infectivity, due to the role of gB in
viral entry (Laquerre etal., 1998).
Heparan sulfate is utilised as a tether in numerous members of the herpesvirus family,
including HCMV (Kari & Gehrz, 1993), HHV-8 (Akula et al, 2001) and BHV-4
(Vanderplasschen et al., 1993).
EBV contains a gC homologue, gp350/220, which mediates the initial attachment of
the virion to the host cell. EBV targets the CD21 (also known as CR2) receptor, a
complement receptor which is highly expressed on the surface of B-lymphocytes and
follicular dendritic cells (Prota et al., 2002). Deletion of the gp350/220 gene from
EBV does not abolish the ability of the virus to infect cells, although efficiency is
reduced (Janz et al., 2000).
1.1.4.2 Binding
Once tethered to the cell, the interaction of virion glycoproteins with host cell
receptors allows binding of the virus to the cell surface. Individual herpesviruses use a
specific receptor or group of receptors to bind to the host cell, and it is these
differences in the host receptor(s) that lead to differences in cell tropism between
members of the herpesvirus family.
Three classes ofhost entry receptors have been identified for HSV so far:
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1. HVEM (herpesvirus entry mediator, a member of the TNF receptor family; also
known as HveA).
2. Neclin-1 (HveC) and nectin-2 (HveB) (members of the immunoglobulin
superfamily). These receptors are expressed on a large range of cell types,
including epithelial cells, fibroblasts and neurons. Nectin-1 may be particularly
important in direct cell-to-cell spread of the virus (Sakisaka et al., 2001).
3. Specific sites in heparan sulphate (3-0-S HS) generated by certain 3-0-
sulfotransferases (all three types of receptor reviewed by Spear, 2004;
Campadelli-Fiuine et al., 2000).
The viral glycoprotein necessary for binding of HSV to these cell surface receptors is
gD. Different regions of this protein are required for binding to different receptors -
the HVEM and 3-0-S HS receptors require the presence of the N-terminus, while the
nectins require other regions to allow successful binding. Evidence suggests gD is
able to assume at least two conformations in complexes with receptors; one form able
to bind HVEM and 3-0-S HS, and the other able to bind the nectins (Spear et al.,
2006). Once bound to the cell surface, the virus envelope then fuses with the cell
membrane to release the capsid into the cell. This process requires the gH/gL
glycoproteins (Roizman & Knipe, 2001).
In the case of EBV, the cell surface receptors necessary for binding to B cells are the
HLA class II molecules. The virus is able to bind to all HLA-DR and -DP molecules,
but is restricted in the HLA-DQ class to those molecules carrying a glutamic acid
residue at amino acid 46 (Haan & Longnecker, 2000). The viral protein that mediates
binding to HLA molecules is gp42. This protein, in complex with gp85 (gH) and gp25
(gL), is necessary for virus penetration of the cell membrane (Li et al., 1997). Gp85
has been show to play a role in envelope fusion with cell membranes.
EBV entry into epithelial cells has different requirements to entry into B cells. There
is no requirement for interaction of gp42 with HLA class II molecules, and instead
glycoproteins gH and gL interact with a novel entry mediator (Molesworth et al.,
2000).
1.1.4.3 Transport to the Cell Nucleus
Following fusion with the cell membrane, the de-enveloped HSV virus is released
into the cell cytoplasm. At this point certain tegument proteins (e.g. Usl I) remain in
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the cytoplasm, while others travel to the nucleus either by association with the capsid,
or by independent means. Host microtubules are required for successful transport of
viral capsids to the nucleus, and evidence suggests proteins of the inner tegument are
responsible for binding to host dynein motors which mediate transport towards the
nucleus (Wolfstein et al., 2006). Following transport, nucleocapsids associate with
nuclear pore complexes. Viral DNA is released and passes into the nucleus, where it
assumes a circular conformation (Roizman & Knipe, 2001).
1.1.4.4 Viral Gene Expression
Herpesvirus gene expression during lytic infection occurs sequentially (Honess &
Roizman, 1974). The first genes to be transcribed are the immediate-early (IE-, or a-)
genes. This group is defined by the presence of their transcripts immediately after
infection and independently of de novo protein synthesis. In practice, these are genes
that are still transcribed in the presence of inhibitors of protein synthesis such as
cyclohexamide. The predominant role of this class appears to be in transactivaiion of
other groups of viral genes.
In the case of HSV six IE genes have been identified. These are ICPO, ICP4, ICP22,
ICP27, ICP47 and Usl.5. These genes share similarities in their promoter region,
including numerous binding sites for cellular transcription factors that are present
upstream of a TATA box.
Immediate early gene transcription is initiated by a combination of viral and host
proteins. Following entry of the virus into the cell, viral protein VP 16 (ICP25, a-TIF)
is transported into the cell nucleus by a cellular protein, HCF (host cell factor). This
VP16-HCF complex is able to bind the host transcription activator Oct-1 to the viral
DNA, allowing induction of IE-gene transcription.
Early (E, or P) gene expression is dependent on protein synthesis, as demonstrated by
the absence of transcripts in the presence of inhibitors such as cyclohexamide. IE
proteins are necessary for production of E gene transcripts, with ICP4 transactivating
this process (Roizman & Knipe, 2001).
The early gene class consists largely of genes required for viral nucleic acid
metabolism, including the thymidine kinase (TK) gene, a component of the viral
ribonucleotide reductase (ICP6) and a DNA binding protein (ICP8).
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Expression of late (L, y) genes is reduced in the absence of DNA synthesis. This class
can be further subdivided into two groups: the early-late (yi, leaky-late), where
expression is enhanced by viral DNA synthesis; and the true late (y2) genes, which
absolutely require DNA synthesis to occur prior to their expression. These subgroups
largely contain genes encoding the structural components of the virion, including gC
and gB.
1.1.4.5 Viral DNA Replication
Following onset of early gene expression, these gene products are able to localise to
specific regions of the nucleus known as Nuclear Domain 10 (ND10) structures (Maul
et al., 1996). At these prereplicative sites viral DNA synthesis is initiated.
Seven viral gene products are essential for viral DNA replication. These are a
polymerase (Ul30), a processivity factor for the polymerase (Ul42), a ssDNA binding
protein (ICP8, or Ul29), an origin binding protein (Ul9) and three proteins that
comprise a helicase-primase complex (Ul5, Ul8 and Ul52) (Uprichard & Knipe,
1997). Host factors such as DNA ligase and topoisomerase II are also likely to be
involved (Roizman & Knipe, 2001).
The two most studied origins of replication in the HSV genome are oriS and oriL.
OriS is present twice, on either side of the S compartment. OriL is found between
ICP8 and the DNA polymerase sequence. Both types of origin contain palindromic
sequence, with oriL being a 144bp palindrome and oriS slightly shorter at 45bp.
Flanking the origin sequences are inverted repeats that act as binding sites for Ul9
(Roizman & Knipe, 2001).
Following binding of Ul9 to the origin, ICP8 then binds to this region, and in
conjunction with Ul9 begins the unwinding of the dsDNA. The presence of Ul9 and
ICP8 recruits the helicase-primase complex to the origin, and this complex generates
a primer that allows the polymerase to begin synthesis of DNA (reviewed by Lehman
& Boehmer, 1999).
Initially replication of circular viral DNA structures gives rise to theta replicative
forms. As DNA synthesis progresses, replication switches from this theta mechanism
to a rolling circle mechanism that generates concatemers. These molecules
accumulate in the nucleus in structures called replication compartments.
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In a manner extremely similar to HSV replication, the EBV lytic cycle requires seven
viral genes - a DNA polymerase catalytic subunit (BALF5), a polymerase accessory
subunit (BMRF1), a single stranded DNA binding protein (BALF2), an origin binding
protein (BZLF1) and three proteins that together form a helicase-primase complex
(BBLF4, BSLF1 and BBLF2/3). Initiation of replication occurs at the oriLyt site in
the genome, and replication occurs in discrete replication compartments in the nucleus
(reviewed by Tsurumi et al., 2005).
1.1.4.6 Assembly of Virions: Capsid Formation and DNA Encapsidation
Formation of the viral capsid can occur following expression of the capsid genes, a
subset of the late gene group. Initial assembly of some capsid proteins occurs in the
cytoplasm prior to import into the nucleus for completion. VP5, VP26 and VP23
(Ul18) all require cytoplasmic association with other capsid or scaffold proteins such
as VP19C (Ul38) or pre-VP22a before they can be imported into the nucleus.
VP5 is the major capsid protein, and forms hexons and pentons that make up the outer
shell. Capsomeres are then linked by complexes of the minor capsid proteins VP19C
and VP23.
Several different types of capsid are assembled in the nucleus. C-capsids contain viral
DNA, and following budding through the nuclear membrane can go on to form
infectious virions. A- and 5-capsids both lack DNA, but B capsids contain the
scaffold proteins VP22a and VP21 and the viral protease VP24. Successful
encapsidation of DNA leads to removal of these proteins. ^-capsids are believed to be
failed capsids, unable to package DNA.
For encapsidation of viral DNA to occur, concatemers generated previously must first
be cleaved. The viral DNA contains signals for cleavage and packaging of DNA, and
these signals control site-specific breakage of DNA to generate single genomes.
1.1.4.7 Assembly of Virions: Envelopment and Egress
Capsids assembled in the nucleus must move into the cytoplasm before their eventual
release from the cell as fully formed virions. The viral proteins Ul31 and Ul34 are
located in the nuclear membrane and are necessary for movement of capsids from the
nucleus to the cytoplasm. In the presence of these two proteins capsids are able to bud
from the nucleus, forming a primary enveloped virion in the perinuclear space.
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From this point onward the exact mechanism of envelopment and movement of the
virus within the cell is disputed. Two pathways are suggested for virion egress, both
shown in figure 1.2. In the first, the reenvelopment pathway, the enveloped
nucleocapsid fuses with the outer nuclear membrane, releasing a deenveloped
nucleocapsid into the cytoplasm. The particle subsequently buds into the trans-Golgi
network and is ultimately released through secretory vesicles. In the second proposed
pathway, called the lumenal pathway, the enveloped nucleocapsid moves through the
cell in the lumen of the endoplasmic reticulum or in vesicles. The particle eventually
transfers into the trans-Golgi network where maturation of the virion glycoproteins
takes place (Roizman & Knipe, 2001).
The most recent evidence suggests the reenvelopmenl model is the most likely-
mechanism for virus egress. Infection with a HSV mutant where gD carries an ER
retrieval sequence shows that the perinuclear virion envelopes contain gD, whereas
extracellular virion envelopes do not. This suggests the virus acquires its final
membrane in a compartment that excludes ER-retrieved gD (Skepper et al, 2001).
Electron microscopy further supports this hypothesis, showing several
alphaherpesviruses (PrV, EHV-1 and HSV) undergoing fusion of the primary
envelope with the outer nuclear membrane to release the deenveloped nucleocapsids
into the cytoplasm. Microscopy further showed nucleocapsids undergoing
reenvelopment in the area of the trans-Golgi network (TGN), and the role of the TGN
in providing the secondary envelope for the nucleocapsid was confirmed by labelling
with a TGN-specific antiserum (Granzow et al., 2001). This evidence points to a
deenvelopment-reenvelopment model of virus egress.
1.1.4.8 Tegumentation
Tegumentation may begin at two different locations, at either the cytosol or the future
envelopment site. Numerous viral proteins are involved in formation of this structure,
and these proteins are necessary for interactions between the capsid on one side and
the envelope glycoproteins on the other. Closest to and interacting with the capsid is
the Ul36 gene product, which forms an icosahedral structure. The Ul37 protein
interacts with Ul36 to form the second layer of tegument covering the capsid. In the
absence of these proteins virion maturation cannot progress. Subsequent stages in
tegumentation are not clearly defined, and there appears to be functional redundancy
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Figure 1.2 Virus Egress from the Nucleus. HSV nucleocapsids bud through the inner nuclear
membrane. At this point two different pathways are proposed: the reenvelopment pathway, where
the envelope of the nucleocapsid is lost when the virus buds into the cytoplasm and is regained
following entry into the golgi pathway; and the lumenal pathway where the envelope is retained and
the virion is transported through the Golgi apparatus to the cell exterior. Adapted from Roizman &
Knipe, 2001.
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in the proteins required for tegument formation (Mettenleiter, 2002b; Mettenleiter,
2004).
1.1.5 Herpesvirus Latency
Latency is a key feature of the herpesvirus family. The ability to remain relatively
undetected in the host for extended periods of time allows the herpesviruses to persist
in the host organism for a lifetime. Sporadic reactivation from the latent state allows
transmission to susceptible individuals.
Different subfamilies of the herpesviruses and individual viruses themselves may
have specific requirements for latency - some are discussed in further detail in
sections 1.3.4.3-1.3.4.5. However, as before, research has focussed predominantly on
the alphaherpesvirus HSV, and the features of latency discussed below relate
predominantly to this virus.
Latency results when immediate early gene expression fails to occur. The exact
mechanism by which this occurs is not clear, but mutant viruses deficient in IE gene
expression undergo a quiescent infection and episomal genomes remain despite
failure to undergo productive infection.
During latency a limited range of transcripts are expressed. In HSV these are
designated the Latency Associated Transcripts (LATs), and are located in the repeats
flanking the Ul region of the virus genome. The activity of viral transcription may be
in part controlled by the acetylation state of histones associated with the genome.
Acetylation of histones is associated with an 'open' conformation of chromatin and
transcriptional activity, while a lack of acetylation is associated with condensed
chromatin and a lack of transcription. During latent infection the latency-associated
promoter is enriched with acetylated histone H3, while IE and E gene promoters show
relatively lower levels of association with acetylated histones. During lytic infection
the reverse is true, with acetylated histones associated with the active IE and E genes.
The role of the LATs may be in downregulation of viral gene expression (Garber et
al., 1997) or in prevention of virus-induced apoptosis (Perng et al., 2000). Recent
studies have shown the presence of a microRNA (miRNA) encoded by the LAT gene




1.1.5.1 Reactivation from Latency
In its natural host, HSV may be reactivated after ultra-violet light, stress, hormone
imbalances, injury to tissues innervated by latently infected neurons and potentially
many other undefined triggers. The exact signal that initiates reactivation is unknown.
In vitro mutation of many genes can result in impaired reactivation from latency.
Mutations in virtually all genes required for viral replication result in this phenotype,
as do mutations in the thymidine kinase, ribonucleotide reductase and ICPO genes
amongst others (Roizman & Knipe, 2001).
ICPO has been implicated in several processes that may be involved in reactivation.
ICPO can reverse the repression of quiescent genomes, and in its absence reactivation
is significantly reduced in vivo. The protein has a RING finger domain that allows E3
ubiquitin ligase activity and hence can target proteins for proteasome degradation.
ICPO can target ND10 proteins, including PML and SplOO, and degradation of these
components may prevent NDlO-induced silencing of viral gene expressioa However
ICPO can interact with numerous other cellular and viral proteins, so the exact
mechanism by which ICPO is involved in de-repression of the viral genome is likely
to be complex (reviewed by Efstathiou & Preston, 2005).
1.2 Gammaherpesviruses
1.2.1 Epstein Barr Virus
EBV was first discovered in 1964 in B lymphocytes cultured from Burkitt's
lymphoma (Epstein et al., 1964). Since its original discovery EBV has been found in
association with a number of other tumour types, including Hodgkin's lymphoma,
nasophaiyngeal carcinoma, certain types of T cell lymphoma and a small percentage
of stomach cancers (reviewed by D.Crawford, 2001). This association with disease is
linked to the ability of EBV to infect and transform B-lymphocytes.
The genome of EBV was the first of the herpesviruses to be cloned into E. coli, and
this enabled in-depth studies of the genome to be made (Arrand et al., 1981). The
genome consists of 172 kb of unique DNA flanked by repeated 0.5 kb terminal repeat




1.2.1.1 Latent Gene Expression
EBV is able to infect primary human B lymphocytes derived from peripheral blood,
tonsils or fetal cord blood. B lymphocytes at earlier stages of development can be
infected albeit at lower efficiencies, and fully differentiated plasma cells are resistant
to infection. A limited range of other cell types are susceptible to infection at low
efficiencies, including T cells and NK cells (Kieff & Rickinson, 2001).
Infection of primary B lymphocytes in vitro results in approximately 10% of cells
undergoing transformation to form lymphoblastoid cell lines (LCLs). These latently
infected cells express a very limited range of viral proteins, incorporating the nuclear
proteins (EBNA1-6) and integral membrane proteins (LMP1, LMP2A and LMP2B).
Several viral RNAs are expressed - the EBERs and the BamHI A fragment rightward
transcripts (BARTs). These viral gene products are able to drive previously resting B
lymphocytes into continuous proliferation. These cells demonstrate an "activated"
phenotype, with immunoglobulin secretion, expression of adhesion molecules and
adherence to each other. It can be suggested that this activation acts to ensure growth
transformation of the host cells and hence increase the number of latently infected B
cells (Kiefif & Rickinson, 2001).
EBV is able to restrict gene expression further during latency. The type of gene
expression described previously is known as type III latency, and this program is seen
following initial infection of naive B lymphocytes in the tonsils (Tierney el al., 1994)
and during infectious mononucleosis (IM). During long-term infection the virus
persists in long-lived memory B cells within the peripheral blood, and at present it is
not clear exactly how B lymphocytes enter the memory compartment. One proposed
hypothesis suggests EBV directly infects pre-existing memory cells (Young &
Rickinson, 2004), although this does not explain the initial infection and proliferation
of naive B cells. An alternative hypothesis proposes the infected cells enter follicles
and differentiate into resting memory cells through the process of germinal centre
reaction. In this scenario viral genes in place of antigen drive this process (Babcock et
al., 2000). EBV may also persist in the epithelial cells of the tonsils in the absence of
symptoms (Pegtel et al., 2004), providing a possible explanation for the association of
EBV with naso- and orophaiyngeal epithelial carcinomas.
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Two other patterns of gene expression have been described - latency I and latency II.
In latency I only EBNA-1, EBERs and BARTs are expressed, while in latency II
LMP-1 and LMP-2 are also expressed.
The differentiation of latently infected B cells occurs in conjunction with a change in
the gene expression pattern, initially from latency III to latency II. This occurs due to
a change in the viral promoter, from the Cp/Wp promoters used for the latency III
program to the Qp promoter. This process is driven by methylation of the Cp/Wp
promoter by host cell factors (Schaefer et al., 1997).
Long-term viral gene expression is still a matter of debate. The latency I phenotype
was first observed in Burkitt's lymphoma-derived B-lymphocytes in vitro (Gregory et
al., 1990). This limited pattern of gene expression allows evasion of CTL attack - the
only viral protein present, EBNA1, interferes with antigen processing (Mukherjee et
al., 1998), although more recent evidence suggests this protein can still enter the
MHC class I pathway (Lee et al., 2004; Tellam et al., 2004). However, within the
long-lived memory B cell population in vivo, viral gene expression does not appear to
be strictly limited to the latency I pattern - while most cells appear to only express
EBERs and BARTs, occasional LMP2A expression is detectable, and EBNA1 is
detected during cell division (Thorley-Lawson & Gross, 2004).
EBNA1 is expressed in all virus-infected cells. It is required for the maintenance and
replication of the genome and is thought to act by tethering the virus to host
chromosomes to ensure retention in daughter cells (Kanda et al., 2001). EBNA1 has
also been shown able to interact with certain viral promoters and hence regulate
transcription, but in vitro only the genome maintenance function is essential for
transformation of B cells (Humme et al., 2003).
EBNA2 is involved in the transformation process. This protein interacts with the
cellular protein RBP-Jk (Jk recombination binding protein) to activate both cellular
(including CD23) and viral genes (including LMP1 and LMP2A). EBNA-LP also
interacts with EBNA2 to allow efficient outgrowth of virus-transformed B cells in
vitro, a process that is modulated by the EBNA3 proteins. The EBNA3 family
includes EBNA3C, which can disrupt cell cycle checkpoints by interaction with
cellular modulators of transcription (e.g. histone deacetylase 1) or proteins controlling
cell cycle progression (e.g. cyclin A).
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LMP1 is an oncogene that induces multiple changes in cells when expressed in vitro.
These include induction of cell-surface adhesion molecules and activation antigens,
and upregulation of anti-apoptotic proteins. LMP1 behaves as a constitutively
activated member of the TNFR superfamily, activating several signalling pathways,
and resulting in induction of the proteins mentioned previously. It is functionally
similar to CD40, and can provide growth and differentiation signals to B cells
(Thorley Lawson, 2001; Young & Rickinson, 2004).
LMP2A can drive the proliferation and survival of B cells in the absence of signalling
through the B cell receptor. The protein is able to induce a range of genes, including
those involved in cell cycle induction, apoptosis inhibition and suppression of cell-
mediated immunity (Thorley Lawson, 2001; Young & Rickinson, 2004).
LMP2B is structurally very similar to LMP2A, although it lacks a 5' exon responsible
for the signalling properties ofLMP2A. Both genes are commonly expressed in EBV-
associated malignancies such as Hodgkin's Disease and nasopharyngeal carcinoma.
Both LMP2A and LMP2B have been shown to promote epithelial cell spreading and
migration in vitro, a process that may contribute to the in vivo pathogenesis of
epithelial-derived tumours (Allen et al., 2005).
The non-coding EBERs are not essential for viral transformation of B-lymphocytes.
However in conjunction with the proteins La and L22, the EBERs can bind to and
potentially inactivate PKR (Nanbo et al., 2002). EBERs are also involved in
tumorigenicity, cell survival and IL-10 induction in Burkitt's lymphoma cell lines
(Young & Rickinson, 2004). The protein products of the BARTs remain to be
conclusively identified, but include the BARF1 protein, which is an early antigen
expressed following induction of the lytic cycle. This protein has oncogenic properties
when expressed in vitro (Young & Rickinson, 2004).
1.2.1.2 EBV Association with Disease
EBV is extremely prevalent in the human population, with more than 90% of adults
being seropositive for the virus (Magrath, 1990), and this figure being closer to 100%
in the developing world. Infection with EBV may occur at a young age with no
obvious symptoms, and this pattern of infection is common in non-industrialised
countries and in low socio-economic groups. In more affluent societies exposure to
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the virus may be delayed until adolescence, where the virus is transmitted by kissing
and related sexual behaviours (reviewed by Macsween & Crawford, 2003). Infection
during adolescence is associated with development of infectious mononucleosis (IM)
in between 50 and 74% of cases.
1.2.1.2.1 Infectious Mononucleosis
Following infection by the predicted salivary route, the virus is able to undergo
productive replication in the oral cavity, as indicated by its presence in saliva.
Evidence suggests this initial infection may occur in either epithelial cells or B cells
(reviewed by Crawford, 2001). An initial incubation period of 30 days then occurs,
with infected B cells circulating in the blood.
Primary infection induces both humoral and cell-mediated immune responses. IgM
and IgG responses to nucleocapsid and envelope proteins are detectable at the time of
presentation with symptoms, as well as IgG responses to some IE and E genes and
EBNA2. Antibodies to the gp350 membrane protein are able to prevent binding to B
cell CR2, but as these arise relatively late during primary infection they are unlikely
to prevent viral spread in the early phase (reviewed by Callan, 2004; Moss et al.,
2001).
The T cell response is predominantly directed against viral lytic antigens.
Uncontrolled T cell responses are damaging, as shown in the case of individuals
affected by X-linked lymphoproliferative syndrome (XLPS). The gene affected in
this case (SH2D1A, or SAP) is expressed in activated T cells, and inhibits the
Signalling Lymphocyte Activation Molecule (SLAM), thereby controlling T cell
activation. In individuals where no functional copy of the gene exists, infection with
EBV results in a severe IM-like syndrome often resulting in death, or if the infection
is survived, in development of B cell lymphoma and/or dysgammaglobulinaemia It is
thought that an uncontrolled CTL response to primary infection causes this syndrome
(reviewed by Macsween & Crawford, 2003).
In the immunocompetent host there is a massive CD8+ T cell lymphocytosis, with
clonal expansion of CD8+ T cells accounting for up to 30% of the entire CD8+
population These expanded populations consist predominantly of cells responding to
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EBV lytic antigens, with a much lower percentage responding to latent antigens. The
high numbers of T cells are not maintained long-term, with most dying following
resolution of primary infection (Callan, 2004). The CD8+ T cells produce large
quantities of a number of cytokines, including lymphotoxin, TNFa, IL-lp and IL-6,
and these may give rise to the symptoms of EM, including fever, lymphadenopalhy,
sore throat and fatigue (Crawford, 2001).
1.2.1.2.2 Burkitfs Lymphoma
In areas of equatorial Africa Burkitt's lymphoma (BL) is endemic, and in around 96%
of cases these tumours contain EBV DNA. The tumours may be found in the jaw,
ovary, mammary gland, liver, intestine and kidney, and are composed of rapidly
proliferating small B cells. While the tumours arise in extra-nodal sites, the cells
resemble germinal centre B cells.
In non-African BL the association of EBV with tumours is less strong, with virus
present in tumour cells in around 20% of cases in Europe and North America, and
between 50-70% in South America, North Africa and Russia
The malignant B cells express only EBNA1, although the EBER and BamA
transcripts are also present. It is thought that the tumour cells are derived from newly
infected tonsillar B cells that have undergone virus-driven transformation and
travelled to the lymph nodes. In this site the virus-infected malignant cells resemble
centroblasts, a form of antigen-activated rapidly proliferating cells that give rise to
germinal centres. Centroblasts are subject to somatic hypermutation events that act to
increase the affinity of the B cell receptor for the antigen (reviewed by Crawford,
2001; Young & Rickinson, 2004).
Both virus- and non-virus-associated BL tumours all show one of three chromosome
translocations, which results in the constitutive expression of the c-myc oncogene.
This drives the cells into continuous proliferation and inhibits differentiation. Errors
in the somatic hypermutation process mentioned above may allow these translocation
events to occur, and hence causing malignant cells to form The viral EBNA1 may
promote cell survival and aid in the oncogenic process (Young & Rickinson, 2004).
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The clustering of BL in Africa is closely linked to geographical areas of endemic
malaria. It is suggested that recurrent bouts of malaria result in immunosuppression,
which allows lytic EBV replication to occur. In conjunction with increased viral
replication and further infection of B cells, malarial antigens can cause polyclonal
activation of B cells, which may activate EBV-infected memory B cells and result in
expansion of the infected B cell pool. Ultimately this leads to a disruption in control
of persistent EBV in individuals who have had several attacks of malaria. These
factors are also replicated by infection with the HIV virus, which causes both
immunosuppression and polyclonal B cell activation (Crawford, 2001).
1.2.1.2.3 B Cell Lymphoproliferative Disease
BLPD occurs in immunodeficient individuals where a lack of EBV-specific CTLs
allows proliferation of latently infected B cells. This is a well-noted effect in
immunosuppressed transplant patients, giving rise to the alternative name Post-
Transplant Lymphoproliferative Disease (PTLD). Between 5 and 30% of transplant
recipients experience this disorder (Thompson & Kurzrock, 2004). Tumours arise
usually within the first year following transplantation when immunosuppression is
most severe. Tumour cells express the latency III programme of viral gene expression
(Young & Rickinson, 2004).
BLPD is also common in HIV-positive individuals, particularly in the latter stages of
AIDS when CD4+ T cell counts are low and immunosuppression is severe. Tumours
are most commonly found in the brain and almost all tumours are EBV-positive
(Crawford, 2001). In AIDS patients EBV is also associated with development of oral
hairy leukoplasia (OHL), a benign lesion caused by viral replication in the superficial
layers of the tongue epithelium (Greenspan et al., 1985).
1.2.1.2.4 Hodgkin's Lymphoma
Approximately 65% of Hodgkin's lymphoma (HL) in the developing world are EBV-
associated (Macsween & Crawford, 2003). Tumours are characterised by the
presence of large multinuclear Reed-Stemberg cells and Hodgkin's cells (known
collectively as HRS cells). HRS cells express the viral genes EBNA1, LMP1 and
LMP2A. LMP1 and LMP2 are both implicated in enhanced cell survival and may
contribute to the malignant phenotype - LMP1 constitutively activates the CD40
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signalling cascade leading to cell proliferation (Lam & Sugden, 2003), while LMP2A
mimics B cell receptor signalling to ensure cell survival (Young & Rickinson, 2004).
EBV infection is an early event in tumour development, a factor that is consistent
with an oncogenic role for the virus (Macsween & Crawford, 2003; Crawford, 2001).
HRS cells are derived from germinal centre B cells that contain functional Ig gene
rearrangements but are defective in Ig transcription. The HRS cells only comprise a
small percentage of the tumour but constitute the malignant element. The composition
of the remaining part of the tumour allows classification into one of three subtypes:
nodular sclerosing (NS), mixed cellularity (MC) and lymphocyte-depleted (LD)
(Young & Rickinson, 2004).
1.2.1.2.5 Nasopharyngeal Carcinoma
Nasopharyngeal carcinoma (NPC) is common in areas of China and Southeast Asia.
NPC arises from squamous epithelial cells and tumours can be classified by the
degree of differentiation of the tumour - tumours are either undifferentiated, or non-
keratinizing or squamous cell carcinomas. There is a 100% association between EBV
and the undifferentiated form of the tumour (Crawford, 2001). EBV gene expression
in NPC is restricted to EBNA1, LMP2A and 2B and the BamA transcripts.
Approximately 20% of tumours also express LMP1 (Young & Rickinson, 2004).
EBV infection takes place prior to outgrowth of the malignant cells.
The predisposition of certain ethnic groups to NPC has been mapped to an
unidentified region of the MHC locus. Dietary and/or environmental factors may also
contribute to the disease, such as salt fish dishes that contain carcinogenic
nitrosamines, and traditional Chinese herbal snulf (Crawford, 2001).
1.2.1.2.6 Other Disease Associations of EBV
Gastric Carcinoma. EBV is found in approximately 10% ofgastric carcinomas. These
tumours express EBNA1, LMP2A and 2B, and the EBERs and BamA transcripts,
similar to the pattern seen in NPC (Young & Rickinson, 2004).
Other tumours where EBV have been implicated include oral hairy leukoplakia,
leiomyosarcoma (in conjunction with HIV infection), and potentially in tumours of
the salivary gland and breast (reviewed by Thorley-Lawson et al., 2004).
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1.2.2 Kaposi's Sarcoma-Associated Herpesvirus
Kaposi's sarcoma (KS) was initially identified in 1872 by Moritz Kaposi, but the
infectious agent causing this disease was not identified until 1994 (Chang et al.,
1994). KSHV (HHV-8) is a member of the gammaherpesvirus subfamily in the genus
rhadinovirus. It is the only human rhadinovirus identified so far, and is closely related
to herpesvirus saimiri.
KSHV distribution is dependent upon geographical and behavioural risk factors. In
the USA virus can be detected in 0-10% of blood donors, while in Africa more than
50% of individuals are sero-positive (Moore & Chang, 2001). The mode of
transmission is not known, but it can be detected in both semen and saliva. As
homosexual men have a particularly high infection rate (up to 40% in some studies) a
sexual mode of transmission has been suggested. In Africa infection in childhood is
more common, suggesting a non-sexual route of transmission is more likely (Moore
& Chang, 2001).
1.2.2.1 KSHV Molecular Biology
The KSHV genome consists of a unique region of 145 kb, flanked by a variable
number of terminal repeats of 801 bp. The unique region consists of regions
homologous to the other herpesviruses containing structural and metabolic proteins,
interspersed with regions containing genes required for latency and host cell
regulation (Moore & Chang, 2001).
In vitro KSHV tends to undergo latent replication. Virus can be propagated within
primary effusion lymphoma (PEL) derived cell lines, and lytic replication can be
induced by the addition of chemicals such as phorbol esters.
KSHV genes can be classified into 3 groups (Sarid et al., 1998). The class I genes are
truly latent and are not induced by chemical treatment. These consist of three genes
located at the right hand end of the genome - LANA-1, v-cyclin, and vFLIP; and one
gene lying outside this region, the LANA-2 gene. These genes have several different
functions - LANA-1 is required for episome maintenance and tethering to host
chromosomes; v-cyclin constitutively activates CDK6; v-FLIP inhibits Fas-mediated
23
Chapter One Introduction
apoptosis, and LANA-2 is a B-cell specific latency gene (reviewed by Jenner &
Boshoff, 2002).
Class II genes are expressed at low levels in unstimulated cells but are phorbol-
inducible and expressed during both lytic and latent infection. Class III gene
transcripts are only detectable following phorbol treatment and consist of true lytic
genes, including those for DNA replication and capsid assembly (Moore & Chang,
2001).
The ability of KSHV to cause tumours is a key feature in the diseases caused by the
virus (see later for further details). Many viral genes are able to contribute to this
process by interfering with the normal cell cycle progression and increasing the
lifespan of the cell. Some examples of these genes are given below.
Numerous viral genes have been shown in vitro to have the ability to transform rodent
cells. These include Kl, vIL-6, vIRFl and ORF74 (vGPCR). ORF72 (v-cyclin) is also
involved in cell cycle regulation - v-cyclin closely resembles a D-type cyclin, and
acts at the Gl-S checkpoint to prevent cell senescence induced by pRB. LANA-1 can
also interact with pRB to prevent cell cycle arrest (reviewed by Moore & Chang,
2001; Jenner & BoshoIF, 2002).
Inhibition of apoptosis is an important process to prevent death of the infected cell
before new virions can be produced to infect a new host. KSHV encodes several
proteins able to alter host apoptotic pathways and hence increase cell survival.
Included in this group is the vBcl-2 (ORF16), which contains the anti-apoptolic BH1
and BH2 domains and is able to inhibit Bax-related apoptosis.
Viral FLIP (Fas-ligand interleukin converting enzyme [FLICE|-like caspase inhibitor)
(ORF71) is able to act as an inhibitor of the Fas-TNF-receptor signalling pathway by
preventing caspase 8 recruitment and hence inhibiting apoptosis.
Three different viral proteins target the pro-apoptotic host gene p53. Firstly, LANA-1
can bind p53 and repress its transcriptional activity and its ability to induce apoptosis.
LANA-2 (ORF10.5) similarly is also able to inhibit p53-induced transcription and
apoptosis. Viral IRF1 (ORF K9) acts in a similar manner to disrupt p53-induced
apoplosis.




KS is found in several distinct subgroups of the population: in immunosuppressed
transplant recipients and AIDS patients; in HIV-negative individuals in Mediterranean
countries (classic KS) and African countries (endemic KS), and also in HIV-negative
homosexual men (Schulz et al., 1998).
Classic KS affects predominantly elderly males, where it has a chronic course and
rarely metastasises to other organs. It presents as multiple reddish-brown plaques and
nodules on the lower extremities. Patients survive on average 10-15 years before
death from unrelated causes. In contrast, endemic KS can present in a number of
different ways: (1) as a benign nodular cutaneous disease in young men; (2) as an
aggressive localised cutaneous disease invading soft tissue and bone, causing death
within 5-7 years; (3) mucocutaneous and visceral disease, and (4) lymphadenopathic
disease spreading to the lymph nodes and visceral organs, usually in the absence of
skin lesions, and occurring in young children (Hengge et al., 2002).
AIDS predisposes individuals already infected with KSHV to develop KS - the risk
of developing symptoms is more than 20,000 times greater than the general
population, and 300 times greater than other immunosuppressed patients. KS presents
at multiple sites, with lesions frequently progressing to form tumours. With the
development of improved treatment for AIDS in the western world AIDS-KS is rarely
seen (Hengge et al., 2002).
Early KS lesions consist of small endothelial-lined spaces surrounding normal blood
vessels. As the disease progresses, these patches expand to form a spindle-celled
vascular process that expands throughout the dermis. These processes further expand
to form sheets of spindle cells and vascular spaces.
The malignant spindle cells that cause the disease are thought to derive from a
multipotent precursor cell that under normal circumstances gives rise to hematopoietic
and endothelial cells. During the early stages of disease only 10% of spindle and
endothelial cells are positive for virus, but in late-stage lesions more than 90% of
spindle cells contain virus, suggesting that virus provides a growth advantage to
infected cells (reviewed by Jenner & Boshofif, 2002).
The role of KSHV in development in KS is not fully understood. Models suggest that
virus reactivates from latently infected B cells following immunosuppression or as a
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result of local cytokine production. The virus is then able to infect the precursor cells.
KSHV has been shown able to induce differentiation of endothelial cells to lymphatic
endothelial cells in vitro, and the same process may affect differentiation of spindle
cells in vivo (Carroll et al., 2004).
1.2.2.2.2 Body Cavity-Based Primary Effusion Lymphoma (BCB-PEL)
BCB-PEL is a rare, rapidly fatal malignancy first described in AIDS patients. The
disease presents as a malignant peritoneal, pericardial or pleural effusion in the
absence of an identifiable tumour mass.
KSHV-infected cells that comprise this lymphoma are often co-infected with EBV, in
particular in the case of HIV-positive individuals. Lymphomas of HIV-negative
people are more likely to carry only KSHV and not EBV (Leao et al., 2002).
In this disease the cells harbouring the virus have been identified as preterminally
differentiated, post-germinal-center-stage B cells. Virus is present in these cells at
high copy number (50-150/cell) (reviewed by Boshoff & Chang, 2001). Gene
expression is limited to the latent genes LANA, v-cyclin, v-FLIP and kaposin, as well
as the vIL-6 homologue. This gene has been shown to promote B cell proliferation in
vitro and may well perform the same function in vivo (Schulz, 2000). vFLIP may be
particularly important for the survival of PEL cells - in vitro in the absence of this
gene PEL cells undergo spontaneous apoptosis (Guasparri et al., 2004).
1.2.2.2.3 Multicentric Castleman's Disease
MCD is a lymphoproliferative disease, causing lymphadenopathy, fever and splenic
infiltratioa KSHV is strongly associated (nearly 100%) with MCD in AIDS patients,
and is present in approximately 50% of cases in HIV-negative individuals. The
KSHV-positive MCD is characterised by the presence of large plasmablastic cells
harbouring the virus. These plasmablasts are thought to originate from naive B cells
(reviewed by Jenner & Boshoff, 2002). The IL-6 receptor is expressed by the majority
of KSHV-positive cells and a proportion of cells also express vIL-6 (Oksenhendler et





Herpesvirus saimiri (HVS) is the prototypic virus of the rhadinovirus genus. This
virus is regularly found in squirrel monkeys (Saimiri sciureus) from the South and
Central American rainforests (Melendez et al., 1968). Infection of squirrel monkeys
produces no obvious signs of disease; however experimental infection of other New
World primates such as tamarins, common marmosets and owl monkeys can cause T-
cell lymphoma as early as two months following infection.
Three main subgroups of HVS exist, named A, B and C (Medveczky et al., 1984).
These are classified according to pathogenic properties and sequence divergence in
the non-repetitive terminal regions. Generally, subgroup C possesses the strongest
oncogenic properties, and subgroup B the weakest. Differences also exist in the ability
to infect different primate species - tamarins are susceptible to all three subgroups,
whereas common marmosets do not show signs of disease following infection with
HVS from subgroup B (reviewed by Fickenscher & Fleckenstein, 2001).
1.2.3.1 Molecular Biology of HVS
The genome of HVS is composed of 113 kb of unique sequence flanked by a variable
number of 1444 bp terminal repeats (Albrecht et al., 1992). The genome is similar to
that of other Rhadinoviruses, including KSHV and MHV-68. Unlike many other
gammaherpesviruses, HVS is able to undergo lytic replication in vitro, allowing study
of productive replication, and the generation of recombinant viruses. HVS is able to
infect a variety of human cells and persist at high copy number in episomal form.
The HVS genome contains large blocks of homology to the other gamma-2-
herpesviruses, as well as blocks of genes unique to the virus. These unique blocks
contain the transforming oncogenes as well as several homologues of cellular genes.
The transforming genes are located at the left-hand end of the genome. Variation in
transforming genes is found between the three subgroups - A contains a single gene
in this position, saimiri transformation-associated protein of subgroup A (stpA); the
homologous gene in subgroup B (stpB) lacks transforming ability, and subgroup C
carries two genes, stpC and tip (tyrosine kinase interacting protein). StpA and stpC
share limited homology, but there is no obvious relationship between StpA and tip.
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StpC is thought to mediate its oncogenic properties through its ability to activate
NFkB. Both StpA and StpC have been shown to interact with TNF receptor-
associated factors (TRAFs). These TRAFs are crucial for initiation of signalling
pathways that ultimately result in activation of NFkB. Expression of StpC in
conjunction with a TRAF protein in epithelial cells results in activation of NFkB, a
process that is abolished if the TRAF is mutated to prevent binding of StpC. The non-
transforming StpB can be converted to a transforming state if a region of StpC
containing 18 collagen-like repeats is added. This alteration allows StpB to induce
NFkB in epithelial cells.
StpC induces activation and subsequent phosphorylation and degradation of I-kB
kinase (IKK) in both T-lymphoid and non-lymphoid cells. Evidence suggests that
StpC binds to the TRAFs and activates NFKB-inducing kinase (NIK), which then
activates IKK This results in degradation of I-kB and activation of NFkB (reviewed
by Tsygankov, 2005).
The tyrosine kinase interacting protein (Tip) of HVS is also able to stimulate T cells.
Tip is thought to have many potential targets in the host cell and may affect a number
of different pathways. Interaction of Tip with a host protein Lck (a Src-family protein
tyrosine kinase) has been shown to lead to activation of Lck tyrosine kinase activity in
vitro. Lck plays a role in T cell signalling, and constitulively active Lck mutants have
oncogenic potential. This suggests the ability of Tip to activate Lck signalling may
result in activation of T cells and lead to oncogenesis.
However not all evidence supports this hypothesis, and in fact in some cases this is
directly contradicted. Expression of Tip in human Jurkat T cells causes
downregulation of Lck-mediated signal transduction. Tip can also suppress the
transforming ability of a constitutively active Lck mutant in fibroblast cells, a process
that is enhanced by mutation of Tip that enhances binding to Lck. This evidence
suggests that Tip functions in a manner similar to EBV LMP-2A - this protein
inhibits B cell-receptor-mediated signalling and induces latency by blocking viral
replication (reviewed by Fickenscher & Fleckenstein, 2001; Jung et al., 1999).
Tip is also able to induce activation of STAT1 and STAT3 transcription factors in a
Lck-dependent manner. When Tip binds to Lck, Lck is activated and in turn
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phosphorylates Tip. This phosphorylation allows recruitment of STAT1 and STAT3,
which are then tyrosine phosphorylated by Lck. However, removal of the tyrosine
phosphorylation sites of Tip can still result in STAT3 activation. Therefore, while Tip
is known to enhance Lck-dependent activation of STATs the mechanism is not yet
clearly understood (reviewed by Tsygankov, 2005; Fickenscher & Fleckenstein,
2001).
Other transcription factors are known to be activated by Tip. NF-AT, a transcription
factor with a role in T-cell stimulation, is activated by Tip, but the mechanism for this
process is unclear. Some evidence points to a role for Lck in this process, but in the
presence of protein tyrosine kinase inhibitors NF-AT activation can still occur,
suggesting a Lck-independent mechanism (reviewed by Tsygankov, 2005).
Several other genes are present in the HVS genome that are involved in stimulating or
enhancing T cell proliferation. These include the vIL-17 (ORF13) gene, which
activates NF-kB and induces expression of IL-6, IL-8 and surface ICAM-1. Viral IL-
17 enhances proliferation of primary T cells induced by PHA.The product of ORF14
(viral superantigen, vSag) binds to MHC class II molecules and stimulates T cell
proliferation. It is not clear how essential the gene is for transformation in vivo.
The viral genome also contains anti-apoptotic genes such as ORF16 (Bcl-2
homologue) and ORF71 (vFLIP). Both genes are expressed during lytic infection and
may prevent induction of apoptosis in lytically infected cells (Tsygankov, 2005;
Fickenscher & Fleckenstein, 2001).
1.2.4 Gammaherpesviruses of Veterinary Importance
Malignant catarrhal fever is a generally fatal disease of cattle, deer, pigs and several
other susceptible species. The cause of disease is infection with either alcelaphine
herpesvirus-1 (A1HV-1) or ovine herpesvirus-2 (OvHV-2). In their natural hosts, the
wildebeest and domestic sheep respectively, these viruses cause no overt signs of
disease. However, in susceptible species the disease is characterised by hyperplasia of
lymphoid organs, accumulation of T lymphocytes in many tissues, and vasculitis.
These changes occur despite limited evidence of viral replication (reviewed by
Coulter et al., 2001).
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Biological characteristics and preliminary sequence analysis allowed classification of
the A1HV-1 virus as a rhadinovirus, and the sequencing of the genome in 1997
(Ensser et al., 1997) confirmed previous findings. Of the 70 putative ORFs of A1HV-
1, 61 show homology to HVS, the prototypic gamma-2-herpesvirus. Creation of a
cosmid library of the OvHV-2 genome allowed sequencing of the genome
(Rosbottom, 2003), confirming that while similar to A1HV-1, OvHV-2 is in fact a
separate species.
A1HV-1 can be grown in tissue culture, allowing investigation of the function of viral
genes in vitro. OvHV-2 can be propagated (but not easily isolated) in both bovine and
rabbit T cell lines, with the bovine cells supporting predominantly latent infection,
and the rabbit cells undergoing what appears to be an abortive productive infection
(Rosbottom etal., 2002).
Equine herpesvirus-2 (EHV-2) and equine herpesvirus-5 (EHV-5) were originally
classified as p-herpesviruses based on their biological properties. Later sequence
analysis resulted in their reclassification as y-herpesviruses, with genome structures
more closely related to HVS (a gamma-2-herpesvirus) than EBV (a gamma-1-
herpesvirus) (Telford etal., 1993; Telford etal., 1995).
EHV-2 has been implicated in immunosuppression in foals, upper respiratory tract
disease, conjunctivitis, general malaise and poor performance. An alternative role has
been suggested in the reactivation of EHV-1 and EHV-4 (Welch et al., 1992; Purewal
et al., 1992). EHV-2 may also be a predisposing factor for Rhodococcus equi
infection of the respiratory tract (Nordegrahn et al., 1996).
EHV-2 infection is common, with evidence showing infection of between 56 and 68%
of tested horses in Sweden, and 71% of tested horses in England positive by PCR for
the virus. By comparison infection with EHV-5 is substantially lower, with nearly
25% of English horses testing positive for the virus (Nordengrahn et al., 2002).
Bovine herpesvirus-4 (BoHV-4) is found world-wide and has been isolated in a
variety of clinical diseases as well as in healthy cattle. In vitro BoHV-4 is able to
infect a broad spectrum of cells, including B-lymphocytes, T-lymphocytes,
macrophages, endothelial cells, and liver, kidney and mammary gland cells. Most
non-bovine cells do not support viral replication in vitro (reviewed by Ackermann,
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2006), but in vivo it is able to infect cattle, buffalo (Dewals et al., 2005), rabbits
(Osorio et al., 1982), lions and domestic cats (Kruger et al., 2000).
Genome analysis shows BoHV-4 is a member of the gammaherpesvirus subfamily,
and is more closely related to HVS than EBV (Lomonte etal., 1996).
Porcine gammaherpesviruses PLHV-1, -2 and -3 are highly prevalent in domestic and
feral pigs. PLHV-1 has been shown to be associated with lymphoproliferative disease
in immunosuppressed and post-transplant pigs, and pathogenesis closely resembles
the EBV-associated PTLD in humans.
Porcine herpesviruses are currently of interest because of developments in
transplantation of organs from pigs to humans. Human herpesviruses are able to
trigger graft rejection and transplant failure. Interactions between human
herpesviruses and PLHV-1 have been demonstrated in vitro, indicating that
xenotransplantation may be affected by interactions between human and porcine
herpesviruses (Santoni et al., 2006).
1.2.5 Animal Models of Gammaherpesvirus Infections
Initial infection with gammaherpesviruses is in many cases an asymptomatic process.
The virus may persist for many years before symptoms become apparent, and while it
is possible from this point to investigate the mechanisms of disease progression, it is
not possible to determine what factors are involved prior to onset of symptoms.
In the case of EBV initial infection is apparent in the few individuals that develop
infectious mononucleosis; in the majority of cases primary infection goes undetected.
To overcome the lack of subjects for the study of acute infection and to allow
investigation of factors preceding the numerous EBV-related lymphomas, the
development of a suitable animal model is an important process. This allows
investigation of the contribution of viral and host factors to the disease progression, as
well as development of treatments and vaccines.
Initially attempts were made to develop models of infection using EBV infection of
New World primates.
Inoculation of cotton-top tamarins (Sagunis oedipus) with EBV causes an acute
polyclonal B cell proliferation, with some animals succumbing to lymphoproliferative
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disease. This feature has allowed use of this model for post-transplant
lymphoproliferative disease and potential vaccines (Epstein et al., 1985). However,
there are a number of differences to human infection with EBV. During acute
infection disease progresses much more rapidly, with tumour formation occurring
within 2-3 weeks following infection; and onset of lymphoproliferative disease occurs
in the majority of animals infected (Shope et al., 1973). These characteristics are not
representative of acute EBV infection in humans, and while useful as a model for
PTLD the cotton-top tamarin may not be as useful for the study of acute infection.
Infection of the common marmoset (Calithrix jacchus) causes an IM-like syndrome
(Wedderbum et al., 1984), but this does not replicate the B cell involvement of EBV
in humans (Emini et al., 1986) and no evidence of EBNA-1 expression (a
characteristic feature of long-term persistence during EBV infection in humans) has
been found at late time points (Farrell et al., 1997). Therefore the common marmoset
is not a suitable model for the study of long-term EBV persistence.
Attempts to infect Old World primates with EBV failed, possibly as a result of cross-
reactive immunity from pre-existing Lymphocryptovirus (LCV) infection, use of a
defective EBV isolate, problems with the route of inoculation, or a potential species
restriction for efficient B cell immortalization by LCVs (Moghaddam et al., 1998;
Wang et al., 2001).
Lymphocryptoviruses closely related to EBV have been known since the 1970s to
infect Old World primates. The genomes of these viruses are colinear and encode
highly homologous structural proteins. LCV-infected cell lines can be established
from lymphocytes taken from both healthy and diseased primates, including
chimpanzees, gorillas, orang-utans and various macaque species. These cell lines
produce virus able to immortalise B cells, and during latent infection also express a
nuclear antigen similar to the EBV EBNA proteins (reviewed by Wang et al., 2001).
In vivo LCV infection resembles EBV infection in humans, with sero-conversion
occurring in the majority of young animals. In the case of rhesus macaques (Macaca
mulatto) infected with a rhesus LCV by an oral route, animals shed virus in oral
secretions and harbour persistent, asymptomatic LCV infection in the peripheral
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blood (Moghaddam et al., 1997). These similarities allow investigation of acute and
persistent infection in an animal virus analogous to EBV.
Simian LCVs have proved useful in understanding interactions between the virus and
host during immunosuppression. Discovery of LCV-induced tumours (EB-like
cynomolgus B-lymphotrophic herpesvirus) in cynomolgus monkeys
immunosuppressed as a result of infection with SIV mirrors the development of EBV-
positive B cell lymphomas in AIDS patients (Feichtinger et al., 1992). This further
emphasises the usefulness of Old World primate models in the study of EBV-related
disease in both the immunocompetent and immunosuppressed host.
KSHV is difficult to study in vivo owing to the asymptomatic nature of primary
infection - as yet no equivalent to the infectious mononucleosis disease caused by
primary EBV infection has been detected. Investigation of events occurring during
initial infection have been limited primarily to in vitro studies, and these are limited
owing to the persistence of the KSHV genome in tissue culture predominantly in the
latent state.
A number of viruses have been identified in primates that are closely related to KSHV
and several of these have been identified as potential animal models for the study of
KSHV. The rhadinovirus genus contains members that naturally infect both Old- and
New-World primates. Amongst those that infect New World primates are herpesvirus
saimiri and herpesvirus ateles (a virus of spider monkeys) (Melendez et al., 1972),
while those that infect Old World primates include rhesus monkey rhadinovirus
(RRV) (Desrosiers et al., 1997) and the PapRV2, a herpesvirus of baboons (Whitby et
al., 2003).
Advantages of the use of primate viruses for the study of KSHV include easy growth
in tissue culture - the RV2mac virus, a rhadinovirus of macaques (Macaca mulatto)
replicates lytically in vitro to produce high viral titres, allowing production of
recombinant viruses and the study of individual viral genes within the context of an in
vitro viral infection (reviewed by Damania & Desrosiers, 2001).
The presence of largely colinear genomes in a number of Old World primate
rhadinoviruses allows investigation of both acute and chronic infection in an
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analogous animal model. The RV2mac virus contains homologues to nearly all KSHV
ORFs, with the exceptions of K3, K5, K7 and K12, and transcription profdes for both
viruses are also very similar (Dittmer et al., 2005).
As with EBV, the coinfection of macaques with SIV and one of the many rhesus
rhadinoviruses allows in vivo modelling of the interactions between HIV and KSHV.
Development of a disease closely related to the multicentric plasma cell variant of
Castleman's disease has also been observed in rhesus macaques coinfected with SIV
and a rhesus rhadinovirus, and hence more than one KSHV-associated disease can be
studied in these primate models (Damania & Desrosiers, 2001).
While infection of Old World primates with their natural LCVs and rhadinoviruses
may produce excellent models for the mechanisms of EBV and KSHV disease, the
reality of keeping primates is much more difficult. High security, large expense and
strict government regulations mean that use of primates in research is extremely
limited. Added to this are the difficulties in generating transgenic animals for the
investigation of viral-host interactions and the relative lack of understanding of many
primate immune systems, and there are arguments for the development of more
simple models of gammaherpesvirus infection.
Increasingly mice are the animal of choice for the study of gammaherpesviruses in
vivo as they are small and easy to keep.
Murine models have been developed for both EBV and KSHV. In the case of EBV,
SCID (severe combined immunodeficiency) mice inoculated with PBMC from EBV
seropositive individuals develop EBV-positive BPLD-like tumours (reviewed by
Johannessen & Crawford, 1999). However no murine model exists at present for the
other EBV-related diseases. Similarly, a model for KSHV exists whereby SCID mice
implanted with human fetal thymus and liver grafts are susceptible to infection and
undergo an initial lytic infection followed by establishment of latency in CD19+ B
cells (Dittmer et al., 1999).
In addition to infection of mice with human viruses, it is also possible to infect with
murine gammaherpesviruses. Murine gammaherpesvirus-68 (MHV-68) is able to
cause both productive and latent infection in laboratory mice in a manner analogous
to EBV infection (Sunil-Chandra 1992a; Sunil-Chandra, 1992b). The ease with which
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recombinant viruses can be generated allows investigation of the role of individual
genes in vivo, the majority of which are homologous to genes in the
gammaherpesviruses EBV and KSHV. MHV-68 therefore provides a model system in
which interactions between a gammaherpesvirus and its natural host can be studied,
and from which parallels with EBV, KSHV and important veterinary
gammaherpesviruses can be drawn.
1.3 Murine Gammaherpesvirus-68
MHV-68 was originally isolated from bank voles (Clethrionomys glaroulus) in 1980,
along with the related viruses MHV-60 and MHV-72. At the same time two further
viruses, MHV-76 and MHV-78 were isolated from wood mice (Apodemus flavicollis)
(Blaskovic et al., 1980). Suspensions of tissues (lung, spleen, liver, kidney and heart)
were diluted and inoculated into the brains of newborn mice, and passaged from
mouse to mouse. Different isolates were obtained from different passages. The
isolated viruses were able to infect a range of cell lines derived from a number of
different species (Svobodova et al., 1982).
Initial studies of the virus led to classification of MHV-68 as an alphaherpesvirus.
However later studies revealed MHV-68 was able to cause pneumonia in the lungs of
newborn mice, with viral antigen detectable in a range of tissues and cell types. These
mice failed to develop neurological disease (Rajcani et al., 1985). Sequence analysis
led to reclassification of MHV-68 as a gammaherpesvirus in the rhadinovirus genus
(Efstathiou et al., 1990), and this classification is further confirmed by the ability of
the virus to establish latent infection in B lymphocytes, macrophages, dendritic cells
and epithelial cells (Flano et al., 2000; Sunil-Chandra et al., 1992b; Week et al.,
1999a; Stewart etal., 1998).
MHV-68 is endemic in the UK wood mouse population (Blasdell et al., 2003), and it
is likely that this is the natural host species. More recently MHV-68 has been
designated murid herpesvirus-4 (MHV-4) strain 68, with the other MHV isolates
MHV-76, -60 and -72 similarly designated MHV-4 strain 76, -60 and -72.
1.3.1 MHV-68 Genome
The genome of MHV-68 consists of a single unique region of 118,237 bp DNA
flanked by a variable number of 1,213 bp terminal repeats. The unique region consists
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of 46% G+C, while the terminal repeats are composed of 77.6% G+C. Within the
unique region are two internal repeats: a 40 bp repeat located at genome co-ordinates
26778 and 28191, and a 100 bp repeat located at co-ordinates 28981-101170. The
strain of MHV-68 used for sequencing is designated yHV-68 WUMS (Virgin et al.,
1997).
The unique region of the MHV-68 genome is largely colinear with the genomes of
other rhadinoviruses, including KSHV and HVS (see figure 1.3). The unique region
comprises 73 open reading frames (ORFs) along with eight viral tRNA-like molecules
and nine predicted microRNAs (Bowden et al., 1997; Pfeffer et al., 2005; Virgin et
al., 1997). As with other rhadinoviruses, MHV-68 possesses a number of cellular
homologues, including a regulator of complement activation (ORF4), a Bcl-2
homologue (Mil), a cyclin D homologue (ORF72) and a G-protein coupled receptor
(ORF74) (Kapadia et al., 1999; Wang et al., 1999; van Dyk et al., 1999 Wakeling et
al., 2001).
MHV-68 also contains a number of genes unique to this virus, with a significant
number of these clustered at the left-hand end of the genome. These are Ml, M2, M3
and M4. This region also contains the tRNA-like molecules and the predicted
microRNAs (Bowden et al., 1997; Pfeffer et al., 2005). This region (the first 9.5 kb of
the genome) is absent from the naturally occurring deletion mutant MHV-76 (Macrae
et al., 2001; Clambey et al., 2002).
1.3.2 MHV-68 Virions
MHV-68 virion structure is similar to other herpesviruses (Ciampor et al., 1981;
Svobodova et al., 1982). The capsid, tegument and glycoprotein genes homologous to
those of other herpesviruses can be predicted to fulfil the same role in the MHV-68
virion. The composition of the MHV-68 capsid, tegument and envelope was
investigated by Bortz et al. (2003). This study identified 5 capsid proteins (ORF25,
ORF62, ORF26, ORF65 and ORF29); 3 tegument proteins (ORF75c, ORF45 and
ORF11); 2 envelope proteins (ORF8 and ORF22); and 4 proteins of undetermined
location (ORF20, ORF24, ORF48 and ORF52). In addition, several other studies have
identified components of the MHV-68 envelope; these include M7 (Stewart et al.,
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Figure 1.3 The Genome of MHV-68 is Largely Colinear with the Genomes of
KSHV and HVS. Diagrammatic representation of the genome of MHV-68 aligned with the
genomes of KSHV and HVS. Open boxes represent conserved gene blocks. Adapted from
Nash et al, 2001.
Chapter One Introduction
1.3.3 MHV-68 Infection In Vitro
MHV-68 is able to infect and successfully replicate in a range of cell lines, including
epithelial and fibroblast lines (Svobodova el al., 1982). While MHV-68 undergoes
productive infection in the majority of cell lines, there are a limited number of lines in
which MHV-68 is able to establish a persistent infection. These include the NSO line
(derived from mouse myeloma B cells) (Sunil-Chandra et al., 1993) and Sll cells
(Usherwood et al., 1996c). In the NSO cell line both circular (episomal) and linear
forms of the viral genome can be detected. Following treatment with acyclovir the
amount of linear virus DNA molecules is substantially reduced, indicating the linear
form of the genome is predominantly associated with lytic infection, whereas the
episomal form is associated with latent infection (Sunil-Chandra et al., 1993).
Many MHV-68 genes have been assigned functions based on their sequence
homology to the genes of other herpesviruses whose roles are already known (Virgin
et al., 1997). However more recently the use of signature tagged transposon
mutagenesis has identified conclusively a number of MHV-68 genes essential for the
replication process, as well as several genes not essential but that significantly
enhance viral replication (Moorman et al., 2004; Song et al., 2005). To date 41 genes
have been shown essential for viral replication; these include 17 genes essential for
replication in the a-, J3- and y-herpesvirus subfamilies, including MHV-68 ORF6 (a
ssDNA binding protein), ORF8 (gB), ORF9 (DNA polymerase), ORF22 (gH) and
ORF64 (tegument protein). A number of the essential genes have homologues only
within the gammaherpesvirus subfamily: these include ORF45, a homologue of the
KSHV IRF7 binding protein (Jia et al., 2005).
Gene expression in MHV-68 occurs in a cascade fashion, with transcription of
immediate early genes preceding early gene transcription, and late gene expression
occurring subsequently to early gene expression (Ebrahimi et al., 2003). MHV-68
transcription can be detected from 3 hours post-infection in vitro. The replication
genes ORFs 6 (ssDNABP), 9 (DNA polymerase), 60 (ribonucleotide reductase
subunit) and 61 (ribonucleotide reductase subunit) are transcribed with similar
kinetics, with a defined early peak of transcription. Showing similar kinetics are the
ORF57 and M6 genes. Other genes can be clustered into three general expression
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patterns - one with a peak at 5 hours p.i., with a gradual decrease in transcript levels
(including ORF50/Rta, ORF37 (alkaline exonuclease, and gL); a second group with a
peak at approximately 8 hours p.i., including the structural genes ORFs 25 (capsid),
33 (tegument), 38 (membrane) and M7 (gpl50), as well as several genes of unknown
function (ORFs 20 and 52). The final group shows a peak of transcription at 12 hours
post-infection, and includes a second group of structural proteins, including ORFs 19
(tegument), 66 (capsid), 68 (glycoprotein), and a gene of unknown function, M9 (Ahn
et al., 2002; Martinez-Guzman et al., 2003). From this temporal analysis of viral gene
expression it is possible to build up a profile of the events of MHV-68 replication, and
also to hypothesis about the functions of unknown genes such as M6 and M9 based on
similarities of their expression pattern to genes of known function.
Along with the essential replication proteins, a number of non-essential genes are also
expressed during in vitro infection. The M4, K3 and ORF73 genes are expressed with
immediate early kinetics, while the cellular homologues (ORF72, Ml 1 and ORF74)
are expressed with early-late kinetics. The early-late group also includes the
abundantly expressed M3 gene, which encodes a chemokine binding proteia
Following the assembly of new virions in a manner that has not been investigated (but
is assumed analogous to the process observed for HSV-1), MFTV-68 can exit the cell
into the extra-cellular space, or can infect adjacent cells. The M7 (gpl50) gene of
MHV-68 encodes a glycoprotein necessary for viral egress into the extra-cellular
space (de Lima et al., 2004; Stewart et al., 2004). In contrast, the ORF27 (gp48) gene
has been identified as involved in the process of egress directly into adjacent cells
(May et al., 2005c). gp48 must be localised to the plasma membrane for efficient
movement of virions into new cells, a process that requires the viral ORF58 product
(May et al., 2005b).
1.3.4 MHV-68 Infection In Vivo
Investigation of the virus revealed MHV-68 was able to infect inbred laboratory
strains of mice. In 1992 Sunil-Chandra el al. demonstrated that MHV-68 was able to





The intranasal route of infection is commonly used as an experimental method of
inoculation. An alternative strategy is infection via the intraperitoneal (i.p.) route
(Week et al., 1996). The natural route of transmission of the virus has not been
conclusively determined. The discovery of virus in the lungs of the postulated natural
host of MHV-68, the wood mouse, would suggest that the aerosol route of
transmission may occur in the wild. However the housing of infected mice with
uninfected mice does not easily result in transmission of the virus, suggesting the
intranasal route may not be the most efficient (Gaspar-Smith & Bost, 2004). Other
potential natural routes of transmission are via breast milk (Raslova et al., 2001), or
via the digestive system (Peacock & Bost, 2000).
Following inoculation by the intranasal (i.n.) route, mice develop an infection of the
lung, with virus detectable as early as 1 day post-infection, the peak of replication
occurring on d3-5, and clearance of the virus by dlO. While virus cannot be detected
by plaque assay after dlO, detection by PCR is possible for extended periods
following infection (Stewart etal., 1998).
MHV-68 localises to the alveolar epithelium and mononuclear cells (Sunil-Chandra et
al., 1992a). In these cells gene expression is similar to expression during in vitro
infection, with detection of both lytic and latent transcripts (Martinez-Guzman et al.,
2003). A number of genes not required during acute infection in vitro have however
been shown to play a role during acute infection in vivo. These include the thymidine
kinase (ORF21) gene (Coleman etal., 2003), the dUTPase (ORF54) gene (Song et al.,
2005), ORF73 (Moorman et al., 2003a; Fowler et al., 2003) and ORF75a (Song et al.,
2005).
Thymidine kinase (TK) and dUTPase are both required for nucleic acid metabolism,
producing dTMP and dUMP respectively, both of which can be converted to dTTP.
Cellular dTMP can be synthesised de novo, with the methylation of dUMP by
thymidylate synthase, or it can be salvaged from dT by thymidine kinase. This second
pathway predominates, and the process is limited by the presence of cellular TK,
which is restricted to S phase. In non-cycling cells cellular TK is not present, and
hence the supply of dTMP is limited and viral replication cannot occur. The presence
of a viral thymidine kinase overcomes this restriction and allows viral replication in
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non-cycling cells. In vitro a TK-deficient virus shows no replication deficit, most
likely due to the presence of pre-existing dTMP pools. However in vivo the TK-
deficient virus is severely impaired during acute infection of the lung, with viral
replication 10,000 times lower than that of the wild-type MHV-68 (Coleman et al.,
2003). This implies that during acute infection the virus is infecting cells without a
pre-existing dNTP pool, which suggests the virus is infecting fully differentiated
epithelial cells that have exited the cell cycle.
ORF73 shows homology to the KSHV LANA-1 gene (Virgin et al., 1997). The
LANA-1 protein of KSHV is multifunctional, involved in episome maintenance and
tethering to host chromosomes, as well as prevention of apoptosis and disruption of
cell cycle control (reviewed by Jenner & Boshoff, 2002). The MHV-68 gene is 24.2%
homologous to the KSHV gene (Virgin et al., 1997), and it has not been determined if
the MHV-68 ORF73 shares all properties of LANA-1. Following low-dose infection
(1 x 103 pfu) with an ORF73-deficient virus, delayed replication kinetics were
observed (Moorman et al., 2003a). However at higher doses (1 x 104 pfu) the absence
of ORF73 does not appear to affect acute infection in the lung (Fowler et al., 2003;
Moorman et al., 2003a).
ORF75a is a tegument protein of unknown function, and it is not clear how this
influences acute replication in vivo while having no effect during in vitro infection
(Song et al., 2005).
The deletion mutant MFIV-76 also shows an attenuated phenotype in the lung
following intranasal infection. This virus, lacking M1-M4 and 8 vtRNAs, produces
lower viral titres in the lung and is cleared more rapidly than MHV-68 (Macrae et al.,
2001). This phenotype has not been attributed to any individual gene missing from the
MHV-76 genome, and may result from a combined effect of the missing genes and/or
tRNAs (see section 1.3.5.1 for further discussion).
Infection of the lung is accompanied by an infiltration of lymphoid cells into the
peribronchiolar, perivascular and interstitial areas (Sunil-Chandra et al., 1992a). This
infiltrate consists predominantly of T cells, monocytes and macrophages (Sarawar et
al., 2002), with the T cell population consisting predominantly of CD8+ T cells.
CD8+ T cells have been shown to play a key role in control of MHV-68 acute
infection in the lung - depletion of CD8+ T cell subsets by antibody results in
elevated viral titres at early time points accompanied by a failure to clear the virus.
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CD4+ T cell depletion does not have such an extreme effect during initial infection -
the virus does not replicate to the extremely high titres observed in CD8+-depIeted
mice, and while acute infection is prolonged the virus is eventually cleared (Ehtisham
etal., 1993).
The type I interferon response is extremely important in the initial response to
infection. Infection of mice lacking a functional type I interferon receptor (IFN-a/p-
R" ") causes significant mortality (80%) at the usually non-lethal dose of 4 x 105 pfu.
Infection of these mice with the lower dose of 4 x 103 pfu still results in 50%
mortality within 7-8 days of infection. IFN-oc/p-R~A mice have 100- to 1000-fold
higher viral titres in the lungs, and those that survive past 8 d.p.i. still harbour
infectious virus in the lungs at 3 weeks post-infection, indicating impaired clearance
(Dutia et al., 1999). Virus is also able to disseminate to other organs such as the
adrenal gland and liver (Dutia et al., 1999; Barton et al., 2005).
1.3.4.2 Viral Dissemination
The next stage of infection is the trafficking of MHV-68 to the mediastinal lymph
node. This process is most likely mediated by the dendritic cells (S. Selverajah,
unpublished data). Preformed infectious virus cannot be detected in the MLN at this
point and therefore the virus is most likely cell-associated (Stevenson & Efstathiou,
2005). Infected dendritic cells, macrophages and B cells can all be detected in the
MLN (Nash et al., 2001); however in the absence of B cells virus still reaches the
MLN but fails to disseminate to other lymphoid organs, suggesting the B cell is the
major cell type required for trafficking of the virus to other organs (S. Selverajah,
2001).
1.3.4.3 Acute Phase Latency in the Spleen
Upon reaching the spleen MHV-68 establishes a latent infection, with MHV-68
detected within germinal centre B cells, macrophages and dendritic cells (Flano et al.,
2000). During establishment of latency there is a rapid expansion of germinal centre B
cells, a process that is dependent on the presence of CD4+ T cells. In the absence of
CD4+ cells there is a substantial reduction in the ability of the virus to establish
latency (as measured by infectious centre assay) as well as an absence of the
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splenomegaly characteristic of MHV-68 infection (Ehtisham et al., 1993; Usherwood
et al., 1996a). Splenomegaly usually peaks on dlO, and the increase in cell number is
due to an expansion of the B cell, CD8+ and CD4+ T cell subsets (Usherwood et al.,
1996a). Splenomegaly is driven by viral factors located in the left-hand end of the
genome - following infection with MHV-76 splenomegaly fails to occur, indicating
the 9.5 kb deleted region is important for this feature of infection (Macrae et al.,
2001). The exact gene or genes required for this process have yet to be identified.
Following the peak of latency, numbers of latently infected cells decline to levels at
the limit of detection (Sunil-Chandra et al., 1992a).
In addition to the increase in both B and T cells that result in splenomegaly, there is
an increased number of circulating T cells, specifically the Vp4+CD8+ subtype. This
increase is observed from d21 and is reminiscent of the infectious mononucleosis
observed during EBV infection. A viral superantigen has been suggested to drive this
rapid proliferation of CD8+ T cells in conjunction with CD4+ cell-derived cytokines
(Tripp etal., 1997; Coppola et al., 1999). While this process does not occur following
infection with MHV-76, the exact viral factor(s) that drive this process have not yet
been identified.
The type II interferon response is also important in control of pathology in the spleen.
In the absence of a functional type II response, both the spleen and MLN of mice
infected with MHV-68 show fibrosis and atrophy at 17 days post-infection. Absence
of a type IIIFN response results in altered levels of some cytokines - IL-lp, TNF-a
and TGF-pi are elevated in the spleens of IFNyR" " mice, all of which are involved in
induction of fibrosis. Other chemokines are present at reduced levels in the spleens of
IFNyR"7" mice - IP-10 and MIG (both involved in T cell recruitment) are both
downregulated. IP-10 is also known to inhibit fibroplasia and deposition of
extracellular matrix proteins, so a reduction in levels may contribute to the phenotype
observed in IFNyR" " mice (Ebrahimi et al., 2001).
IFNy is also involved in control of persistent replication in the PECs and to a lesser
effect in the spleen. In the absence of IFNy significant levels of persistent replication
are detected in the PECs from dl6 to d42, but in the spleen only on dl6 (Tibbetts et
al., 2002). This suggests an alternative mechanism may control persistent replication
43
Chapter One Introduction
in the spleen. Reactivation from latency is an important factor in maintenance of
persistent replication in IFNy"7" mice (discussed in section 1.3.4.6).
The switch from lytic to latent infection requires a change in gene expression patterns.
During latency the genes involved in viral replication and production of new virions
are not required and transcription must be curtailed; other genes necessary to maintain
the virus in a quiescent state must be activated. Host factors such as NF-kB have been
identified as able to inhibit MHV-68 lytic replication and drive the virus into a latent
state (Brown et al., 2003). This process may occur by the interaction of NF-kB with
the MHV-68 RTA.
RTA (Replication and Transcription Activator), or ORF50, plays a key role in the
lytic-latent switch. Upregulation of the gene by alteration of the promoter region
results in accelerated lytic growth in vitro, and a deficit in latency establishment in the
spleen in vivo. Virus was also cleared more rapidly from the lung (May et al, 2004;
Rickabaugh et al., 2004). Infection with an ORF50.stop virus is difficult as this virus
is not replication competent; however in vivo infection shows that in the absence of
RTA viral persistence is established in the lungs, although when measured at d42 lung
viral load is reduced compared to mice infected with wild-type virus. By 4 months
post-infection the situation is reversed, with the ORF50.stop virus resulting in a
higher viral load than the wild-type virus. At no time point was virus detected in the
spleen (Moser et al., 2006). This result suggests that while lytic replication is not
essential to seed persistent virus in the lungs, it may be required in order for the virus
to traffic to the spleen.
Both over- and under-expression of the RTA gene causes a failure in establishment of
latent infection in the spleen. This suggests that initial lytic replication is essential for
virus to traffic to the spleen, and that upon reaching the spleen RTA expression must
be downregulated to allow for normal establishment of latency.
Several other genes have been implicated in the establishment of latency in the spleen.
ORF73 is one of the few viral genes identified as absolutely essential for the
establishment of latency. By homology to the LANA-1 protein of KSHV, the ORF73
gene product is involved in maintenance of the viral episome, and this function has
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been confirmed for the MHV-68 ORF73 in vitro (Fowler et al., 2003). In the absence
of ORF73, MHV-68 fails to establish latency in the spleen following inoculation by
either the intranasal or intraperitoneal route (Fowler et al., 2003). I.p. vaccination
with an ORF73-deficient virus can protect against a later intranasal challenge with
wild-type virus, with no evidence of establishment of latency in either the lung or the
spleen following the challenge (Fowler et al., 2004).
Ml is one of the unique genes of MHV-68. Ml has been suggested to affect
establishment of latency in the spleen following i.p. inoculation. Infection with a virus
where Ml is disrupted by a LacZ cassette results in reduced viral titres at d4 and d9
post-infection; however these results were not reproduced when infecting with an Ml
deletion mutant. This suggests the observed phenotype may be due to the presence of
a large expression cassette in the Ml .LacZ virus rather than a true attribute of the Ml
gene (Clambey et al., 2000).
The M2 gene of MHV-68 is also involved during acute-phase latency. M2 is
dispensable for replication in vitro, but is one of the few viral genes expressed in the
latently infected Sll cell line (Husain et al., 1999). Following intranasal (but not
intraperitoneal) inoculation, M2 is required for establishment of normal viral load.
Infection with an M2-deficient virus results in a 10-fold deficit in viral load compared
to infection with wild-type MHV-68 at 16 days post-infection (Jacoby et al., 2002),
although splenic lymphocytosis is unaffected (Macrae et al., 2003). This suggests that
proliferation of latently infected cells and uninfected cells may occur independently or
are driven by different viral factors. M2 also plays a role in long-term control of viral
load in the spleen, and this is discussed later.
M3 is a broad-spectrum chemokine binding protein, able to bind to CC, CXC, C and
CX3C chemokines (Parry et al., 2000). Expression of M3 can prevent chemokine-
induced chemotaxis and may interfere with the migration of lymphoid cells (Jensen et
al., 2003). M3 is consistently expressed in the spleen from d7 to dlO, with transcripts
rarely detectable by d21 (Simas et al., 1999). Studies where M3 is disrupted by the
presence of a LacZ cassette have shown the virus to be deficient in establishment of
latency - the M3-deficient virus shows evidence of initial lymphoid colonisation, but
entry into germinal centres is impaired, and at dl3 and d21 there is a substantial
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reduction in the number of splenic follicles harbouring virus (Bridgeman et al., 2001).
This suggests a further role for immune evasion in latency amplification; however a
later study where M3 is disrupted by a more subtle process (the insertion of a stop
codon) revealed no requirement for M3 in the spleen (van Berkel et al., 2002).
M4, one of the unique left-hand end genes of MHV-68, is necessary for establishment
of normal viral load in the spleen (Evans et al., 2006; Geere et al., 2006 Townsley et
al., 2004). The M4 ORF encodes a secreted glycoprotein of unknown function (Evans
el al., 2006). While M4 is dispensable for in vitro replication, in vivo in the absence of
the gene splenic viral load is reduced between 10 and 100-fold from as early as 14
days post-infection. This deficit appears to be resolved by 42 days post-infection.
Reports vary as to whether M4 contributes to splenomegaly; however it is clear that
M4 contributes to viral expansion during acute-phase latency.
K3 encodes a protein able to cause inhibition of MHC class I antigen presentation.
Several homologues exist amongst the other gammaherpesviruses, including the K3
and K5 genes of KSHV, the major immediate early protein of BoHV-4 and HVS
ORF12 (Stevenson et al., 2000). MHV-68 K3 is an ER-associated protein able to
ubiquitinate H-2Db, -2Kb, -2Dd and -2Kd, and target them for degradation by the
proteasome (Boname & Stevenson, 2001). K3 is required for expansion of latently
infected cells in germinal centres, and in the absence of the gene a reduction in
infective centres is observed during establishment of latency (dl3 and dl 7) in
conjunction with reduced viral load compared to wild-type virus. The absence of K3
also leads to an increased number of virus-specific CD8+ CTLs (Stevenson et al.,
2002). This suggests that immune evasion of CTLs is an important requirement for
latency expansion in the spleen.
1.3.4.4 Long-Term Viral Persistence in the Spleen
Long-term latency in the spleen is maintained in both memory and germinal centre B
cells (Flano et al., 2002). Low levels of latent virus are also detectable in splenic
macrophages and dendritic cells (Flano et al., 2003), and this maintenance of virus in
non-B cells correlates with other studies demonstrating the persistence of virus in the
spleens of B cell (MuMT)-deficient mice (Week et al., 1996). Maintenance of latency
is dependent on the development of memory B cells, as shown by the progressive loss
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of latency in CD40" B cells (CD40 is required to deliver survival signals to germinal
centre B cells that allows them to become memory B cells) (Kim et al., 2003).
CD4+ T cells are important for long-term control of the infection. MHC class II
mice (I-Ab / ) are constitutively CD4+-deficient. Infection of these mice with MHV-68
initially produces a disease similar to that observed in wild-type mice, with the virus
cleared with only a small delay from the lung, and subsequent establishment of
latency in the spleen. However from d22 onwards virus was consistently detected in
the lungs of the MHC class Ir mice, with increasing titres detected until 135 days
post-infection, by which point most mice had died from a wasting disease (Cardin et
al., 1996). In this situation despite a functional CD8+ T cell population, infection
cannot be controlled (Belz et al., 2003). Viral evasion of CD8+ T cells has been
linked to the development of this wasting syndrome, specifically viral inhibition of
MHC class I antigen presentation by the K3 gene (Stevenson & Efstathiou, 2005).
M2 is required for the long-term control of viral load in the spleen. The requirements
for M2 during establishment of latency were mentioned previously; however despite
an initial reduction in viral load following infection with an M2-deficient virus, viral
load at late time points post-infection (up to d46) is significantly higher than wild-
type virus (Macrae et al., 2003; Jacoby et al., 2002). It would appear that in the later
stages of infection M2 is involved in inhibition or prevention of over-expansion of
virus-infected cells. As this phenotype is not observed following infection with MHV-
76, it is likely dependent on the action of another region of the left-hand end of the
genome.
1.3.4.5 Alternative Sites of Long Term Persistence
Several other sites of long-term viral persistence exist. At three months post-infection
these include the blood, brain, kidney, liver, bone marrow, nasopharyngeal-associated
lymphoreticular tissue (NALT) and lungs. The frequency of genome positive cells in
the majority of these organs and tissues is low - 1/120,000 for bone marrow, and
1/63,000 in the NALT, in contrast to 1/7,700 in the spleen at the same time point
(Flano et al., 2003). It has not been shown conclusively that this virus present at low
levels is not an artefact present as a result of an abortive infectioa
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In 1996 the lung was shown to harbour low levels of viral DNA up to 1 month post¬
infection even in the absence of any detectable infectious virus (Usherwood et al.,
1996b). The presence of virus in the lungs in latent form was later demonstrated by
Stewart et al. (1998). MHV-68 was shown to persist in the lungs of both wild-type
(C57/B16) and B cell deficient (MuMT) mice as late as 12 months post-infection. As
only episomal forms of the virus were detectable, and vtRNAs were detectable by in
situ hybridisation in the absence of indicators of lytic replication (in this case
hybridisation to viral thymidine kinase), this was taken to indicate ongoing latent
infection. Latent virus was detected in both wild-type and MuMT mice, indicating
that persistence in the lung could occur independently of the presence of B cells. The
cell type identified as harbouring the virus in MuMT mice was the epithelial cell.
Further evidence to support the presence of a latent infection in the lung came from
the treatment of infected mice with 4'-S-EtdU (an antiviral compound that causes
inhibition of DNA synthesis by chain termination, in a manner similar to Acyclovir)
for a month prior to sampling of the lungs. Treatment did not abolish the presence of
virus in the lungs of wild-type or MuMT mice up to 2 months post-infection,
indicating viral persistence is maintained even in the absence of lytic replication.
Flano et al. (2003) confirmed the importance of the lung as a site of viral persistence
by demonstrating that the lung has the highest frequency of genome positive cells
(1/21,000) outside the spleen (1/7,700) of any organ investigated thus far. While
agreeing with the findings of Stewart et al. (1998) that the lung is an important site of
latency, this study suggested an alternative site to the epithelial cell as harbouring
latent virus. This study involved the separation of the different populations of lung
cells by FACS and investigation of frequency of genome positive cells. Results
showed while initially all populations (B cells, macrophages, dendritic cells and
"null"' [predominantly stromal and epithelial] cells) harboured virus, long-term
persistence was maintained only in the B cell population. This controversy remains to
be resolved.
1.3.4.6 Reactivation from Latency
At times in the viral life cycle it is predicted that the virus must reactivate from the
latent state to produce new virions for transmission to other hosts. The exact trigger
for reactivation is unknown; however again the RTA gene is known be involved.
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Expression of RTA in the latently infected SI 1 cell line is sufficient to disrupt latency
and initiate lytic gene expression. This ultimately leads to viral DNA replication and
production of infectious viral particles (Wu et al., 2000).
The type I interferon response is important in control of viral reactivation. Despite
establishing normal levels of latency, IFN-a/p-Rv" mice display substantially higher
levels of reactivation in both the spleen (5-fold) and PECs (40-fold) than
immunocompetent mice at 28 days post-infection. In vivo depletion of IFN-a/p in
wild-type mice prior to sampling produces a similar result, with depleted mice
showing greater levels of reactivation than undepleted mice. However at later time
points (161 d p i.) the role of type I interferon appears to diminish, with both wild-
type and IFN-a/p-R"7" mice showing similar levels of virus reactivation (Barton et al.,
2005).
Type II interferon is similarly involved in control of viral reactivation. In vitro
experiments have demonstrated that latently infected cells reactivate virus at reduced
levels when incubated in the presence of IFNy. In vivo depletion of IFNy following
establishment of latency increases the frequency of cells that reactivate virus,
confirming the role of type II interferon in control of reactivation from latency in
PECs (Steed etal., 2006).
In the absence of a functional type II interferon response, reactivation is essential for
persistent replication of MHV-68. Infection of IFNy" " mice with reactivation-deficient
viruses (Mil- and v-cyclin-deficient viruses, see below for details) results in
significantly lower levels of persistent replication in the PECs. This suggests
persistent replication in IFNy" " mice is a distinct process to acute replication, with
different genetic requirements (Gangappa etal., 2002).
Reactivation is not an essential factor in maintaining long-term viral load in the
memory B cells of the spleen. Infection of wild-type mice with a reactivation-
deficient virus does not affect viral load in the spleen at late time points (up to 6
months) post-infection. In contrast, B cell deficient mice are unable to maintain viral
load in the absence of reactivation, indicating that viral reactivation is only essential
in the absence of B cells (van Dyk et al., 2003).
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Several viral genes have been implicated in reactivation.
ORF72 (v-cyclin) is a homologue of mammalian D-type cyclins. V-cyclin is required
for reactivation from latency in both splenocytes and PECs (van Dyk et al., 2000). As
mentioned previously, failure to reactivate from latency has no bearing on long-term
viral load in the spleens of immunocompetent mice (van Dyk et al., 2003). MHV-68
v-cyclin can bind to cellular cdk2 and cdc2, and through interactions with these
proteins can drive the cell into S phase (Upton et al., 2005), a stage of the cell cycle
conducive to viral replication.
ORF74 has previously been identified as a latency-associated transcript (Virgin et al.,
1999), and by homology to KSHV and HVS has been identified as a G protein-
coupled receptor (GPCR). ORF74 is expressed at late time points post-infection (up to
10 months), but is one of the rare genes where transcription occurs predominantly in
the lungs and less frequently in the spleen. MHV-68 ORF74 has transforming ability
in vitro, an ability also observed in the KSHV GPCR (Wakeling et al., 2001).
Disruption of ORF74 leads to a reduction in reactivation from latency (Moorman et
al., 2003b).
Ml 1 is a partial bcl-2 homologue, containing the anti-apoptotic but not the pro-
apoptotic capabilities of bcl-2 (Wang et al., 1999). As with ORF74, Mil has been
identified as a latency-associated transcript, and can be detected as a bicistronic
transcript with ORF74 (Virgin et al., 1999; Wakeling et al., 2001). Perhaps
unsurprisingly given its association with ORF74, Mil is another gene expressed at
relatively high levels in the lung at late time points post-infection (Roy et al., 2000).
Disruption of Ml 1 does not affect establishment of latency in the spleen or the PECs,
but reactivation from the PECs is 4-5 fold less efficient than wild-type virus
(Gangappa etal., 2002).
The Ml gene of MHV-68 has been implicated in control of viral reactivation.
Sequence analysis shows putative homology to a poxvirus serpin homologue (Virgin
et al, 1997), although the MHV-68 Ml gene lacks certain conserved regions
important for serpin function (Clambey et al., 2000). Following deletion of Ml, the
virus exhibits enhanced reactivation from latency in the PECs and the spleen at d42-
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50 (Clambey et al., 2000). This suggests Ml plays an important role in suppression or
control of viral reactivation.
1.3.4.7 MHV-68 Association with Lymphoproliferative Disease
Long-term in vivo infection can produce lymphoproliferative disease in mice. Over
the course of a 3 year study, 9% of mice developed lymphoproliferative disease.
These disorders predominantly affected the spleen, mesenteric lymph nodes, liver,
lung and kidney, and clinical signs of illness were detectable from 165 to 825 days
post-infection. Development of lymphomas was associated with an increased number
of latently infected genome-positive cells compared to latently infected but clinically
normal mice. Occasional positive cells resembling lymphoid cells were seen in the
tissue parenchyma, suggesting a possible route of spread (Sunil-Chandra et al, 1994).
Host factors have been identified that control development of lymphoproliferative
disease - infection of BALB mice deficient in p2-microglobulin (and hence deficient
in MHC class I antigen presentation) results in development of disease at a
significantly higher rate (67%) and at earlier time points than in wild-type BALB/c
mice (22%) (Tarakanova et al, 2005).
1.3.5 Other Strains of Murid Herpesvirus-4
The isolation of a number of related viruses at the same time as MHV-68 has
provided opportunities to investigate naturally occurring deletion mutants of MHV-68
that are able to persist in vivo.
1.3.5.1 MHV-76
MHV-76 was isolated from the yellow-necked wood mouse (Apodemus flavicollis)
(Blaskovic et al., 1980). Characterisation of this strain of MHV-4 showed the viral
genome is essentially identical to MHV-68, with the exception of a deletion of the
first 9,538 bp at the left-hand end of the unique region of the genome. This region
contains the genes Ml, M2 and M3; most of the 5' end of M4, and the 8 vtRNA-like
molecules. MHV-76 most likely arose during in vitro culture of MHV-68 - the
genome of MHV-76 is identical over several thousand base pairs to MHV-68,
indicating an extremely close relationship. In vitro growth of MHV-76 shows no
significant difference to growth of MHV-68, indicating that none of the genes
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contained in the missing region are essential for replication (Macrae et al., 2001;
Clambey et al., 2002).
In vivo MHV-76 replicates to lower levels in the lung than MHV-68, viral titres peak
slightly earlier (d4 rather than d6), and is cleared more rapidly (dlO rather than dl2).
Splenomegaly is reduced compared to an MHV-68 infection, and latency is
established at much lower levels. At late time points post-infection (up to 5 months
p.i.) MHV-76 is able to persist in the spleen but less efficiently in the lung (Macrae et
al., 2001).
The inflammatory response to MHV-76 is much greater in the lungs during acute
infection than the response to MHV-68. This response starts earlier and is much more
severe, although it is resolved with similar kinetics. No obvious differences have been
observed in the spleen (Macrae et al., 2001).
These results indicate that in the left hand region of the genome is a factor involved
during acute replication in the lung, and a factor potentially involved in immune
evasion; there is also a factor involved in driving splenomegaly, and a factor involved
in establishment of latency in the spleen. There may also be a factor involved in long-
term persistence in the lung. Work is ongoing to establish the exact role of the unique
genes and the tRNAs in pathogenesis (as mentioned previously). It is possible that
some of the features of MHV-76 infection may be due to a combination of unique
genes, as no single gene mutation can account for some of the characteristics of
infection.
It is also possible that factors exist in the left-hand end of the genome that have yet to
be characterised. Work by Dutia et al. (2004) has identified two transcripts of 4.3 and
3.2 kb that do not correspond to any previously identified transcript. These may
contribute to viral pathogenesis, and the deletion of the left-hand end of the genome in
MHV-76 may abolish these transcripts, accounting for some of the differences
between MHV-68 and MHV-76.
1.3.5.2 MHV-72
MHV-72 was isolated from the bank vole (Clethrionomys glareolus) (Blaskovic et al.,
1980). This virus lacks approximately 7000 bp of unique sequence from the left-hand
end of the genome. The remaining sequence is very similar to the genome of MHV-
68; however MHV-72 lacks genes M1-M3 as well as the viral tRNA-like molecules
(Oda et al., 2005).
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In vivo infection with MHV-72 fails to cause splenomegaly up to 1 month post¬
infection. This is similar to the phenotype of a mutant virus, MHV-76inM4, where the
M4 gene has been inserted into the genome of MHV-76 (Townsley el al., 2004),
resulting in a similar genome composition to MHV-72. This confirms that M4 is not
involved in induction of splenomegaly.
However the inclusion of approximately 2.5 kb in the genome of MHV-72 that is
absent in the genome of MHV-76 confers on MHV-72 the ability to induce tumour
formation and lymphoproliferative disease, a characteristic not observed in MHV-76
infection (Oda el al., 2005). This suggests that either M4 or the sequence 5' of the
ORF has tumorigenic properties. A very similar isolate to MHV-72, MHV-Sumava,
also possesses the ability to cause tumour formation in vivo (Mistrikova et al., 2004).
1.3.5.3 MHV-60
MHV-60 is the third virus along with MHV-68 and MHV-72 to be isolated from the
bank vole (Blaskovic et al., 1980). Unlike MHV-76, MHV-60 is able to induce
splenomegaly and is also implicated in development of lymphoproliferative disorders
and/or tumours (Pappova et al., 2004).
1.4 Project Outline
As shown above, the in vivo pathogenesis of MHV-68 has been extensively studied.
However there remain a number of factors about which relatively little is known. The
aim of the project was to further the understanding of MHV-68 pathogenesis in three
separate but related areas: firstly in the study of MHV-68 persistence in the lung, and
the viral genes required for this process; secondly in the study of an MHV-68 mutant
carrying a mutation in an apparently non-coding region of the left end of the genome
that causes altered pathology during acute infection of the lung; and finally in the
investigation of the role of the viral Ml gene during in vivo infection.
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2.1. Extraction of DNA
2.1.1 .From Bacteria
2.1.1.1 Small scale isolation of plasmid DNA using a QIAprep Miniprep
kit (Qiagen)
Plasmid DNA was purified using a QIAprep spin miniprep kit (QIAGEN, UK)
according to the manufacturers instructions. A single isolated bacterial colony was
transferred to 5 ml of sterile LB containing the required antibiotic (lOOpg/ml, either
ampicillin, kanamycin or chloramphenicol) before overnight incubation at the
appropriate temperature (30°C or 37°C) with orbital shaking. The culture was pelleted
by centrifugation at 4000 x g for 6 minutes and the supernatant discarded. The pellet
was resuspended in 250 pi of buffer PI and transferred to a microfuge tube. 250 pi
buffer P2 was added and the tube contents mixed by inversion. 350 pi buffer N3 was
added and the tube contents mixed by inversion prior to centrifugation for 10 minutes
at -17,900 x g. The resulting supernatant was transferred to a QIAprep spin column
and the DNA bound to the membrane by centrifugation (-17,900 x g, 1 minute). The
membrane was then successively washed with 0.5 ml of buffer PB (-17,900 x g, 1
minute) and 0.75 ml of buffer PE (-17,900 x g, 1 minute) before the membrane was
dried (-17,900 x g, 3 minutes) and the plasmid DNA eluted into 20 pi of buffer EB.
2.1.1.2 Large Scale Preparation of Plasmid DNA (Maxiprep)
Large scale preparation of plasmid DNA was carried out using a Qiagen Plasmid
Maxi kit. Briefly, following a modified alkaline lysis procedure the plasmid DNA is
bound to QIAGEN Anion-Exchange Resin under low-salt low-pH conditions. RNA
and proteins are removed by medium-salt washing and plasmid DNA is then eluted in
a high-salt buffer. Finally the DNA is concentrated and desalted by isopropanol
precipitation.
A single colony was used to inoculate 5mls of LB containing the appropriate
antibiotic. Following incubation for 8 hours at 37°C with orbital shaking the culture
was then diluted 1 in 50 in fresh LB (with antibiotic) to a final volume of 250 ml. This
culture was incubated at 37°C with orbital shaking for 16 hours. Cells were pelleted
by centrifugation at 6000 x g for 15 minutes at 4°C. Resuspension in 10 ml of buffer
PI (50 mM Tris-Cl; 10 mM EDTA; 100 pg/ml RNase A) was followed by lysis with
the addition of 10 ml buffer P2 (200 mM NaOH; 1% SDS (w/v)) followed by a 5
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minute incubation at room temperature. This reaction was neutralized by the addition
of 10 ml pre-chilled buffer P3 (3.0 M potassium acetate, pH 5.5) followed by a 20
minute incubation on ice. The cell lysate was then centrifuged at 4°C and 20,000 rpm
for 30 minutes. The supernatant containing the plasmid DNA was removed and
centrifuged again (4°C, 20,000 rpm, 15 minutes). During this period a Qiagen-tip 500
anion-exchange column was equilibrated by the addition of 10 ml buffer QBT (750
mM NaCl; 50 mM MOPS, pH 7; 15% isopropanol (v/v); 0.15% Triton® X-100(v/v)).
Addition of the lysate to the Qiagen-tip 500 was followed by two washes of the
column with 30 ml buffer QC (1.0 M NaCl; 50 mM MOPS, pH 7; 15% isopropanol
(v/v)). DNA was eluted in 15 ml buffer QF (1.25 M NaCl; 50 mM Tris-Cl, pH 8.5;
15% isopropanol (v/v)), precipitated by the addition of 10.5 ml isopropanol and
centrifuged at 15,000 x g for 30 minutes at 4°C to pellet the DNA. The pellet was
washed in 70% ethanol (v/v) and centrifuged again at 15,000 x g for 10 minutes.
Following removal of the ethanol the plasmid DNA was resuspended in 200 pi Tris-
EDTA (pH 8.0).
2.1.1.3 Small Scale Isolation of BAC DNA using a PhasePrep BAC DNA
kit (Sigma)
BAC DNA was purified using the PhasePrep BAC DNA kit according to the
manufacturer's instructions. A single colony was added to 10 ml LB containing the
appropriate antibiotic and the cells were grown overnight at 37°C with orbital
shaking. Cells were pelleted by centrifugation at 5000 x g for 10 minutes and
resuspended in 250 pi resuspension buffer. The bacteria were lysed by addition of 250
pi lysis buffer with a 5 minute incubation period at room temperature. Addition of
250 pi chilled neutralisation buffer with a 5 minute incubation period on ice
terminated the lysis reaction. The sample was then centrifuged at 16,000 x g for 5
minutes at 4°C to pellet the cell debris. Supernatant was then transferred to a fresh
tube and 450 pi isopropanol added to precipitate the DNA. The sample was
centrifuged at 16,000 x g for 20 minutes at 4°C to pellet the DNA. The pellet was
washed in 70% ethanol and resuspended in 500 pi elution solution. Residual RNA
was digested by the addition of 1 pi of RNase cocktail followed by a 5 minute
incubation at 60°C. 40 pi sodium acetate buffer solution (3 M, pH 7.0) was added to
adjust the salt concentration. Endotoxins were removed by the addition of 100 pi
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endotoxin removal solution followed by a 5 minute incubation on ice then a 5 minute
incubation at 37°C. The sample was centrifuged for 3 minutes at 16,000 x g to
separate the phases, and the clear upper phase containing the BAC DNA was
transferred to a fresh tube. DNA was precipitated by the addition of 540 pi DNA
precipitation solution and pelleted by centrifugation at 16,000 x g for 20 minutes at
4°C. The pellet was washed with 70% ethanol, centrifuged again at 16,000 x g for 5
minutes at 4°C and the supernatant discarded. The pellet was allowed to air dry for 5
minutes to remove any excess ethanol before resuspension in 15 pi of dtDO.
2.1.2 From Animal Tissues
2.1.2.1 Extraction of DNA from Animal Tissues using a Qiagen DNeasy
Tissue Kit
Animal tissues previously frozen and stored at -80°C were defrosted and the DNA
extracted according to the manufacturer's instructions. Briefly, up to 25 mg tissue (10
mg if extracting DNA from spleen) was incubated overnight at 55°C in Buffer ATL in
the presence of proteinase K (0.4 mg) to lyse the cells. Following addition of 200 pi
Buffer AL samples were incubated at 70°C for 10 minutes. Addition of 200 pi ethanol
precipitated the DNA and the lysate was loaded onto the DNeasy mini column.
Centrifugation at 6000 x g for 1 minute bound the DNA to the membrane. The
membrane was washed once with buffer AW1 (6000 x g for 1 minute) and once with
buffer AW2 (14,000 x g for 3 minutes to allow the membrane to dry). DNA was
eluted by addition of a total of 200 pi buffer AE.
2.1.2.2 Extraction of DNA from Whole Lungs
The protocol was adapted from Molecular Cloning: A Laboratory Manual (Sambrook
& Russell). Lungs were homogenised in 10 volumes (w/v) of lysis buffer (10 mM
Tris-Cl, pH 8.0; 0.1M EDTA, pH 8.0; 0.5% (w/v) SDS). Proteinase K was added to a
final concentration of 100 pg/ml and the lysate was incubated overnight at 50°C in a
sterile 15 ml polypropylene tube (Nunc). Approximately 200 pi of the lysate was then
treated using the Qiagen DNeasy Tissue Kit as stated above, starting from the addition
of buffer AL.
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2.1.2.3 Modification of "Extraction of DNA from animal tissues using a
Qiagen DNeasy Tissue Kit" for use with Lung Homogenate
Lungs were previously homogenised in 2 ml Glasgow's Medium and stored at -80°C
until required. 400 pi homogenate was lysed overnight at 55°C in 0.8 mg proteinase K
and 180 pi buffer ATL. Samples were then processed as before.
2.2. Manipulation of DNA
2.2.1 DNA Digestion with Restriction Endonucleases
Restriction enzymes were purchased from New England Biolabs and were used in
conjunction with the manufacturers buffer. Digests were performed for 3 hours in a
10-50 pi final volume at a temperature recommended by the manufacturer (usually
37°C). 10 units of restriction endonuclease were used per reaction. For all reactions
the volume of enzyme was always less than 10% of the final reaction volume. At the
end of the digestion period the enzyme was inactivated by heating for 15 minutes at
70°C.
2.2.2 Blunt Ending Restriction Fragments
T4 DNA Polymerase (Invitrogen) was used to fill the restriction endonuclease
termini. 5 units of polymerase were used in conjunction with the manufacturers buffer
to incorporate dNTPs (Roche) at a concentration of 1 mM into the ends of the
fragment. Reaction volume was made up to 100 pi using sterile distilled water
(Sigma). The reaction was performed for 15 minutes at 11°C.
2.2.3 DNA Purification
DNA was purified by phenol: chloroform extraction. A phenol:chloroform:iso-amyl
alcohol mixture (25:24:1 ratio respectively) equilibrated to pH 7.8 was added to an
equivalent volume of DNA solution in the presence of 0.1 volumes 3 M sodium
acetate (pH 5.2) and vortexed thoroughly. Following centrifugation at >15,000 x g for
4 minutes, the aqueous phase was removed whilst avoiding contamination with either
the organic phase or interphase. The aqueous phase was dispensed to a fresh tube and
an equivalent volume of chloroform added. The sample was then subject to one round
of chloroform extraction to remove any contaminating phenol.
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2.2.4 Ethanol Precipitation
DNA was precipitated by the addition of 2.5 volumes of ice-cold 96% ethanol (v/v)
directly to the sample. The sample was vortexed prior to incubation at -20°C for 1
hour to enhance precipitation. DNA was recovered by centrifugation for 20 minutes at
17,000 x g. The supernatant was discarded and 1 volume of 70% ethanol (v/v) was
added to the sample before a further centrifugation step (4 minutes, 17,000 x g). The
supernatant was removed and the open tube was left at 37°C until any remaining
ethanol evaporated. The DNA pellet was resuspended in the required volume of
dH20.
2.2.5 Ligation of Blunt-Ended DNA
T4 DNA ligase (Promega) was used in conjunction with the manufacturers buffer to
attach linker sequences to blunt-end DNA fragments (see appendix for linker
sequences). 500 picomoles of linker were added to 1 pg of fragment and ligation was
carried out overnight at 17°C in the presence of 3 units of T4 ligase in a final volume
of 20 pi. The reaction was terminated by heating at 70°C for 15 minutes.
2.2.6 Agarose Gel Electrophoresis
2.2.6.1 Standard Protocol
DNA was electrophoresed on gels consisting of 1% agarose (SeaKem, Flowgen, UK).
Gels were cast with TAE buffer containing 0.5 pg/ml (w/v) ethidium bromide (Sigma,
UK). DNA samples were diluted to a final volume of 20 pi with dH20 before the
addition of 0.1 volumes of loading buffer per sample (15% (w/v) Ficoll type 400 and
0.25% (w/v) orange G in TAE buffer). Electrophoresis was performed at 50 V in a
horizontal electrophoresis apparatus containing TAE buffer. DNA fragment sizes
were estimated by comparison to known DNA molecular weight standards using 2-
log DNA ladder (New England Biolabs). Following electrophoresis, agarose gels
were visualized with a short wave UV transilluminator.
2.2.6.2 For Separation of BAC DNA Digested Fragments
DNA was electrophoresed on gels consisting of 0.8% agarose and cast with TAE
buffer. DNA samples were diluted to a final volume of 20 pi with dH20 before the
addition of 0.1 volumes of loading buffer per sample (as above). Electrophoresis was
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performed at 40 V in a horizontal electrophoresis apparatus containing TAE buffer.
DNA fragment sizes were estimated by comparison to known DNA molecular weight
standards using 2-log DNA ladder (New England Biolabs). Following electrophoresis,
agarose gels were post-stained by immersion in 1 1 TAE containing 100 pi ethidium
bromide for 90 minutes with gentle agitation. Non-specific staining was removed by
washing twice in TAE buffer for 1 hour with gentle agitation. Gels were then
visualized with a short wave UV transilluminator.
2.2.7 Isolation of DNA Fragments from Agarose using a QIAquick Gel
Extraction kit (Qiagen)
DNA fragments of interest were excised with a sterile scalpel blade under long-wave
UV light. The gel fragment was placed into a microfuge tube and incubated for 10
minutes at 50°C in 3 volumes (w/v) of buffer QG (100 mg -100 pi). Following
incubation 1 gel volume (w/v) of isopropanol was added and the mixture transferred
to a QIAquick spin column. Centrifugation (17,900 x g, 1 minute) bound the DNA to
the silica membrane. The membrane was then successively washed with 0.5ml of
buffer QG and 0.75ml of buffer PE before the membrane was dried (17,900 x g, 3
minutes) and the DNA eluted into 20 pi of buffer EB.
2.2.8 Ligation of DNA Fragments into Vector Plasmids
Ligations were performed with approximately 100 ng of vector DNA, with variable
concentrations of insert DNA such that the insert to vector ratio was typically 3:1.
Reactions contained 3 units of T4 ligase in conjunction with the manufacturers buffer
and were made up to a final volume of 10 pi with dfUO. Ligation reactions were
incubated overnight at 17°C.
2.2.9 Quantification of DNA
DNA concentration was assessed by spectrophotometry (CE 2041, Cecil Instruments).
DNA was diluted 1 in 100 in dtBO and absorbance measured at wavelengths of 260
nm and 280 nm. The concentrations of the unknown samples were calculated using
the equation: OD260 x 50 x 100 = DNA concentration (ng/pl).
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2.2.10 Southern Blotting
2.2.10.1 Extraction of High-Molecular Weight Viral DNA
BHK cells were infected at an MOI of 1 and incubated for 90 minutes at 37°C on an
orbital shaker (225 rpm). Cells were added to T175 flasks (1 x 107 cells/flask) in a
final volume of 40 ml and incubated for 6 days at 37°C. Infected cells were removed
with a cell scraper (Nunc) and cell suspensions pooled into 250 ml polypropylene
conical centrifuge flasks. Suspensions were spun for at 1912 x g for 20 minutes at 4°C
to pellet the cells. The pellet was resuspended in 4 ml cold sterile PBS and dounce
homogenised 20 times on ice. The homogenate was then transferred to a universal and
centrifuged at 1912 x g for 20 minutes at 4°C. The supernatant was then stored on ice
while the pellet was resuspended again in 1ml of cold sterile PBS and dounce
homogenised 20 times. After centrifugation again at 1912 x g, 20 minutes, 4°C the
supernatant was added to the previously saved supernatant and the pellet was
discarded.
Virus was purified further by ultracentrifugation through 20% D-sorbitol. 30 ml of
20% D-sorbitol in sterile PBS were placed in SW28 thin walled tubes and virus
supernatant was layered on top. Tubes were filled to the brim with SPBS. Tubes were
ultracentrifuged using a Beckman L8-70M at 28,000rpm for 80 minutes. The
supernatant was discarded and the pellet was resuspended in 0.5 ml 50 mM Tris pH
8.0.
Viral DNA was extracted using high molecular weight buffer (0.25 M EDTA, 0.5%
SDS, 0.2 M Tris pH 8.0). 5 ml of buffer was added along with proteinase K (100
pg/ml) and samples were incubated overnight at 53°C.
An equal volume of phenol:chloroform:IAA (25:24:1) was added and samples were
mixed on a tilting platform for 30 minutes at room temperature. Centrifugation at
1500 x g for 5 minutes separated the mixture. The aqueous phase containing viral
DNA was retained, and the phenol :chloroform extraction was repeated a further 3
times. After the fourth centrifugation the aqueous phase was added to an equal
volume of chloroform and was mixed and centrifuged as before. 1/3 volume of
ammonium acetate (7.5 M) was then added to the aqueous phase, followed by 2
volumes of 96% ethanol at room temperature. Samples were mixed gently and
incubated at -20°C until a precipitate appeared. After transfer to a glass 30 ml corex
tube samples were centrifuged at 8000 x g for 30 minutes at 4°C. Supernatant was
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removed and samples were washed 3 subsequent times in 70% ethanol with
centrifugation at 8000 x g for 10 minutes at 4°C. After briefly allowing the pellet to
air dry the sample was resuspended in 400 pi TE buffer (pH 8.0) and stored at 4°C
until required.
2.2.10.2 Digestion of High Molecular Weight DNA
10 pg DNA was digested by the addition of 100 U of the appropriate enzyme and 40
pi of the corresponding enzyme buffer and made up to a final volume of 400 pi using
H2O. Samples were incubated for 6 hours at the appropriate temperature.
DNA was reprecipitated by the addition of 2 volumes 96% ethanol and placed at -
20°C for 30 minutes. Samples were centrifuged at 10,000 x g for 20 minutes to pellet
the DNA. Pellets were washed twice with 70% ethanol (with centrifugation at 10,000
x g for 10 minutes). The supernatant was discarded and the pellet was briefly allowed
to air dry before resuspension in 10 pi TE buffer (pH 8.0).
2.2.10.3 Electrophoresis and Transfer to Blot
Loading buffer was added to samples prior to separation of DNA fragments on a 0.7%
w/v agarose-TAE gel (15 cm) run at 4 v/cm. The gel was rinsed in deionised H2O and
transferred into denaturation solution (0.5M NaOH, 1.5M NaCl) for 45 minutes with
gentle agitation. Following a second rinse in dHhO the gel was transferred into
neutralisation buffer (1M Tris-HCl (pH 7.5), 1.5M NaCl) for 25 minutes with gentle
agitation. Buffer was removed and replaced with fresh neutralisation buffer for
another 20 minutes. For transfer to the nylon membrane the apparatus was set up as
follows: a large electrophoresis tank (BioRad, UK) was partially filled with lOx SSC.
Two layers of 3MM filter paper (Whatman), presoaked in lOx SSC, were placed in
the tank so the ends were immersed in the lOx SSC. The gel was placed face-down on
the filter paper and a single sheet of uncharged nylon membrane (Hybond N+,
Amersham Biosciences, UK), pre-wet for 5 minutes in dtUO, was placed on top of
the gel. This was covered by three layers of filter paper (pre-soaked in lOx SSC) cut
to the size of the gel. The gel was surrounded by parafilm to prevent short-circuiting
of the blotting apparatus. A stack of dry paper towels was placed on top of the filter
paper to ensure capillary transfer of the DNA. A glass plate with a 500g weight on top
was placed on top of the towels to ensure uniform pressure and even transfer of the
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DNA to the membrane. Following overnight transfer the membrane was removed and
the DNA was cross-linked to the membrane using a Stratalinker 1200 (Stratagene,
UK). The membrane was then wrapped in saran wrap and stored at -70°C until
required.
2.2.10.4 Radiolabelling of a dsDNA Probe
25-50ng of the dsDNA to be used as the probe was denatured by heating at 100°C for
2 minutes. The volume was made up to 45 pi using TE buffer and the sample was
placed on ice. DNA was then added to 1 ready-to-go DNA labelling bead (Amersham,
UK) and left to dissolve. 5 pi (a-32p)dCTP (2000Ci/mmol) was added to the sample
and mixed gently by pipetting. The mixture was incubated for 30 minutes at 37°C and
subsequently denatured by heating at 100°C for 2 minutes.
2.2.10.5 Purification of the Probe
Micro-bio-spin chromatography columns (BioRad) were used according to the
manufacturer's instructions. Briefly the tip of the column was removed and the
column was placed in a 1.5 ml microfuge tube prior to centrifugation for 4 minutes at
1000 x g to remove the buffer solution. After placing the column in a clean 1.5 ml
eppendorf tube the probe was added to the centre of the column and centrifuged for 4
minutes at 1000 x g. The used column was discarded, leaving the labelled probe in the
microfuge tube.
2.2.10.6 Prehybridisation and Hybridisation
Ultrahyb buffer (Ambion) was prewarmed to 68°C. The membrane was transferred to
a roller bottle and 10 ml of preheated Ultrahyb buffer (Ultrahyb) was added.
Prehybridisation was carried out for 30 minute at 42°C.
For hybridisation 25 pi of the probe was added to the roller bottle and hybridisation
was carried out overnight at 42°C. High-stringency washes were used to remove any
probe bound non-specifically to the membrane. All solutions were preheated to 42°C.
The hybridisation buffer containing the probe was removed and replaced with 2 x
SSC, 0.1% SDS for 2 minutes. This wash buffer was removed and replaced fresh
buffer (2 x SSC, 0.1% SDS) for 5 minutes. This wash was repeated using fresh buffer
again. Finally the blot was washed twice with 0.1 x SSC, 0.1% SDS for 15 minutes.
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All washes were carried out at 42°C. For detection of the radiolabeled probe the
membrane was wrapped in saran wrap and placed in a cassette with a sheet of Kodak
Xomat film (Sigma, UK). The cassette was stored overnight at -80°C prior to
development of the film in an X-ray developer.
2.3 Transformation of Competent Cells with Vector DNA
rp* f rpi f
Escherichia coli (ElectroMAX DH10B cells, Invitrogen, UK) were transformed
with plasmid DNA according to the manufacturers directions. 2.5 pi of ligation
reaction was added to 20 pi of electrocompetent cell suspension. The mixture was
then electroporated using a BioRad MicroPulser. 1 ml of S.O.C. medium was then
added to the cell suspension before incubation for 2 hours at 30°C with orbital
shaking. The suspension was then centrifuged for 1 minute at 4000 x g to pellet the
cells and the excess media removed. Cells were then resuspended in a small volume
(approx 10 pi) of S.O.C. medium and plated onto an LB agar plate containing the
appropriate antibiotic (30 pg/ml kanamycin, Sigma, UK). Plates were incubated in an
inverted orientation overnight at 30°C, before long-term storage at 4°C (up to six
weeks).
2.4. RNA Extraction and Manipulation
2.4.1 RNA Extraction from Cells Cultured In Vitro using a Qiagen RNeasy
Mini Kit
RNA was isolated from cells cultured in vitro according to the manufacturer's
protocol. Cells were lysed directly in the culture dish by the addition of 1 volume (600
pi) Buffer RTL (containing P-mercaptoethanol). Samples were homogenised by
passage through a QLAshredder spin column at 18,000 x g for 2 minutes. 1 starting
volume of 70% ethanol was added to adjust binding conditions. Samples were then
loaded onto RNeasy mini columns and centrifuged for 15 seconds at 8000 x g. The
RNA was washed once with Buffer RW1 (8000 x g, 15 seconds) and once with Buffer
RPE (8000 x g, 15 seconds). The membrane was washed one final time in Buffer RPE
and centrifuged at 18,000 x g for 2 minutes to dry the membrane. RNA was eluted by
the addition of 30 pi RNase-free H2O to the spin column followed by centrifugation at
8000 x g for 1 minute.
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2.4.2 RNA Extraction from Animal Tissues using a Qiagen RNeasy Mini
Kit
Samples previously stored at -80°C in RNAlater (Ambion) were defrosted and a 20
pg section was removed from the RNAlaler and homogenised in 1 volume (600 pi)
Buffer RTL (containing P-mercaptoethanol). The protocol was then followed as given
previously for extraction of RNA from cultured cells (section 2.4.1).
2.4.3 Quantification of RNA
RNA was quantified using spectrophotometry as for DNA. The concentrations of
RNA in the unknown samples were calculated using the equation: OD260 x 40 x 100 =
RNA concentration (ng/pl).
2.4.4 Reverse Transcription of RNA
RNA was initially treated using a DNA-free DNase kit (Ambion) to remove any
contaminating DNA. The reaction consisted of 5 pg of RNA, 1 pi DNase I buffer and
2 units of DNase I and the mixture was made up to a final volume of 13 pi using
nuclease-free water. Samples were incubated for 1 hour at 37°C. The DNase enzyme
was inactivated by the addition of 1.3 pi DNase Inactivation Reagent followed by
incubation for 2 minutes at room temperature. Samples were then spun for 1 minute at
6000 x g to pellet the Inactivation Reagent.
5.5 pi DNase-treated RNA was used in the subsequent reverse transcription step, with
the remaining RNA to be kept for use as a -RT control. RNA was added to 1 pi
Oligo-dT primer (Invitrogen), 1 pi lOmM dNTPs (Invitrogen) and 8.5 pi of nuclease-
free H2O (Ambion). Samples were incubated for 5 minutes at 65°C followed by a
brief cooling period on ice. 4 pi 5x First Strand Buffer, 2 pi 0.1 M DTT and 1 pi
RNaseOUT (Invitrogen) were added to the RNA and the samples were incubated for
10 minutes at room temperature and 2 minutes at 42°C. lpl Superscript II Reverse
Transcriptase was then added and samples were incubated at 42°C for 1 hour. The
reverse transcriptase was inactivated by incubation at 70°C for 15 minutes.
2.4.5 Northern Blotting
2.4.5.1 RNA Extraction from Cells Cultured In Vitro using TRI Reagent
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For extraction of large quantities of RNA from cultured cells RNAwiz (Ambion, UK)
was used. 4-5 x 107 cells were harvested by trypsinisation and frozen at -80°C until
required. Cells were later defrosted and the RNA isolated according to the protocol
given by the manufacturer. Briefly cells were resuspended in 5 ml TRI reagent. The
mixture was incubated for 5 minutes at room temperature to dissociate the
nucleoproteins from the nucleic acids. 1 ml of chloroform was added, samples were
shaken for 20 seconds and left to incubate at room temperature for 10 minutes. The
mixture was centrifuged at 12,000 x g for 15 minutes at 4°C and the resulting aqueous
phase transferred into a clean tube. 5 ml DEPC-treated H2O was added, followed by 5
ml isopropanol. After mixing samples were incubated at room temperature for 10
minutes. Samples were spun for 15 minutes at 10,000 x g and 4°C to pellet the RNA.
The supernatant was removed and the pellet washed by the addition of 1 ml 75%
ethanol followed by centrifugation at 10,000 x g for 5 minutes at 4°C. The supernatant
was again removed and pellet was allowed to air dry for 3 minutes. Finally the pellet
was resuspended in 50 pi DEPC-treated H2O.
2.4.5.2 Purification of Poly A+ RNA from Total RNA using a Qiagen
Oligotex mRNA Mini Kit
Up to 0.25 mg of RNA was added to 250 pi Buffer OBB and 15 pi Oligotex
Suspension solution and the final volume made up to 515 pi using RNase-free water.
Samples were incubated at 70°C for 3 minutes to disrupt the secondary structure of
the RNA. Subsequent incubation for 10 minutes at room temperature allowed the
poly-A tails of mRNAs to able to hybridise to a dT oligomer (dCioTw) covalently
linked to the surface of polystyrene-latex particles. The oligotex-mRNA complex was
pelleted by centrifugation for 2 minutes at 18,000 x g and the supernatant removed.
The pellet was resuspended in 400 pi Buffer OW2 and the sample was added to a spin
column. Centrifugation at 18,000 x g for one minute allowed removal of
contaminating unbound rRNA and tRNAs. The spin column was washed again by
addition of 400 pi Buffer OW2 followed by centrifugation at 18,000 x g for one
minute. Poly-A RNA was dissociated from the oligotex particles by the addition of 35
pi hot (70°C) Buffer OEB. Centrifugation at 18,000 x g for one minute eluted the
mRNA. Another 35 pi hot Buffer OEB was added to the column and centrifuged
again to ensure complete elution of mRNA.
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2.4.5.3 Electrophoresis and Blotting
RNA samples were made up in a total volume of 20 pi. 5 pi loading buffer (16 pi
saturated aqueous bromophenol blue, 80 pi EDTA (0.5M, pH 8.0), 720 pi 37%
formaldehyde, 2 ml 100% glycerol, 3.084 ml formamide, 4 ml lOx MOPS buffer, 100
pi dH20) was added to each sample. This was followed by incubation at 65°C for 5
minutes and subsequent chilling on ice. 200 ml 1.2% agarose was melted and cooled
to 65°C whereupon 3.6 ml 37% formaldehyde and 2 pi lOmg/pl ethidium bromide
were added. The gel was run at 30 V for 30 minutes with recirculating running buffer
(100 ml lOx MOPS buffer, 20 ml 37% formaldehyde, made up to 1 1 with RNase-free
H20) prior to loading samples. After loading, samples were electrophoresed at 5-7
V/cm overnight. 5 pg of an RNA molecular weight marker was loaded alongside the
samples as a reference. The gel was then visualised and photographed under short¬
wave UV light before rinsing in RNase-free H20. This was followed by washes in
0.05 M NaOH (20 minutes) and 20 x SSC (40 minutes with agitation). The protocol
then continued as stated previously for southern blotting with the following
alterations: transfer occurred in the presence of 20 x SSC and was allowed to continue
for no more than 4 hours. Paper towels were replaced every 30 minutes to enhance
transfer. After transfer the membrane was soaked in 6 x SSC (5 minutes with
agitation). The RNA was cross-linked to the membrane using a Stratalinker 1200 and
stored at-70°C until required.
2.4.5.4 Prehybridisation and Hybridisation
Northern blots were prehybridised and hybridised as for Southern Blots using dsDNA
probes. After overnight hybridisation the probe solution was removed and replaced
with 1 x SSC, 0.1% SDS at room temperature and washed for 10 minutes in the roller
bottle. This was replaced with 2 x SSC at room temperature and washed for 15
minutes. Successive washes were carried out in 2 x SSC, 0.1% SDS (5 minutes,
twice) and 0.1 x SSC, 0.1% SDS (10 minutes, twice) all at 42°C. The membrane was
exposed to X-ray film using the protocol given for Southern Blotting in section
2.10.6.
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2.5 Polymerase Chain Reaction
2.5.1 Components of Standard PCR Reactions
Standard PCR reactions were typically performed in a 50 pi final volume, and
consisted of
PCR reaction buffer (Invitrogen, UK)
3 mM MgCU (Invitrogen, UK)
100 pM each of dATP, dCTP, dGTP and d l'lP (set of deoxynucleosides, PCR Grade,
Roche)
50 pmol of each primer (MWG Biotech, Germany,)
1 U of Taq DNA polymerase (Invitrogen, UK).
100 ng of template DNA was used for each reaction. PCR reactions were performed
in 0.5ml thermotubes (Abgene) in an Omnigene thermal cycler (Thermohybaid).
Negative control reactions containing dtUO in place of template DNA were always
performed. A modified hot-start procedure was used to increase the specificity of
amplification. Reactions (minus Taq polymerase) were overlaid with mineral oil
(Sigma, UK) before heating to 95°C for 5 minutes. Reactions were held at 80°C while
Taq polymerase was added. PCR programmes typically consisted of 45 seconds
denaturing at 95°C, 45 seconds annealing time at a primer-pair specific temperature
and extension for 2 minutes at 72°C. Following 37 cycles reactions were incubated at
72°C for 10 minutes before cooling to room temperature.
2.6 Real Time PCR
2.6.1 Generation of Standards for Use in Real Time PCR
2.6.1.1 Generation of Standards for Absolute Quantification
2.6.1.1.1 Cloning of PCR Products
• • # #
PCR products were cloned using a TOPO TA Cloning Kit for Sequencing
(Invitrogen) according to the manufacturer's instructions.
Briefly, linearized pCR®4-TOPO® vector (with single 3' thymidine (T) overhangs) is
able to ligate to the PCR insert (with single 3' adenosine (A) residues added by Taq
polymerase during the PCR reaction) by base pairing. Topoisomerase I covalently
linked to the vector is released by the pairing of vector with insert, allowing re-
circularisation of the vector.
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The reaction was carried out using 4 pi of PCR product, 1 pi salt solution (1.2 M
NaCl, 0.06 M MgCl2) and 10 ng pCR®4-TOPO® vector in a final volume of 6 pi. The
reaction mixture was gently mixed and incubated at room temperature for 30 minutes
prior to transformation of One Shot TOP 10 chemically competent cells (Invitrogen,
UK).
2.6.1.1.2 Transformation of One Shot TOP 10 Chemically Competent
E.coli
One Shot TOP 10 chemically competent cells (Invitrogen, UK) were transformed
according to the manufacturers directions. A 50 pi aliquot of competent cells was
thawed on ice and 2 pi of the TOPO cloning reaction added. The mixture was
incubated on ice for 30 minutes prior to heat shocking at 42°C for 30 seconds. The
sample was then immediately replaced on ice and 250 pi S.O.C. medium added
before incubation with agitation at 37°C for 1 hour. 10 pi and 50 pi aliquots were
spread onto LB-kanamycin plates and incubated in an inverted orientation at 37°C
overnight. Colonies were subsequently picked and analyzed further by miniprep and
PCR and/or restriction endonuclease digestion.
2.6.1.1.3 Quantification of Plasmid Copy Number
DNA concentration was assessed by spectrophotometry (CE 2041, Cecil Instruments).
DNA was diluted 1 in 100 in dPUO and absorbance measured at wavelengths of
260nm and 280nm. The concentrations of the unknown samples were calculated using
the equation: OD260 x 50 x 100 = DNA concentration (ng/pl).
The number of copies of plasmid in a microlitre was determined using the following:
The molecular weight of a dsDNA molecule = (number of base pairs) x (660 Da/bp)
Copies DNA per pi = (6.023 x 1023 x mass per pi)/ Molecular weight
n
Appropriate dilutions were then made to give solutions containing 1 x 10 down to 1 x
101 plasmid copies per pi.
2.6.1.2 Generation of Standards for Relative Quantification
A set of primers encompassing the entire region of interest plus approximately 30-40
bp at each end were used to amplify template DNA according to the protocol given
for standard PCR (see section 5). The resulting product was run on a 2% w/v agarose
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gel and the band gel extracted using a Qiagen QiaQuick Gel Extraction Kit according
to the manufacturer's instructions (see section whatever) and eluted into 30 pi buffer
EB. The product was then serially diluted to by a factor of 10 to produce a series of
standards for use in quantitative PCR.
2.6.2 Components of Real Time PCR Reactions
Real time PCR analysis was performed using a Rotorgene (Corbett Research,
Australia) using the intercalating dye SYBR Green to determine levels of dsDNA
product. Reactions were performed in a 20 pi final volume, and consisted of:
PCR reaction buffer containing MgCl2 (20mM)
10 mM each of dATP, dCTP, dGTP and d l'l P (set of deoxynucleosides, PCR Grade,
Roche)
50 pmol of each primer (MWG Biotech, Germany),
0.75 U of FastStart Taq DNA Polymerase (Roche)
0.7 pi of SYBRGreen (Biogene Ltd).
Each reaction contained 100 ng DNA template. Negative reactions performed in
parallel with dFEO used in place of template DNA. Standard dilution reactions were
similarly performed in parallel with plasmid DNA or primary PCR product used as
template. Reactions were carried out in 0.1ml tubes (Corbett Research).
Following a hot start at 95°C for 10 minutes to activate the hot-start Taq polymerase
samples were amplified for 45 cycles. Cycles consisted of 95°C for 30 seconds, 30
seconds at the appropriate anneal temperature for the primer pair (see appendix
whatever) and 72°C for 30 seconds. Reactions were carried out using a RotorGene
3000 (Corbett Research). Fluorescence level was measured at the end of the 72°C
extension phase. After cycle 45 a melt curve analysis was performed to determine the
specificity of PCR products; fluorescence was measured during an incremental
increase of temperature from 65°C to 95°C. All samples including standard dilutions
and negative controls were run in duplicate or triplicate to assess accuracy during
reaction set-up.
2.6.3 Normalisation of Samples
The quality and amount of the template DNA or cDNA was assessed by performing a
real-time PCR reaction on the template using primers for a cellular housekeeping
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gene, and any variation in the results owing to differing amounts or quality of input
DNA was corrected by normalisation.
P-actin was used as a control for normalisation of both DNA and cDNA. Each sample
was allocated a ratio of its p-actin content in relation to the 75th percentile of the P-
actin levels of all samples assayed. This ratio was used to normalise the levels of the
genes of interest (method according to McKimmie, 2005; an example from this work










level of gene x
(Copies/reaction) (Copies/reaction) Column C/71.25 Column B/D
1 10 40 0.561 18
2 50 200 2.807 18
3 12 45 0.632 19
4 10 10 0.14 71
5 8 40 0.561 14
75th percentile 71.25
Table 2.1 Normalisation using a housekeeping gene to determine levels
of gene X (from McKimmie, 2005). Illustrated above is the effect that template
variation can have on apparent levels of the unknown gene. Sample 2 appears to
contain far higher levels of X; however level of the housekeeping gene is far higher
than in any other sample, indicating the elevated level of X is due to a higher amount
of starting template DNA. Normalisation corrects this, revealing sample 2 contains
similar levels of X to those in samples 1, 3 and 5. Conversely the level of starting
template in sample 4 is far lower than other samples, and normalisation reveals the
relative level of X in this sample is elevated compared to the other samples.
The 75th percentile value is used as a reference in place of measures such as the mean
average because this value is less affected by outliers that may skew the results. A
ratio is determined for each sample that measures the deviation of each sample from
the 75th percentile. Levels of the unknown gene (in this case X) are then altered on the
assumption that the ratio of the housekeeping gene to gene X is uniform.
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2.7 Cell Culture
2.7.1 Maintenance of Cell Cultures
All cells were grown at 37°C, 5% humidified CO2 in sterile plasticware (Nunc). Baby
Hamster Kidney fibroblasts (BHK-21) were grown in Glasgow's Modified Eagles
Medium (GMEM) containing 10% new-born calf serum (Invitrogen), 10% tryptose
phosphate broth (Invitrogen), 2mM L-glutamine (Merck BDH), 100 U/ml penicillin
(Merck BDH) and 100 U/ml streptomycin (Merck BDH). Owl Monkey Kidney
epithelial cells (OMK) were maintained in Dulbecco's Modified Eagles Medium
(DMEM) containing 10% fetal calf serum (Invitrogen), 2 mM L-glutamine (Merck
BDH), 100 U/ml penicillin (Merck BDH) and 100 U/ml streptomycin (Merck BDH).
2.7.2 Harvesting and Counting of Cells
Adherent cells were removed from tissue-culture flasks by trypsinisation. Growth
medium was removed and the cells were washed in 0.02% versene. Incubation with
0.25% trypsin (Invitrogen) caused the cells to detach from the plasticware. An equal
volume of fresh medium was added to inactivate the trypsin and cells were
centrifuged for 450 x g for 5 minutes. The supernatant was discarded and the cell
pellet was resuspended in fresh medium. A 50 pi sample was added to an equal
volume of 0.1% trypan blue and unstained cells were counted prior to reseeding.
2.7.3 Reconstitution of Infectious Virus from BAC-cloned MHV-68
Cre 3T3 cells were seeded at 2xl04 cells/well in a 96 well plate. 24 hours post-seeding
cells were transfected with the MHV-68 BAC using Effectene (QLAGEN) according
to the manufacturer's instructions and plates were incubated for 10 days at 37°C with
5% humidified CO2. Infected cells were pipetted up and down to detach them from
the plate and break up any clumps. Following 3 freeze-thaw cycles infected cells were
added to subconfluent 3T3 cells previously seeded in 24 well plates. Plates were then
incubated for 7 days at 37°C with 5% humidified CO2. Wells containing colourless
plaques were selected and infected cells from these wells were harvested again and
passaged twice more through 3T3 cells, first in a 24 well plate and subsequently in a 6
well plate. Virus was then titrated on BHK cells (see section 9.5.1 for method) and
subsequently infected into BHK cells at low MOI. Virus harvested from these cells
was subsequently used to prepare a virus stock.
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2.7.4 Preparation of Virus Stocks
BHK-21s were harvested and counted as described before. Cells were resuspended to
7 • •
a final concentration of 1 x 10 cells/ml and infected with an MOI of 0.001. After
incubation with shaking for 1 hour (37°C, 225 rpm) infected cells were reseeded into
T175 flasks at 4 x 106 cells/flask in a final volume of 40 ml of growth medium. Cells
were then incubated at 37°C until complete cytopathic effect was evident (5-6 days
post-infection). Supernatant was decanted and pooled into 250 ml conical centrifuge
tubes; infected cells were removed from flasks using a cell scraper (Nunc) and added
to the supernatant. After centrifugation (2000 x g at 4°C for 20 minutes) the
supernatant was discarded and cell pellets were resuspended in a minimal volume of
PBS. The cell suspension was then homogenised using a chilled dounce homogeniser
and subsequently sonicated in a glass universal for 15 minutes at. After centrifugation
(2000 x g, 4°C, 20 minutes) the supernatant (containing virus) was decanted into a
fresh universal and stored on ice. The pellet was resuspended in a minimal volume of
PBS and homogenised again with the dounce homogeniser. Following centrifugation
(2000 x g, 4°C, 20 minutes) the supernatant was added to the previously stored
supernatant. Aliquots of the supernatant were frozen and stored at -80°C.
2.7.5 In Vitro Assays
2.7.5.1 Titration of Virus Stocks
BHKs were harvested and counted as before and resuspended to a concentration of 1
1 #
x 10 cells/ml in GMEM. 44 pi virus stock was defrosted and added to 4 ml GMEM
in a sterile plastic bijou and mixed thoroughly to give a 10"1 dilution of virus. Serial
ten-fold dilutions of virus were made by adding 440 pi of the dilution to 3.96 ml of
GMEM. 2 x 106 BFIK-21 cells in a volume of 0.2 ml were added to each dilution and
samples were shaken (225 rpm) for 1 hour at 37°C. 2 ml from each dilution was then
added to 3 ml of medium and plated out into a 60 mm petri dish. The remaining 2 ml
were then plated out in the same way to give a replica. Plates were incubated for 4
days at 37°C, 5% CO2. The medium was discarded and the plates were each fixed
with 3 ml of 10% neutral buffered formalin for at least 30 minutes. The formalin was
then discarded and plates were stained with 0.1% toluidine blue. Plates were scored
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microscopically for cytopathic effect and virus titre was calculated using the equation:
viral titre = (plaque number x dilution)/2.
2.7.5.2 One-Step and Multi-Step Growth Curves
Single- and multi-step growth in vitro was analysed by infection of BHK cells. Cells
in suspension were infected for 90 minutes at an MOI of 5 for single-step or 0.05 for
multi-step. Cells were pellet by centrifugation (450 x g, 5 minutes) and resuspended
in complete Glasgow's medium four times to remove unbound virus. 2 x 106 (one-
step) or 1 x 106 (multi-step) cells were seeded into 24 well plates. At specific time
points post-infection cells were harvested by pipetting up and down several times,
freeze-thawed three times and infectious virus determined by plaque assay. All
infections were performed in duplicate, with each infection titration duplicated.
2.7.6 In Vivo Assays
2.7.6.1 Animal Infections
Animals were purchased from B&K Universal (Hull, UK) or bred in-house. Female
BALB/c mice purchased from B&K Universal were infected at 6-8 weeks of age.
IFNyR-/- mice on a 129/Sv/Ev background and 129 Sv/Ev (wild-type) mice were bred
in-house and infected at 1-3 months of age. All mice were housed in specific
pathogen free conditions. Following halothane anaesthesia mice were infected by
intranasal inoculation with 4 x 105 pfu of virus in a total volume of 40 pi PBS (unless
otherwise stated). At specific times post-infection mice were euthanised by CO2
asphyxiation and specific organs were harvested.
2.7.6.1.1 Lung perfusion
When it was necessary to remove blood from the lungs prior to death mice were kept
under heavy halothane sedation while 30 ml sterile PBS was injected into the right
ventricle. During this procedure the heart would stop beating and the required organs
could then be removed.
2.7.6.2 Titration of Infective Virus in Tissues
For titration of infectious virus in tissues the protocol was identical to that for titration
of virus stocks (section 2.7.5.1) with the following variations: samples were
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homogenised in 1.8 ml medium prior to a freeze-thaw to disrupt cell membranes. The
thawed sample was centrifuged at 2000 x g for 5 minutes to pellet debris. 440 pi
supernatant was then added to 3.96 ml medium and serial dilutions were made and the
protocol continued as before.
2.7.6.3 Infective Centre Assay for the Detection of Latently Infected
Splenocytes
This assay was used to determine the frequency of reactivation of virus from latently
infected cells. Spleens were harvested and stored in 5 ml RPMI medium containing
10% fetal calf serum, 2 mM L-glutamine, 100 U/ml penicillin, 100 U/ml streptomycin
and 50 pM 2-mercaptoethanol. Spleen cells were separated using a scalpel blade to
produce a single-cell suspension in 5 ml RPMI. This was transferred to a pre-rinsed
universal tube and centrifuged at 450 x g for 5 minutes at 4°C. The supernatant was
removed and the pellet was resuspended in the remaining liquid. 1 ml of sterile dt^O
was added to lyse erythrocytes and equilibrium was reestablished by the addition of 9
ml sterile PBS. Any debris was allowed to settle and the cell suspension was then
transferred to another pre-rinsed universal tube. After centrifugation (450 x g, 5
minutes, 4°C) the supernatant was discarded and the pellet resuspended in 5 ml
complete RPMI. Splenocyte cell numbers were determined and 10-fold dilutions were
plated out with 1 x 106 BHK cells (in 5 ml complete RPMI) in 60 mm petri dishes
(Nunc). Each dilution was plated in duplicate. After incubation for 5 days at 37°C
with 5% C02 plates were fixed and counted as before (see section 2.7.5.1).
2.8 Histology
2.8.1 Preparation of Samples for Histology
Mice were euthanised as before without perfusion. Lungs were removed and inflated
by the insertion of a 21-gauge needle into the trachea and injection of 10% neutral
buffered formalin. The trachea was tied off with cotton to prevent escape of formalin
and lungs were stored in 10% neutral buffered formalin until sent for processing to the
Veterinary Pathology Unit, Easter Bush Veterinary Centre. Here samples were
paraffin-embedded and 5 pm sections cut and placed onto uncoated slides. Sections
were stained by staff at Easter Bush with hematoxylin and cosin.
75
Chapter Two Materials & Methods
2.8.2 Immunostaining using a Vectastain ABC kit
Paraffin embedded sections were dewaxed by immersion in xylene for 15 minutes and
rinsed in 100% ethanol for 2 minutes. Slides were treated with 0.3% H2O2 in
methanol for 30 minutes to quench endogenous peroxidase activity. After rehydration
through alcohol (100, 95, 80 then 70% ethanol, 2 minutes for each step) slides were
rinsed twice in dEDO for 1 minute and treated with protease (Sigma, 0.001 g/ml) for 5
minutes. After a 5 minute rinse in TBS slides were blocked for 30 minutes at room
temperature using 5% normal goat serum (NGS, Vectastain) in TBS. Excess blocking
serum was blotted onto a paper towel and replaced with the primary antibody (Rabbit
B polyclonal MHV-68) diluted 1/500 in 2% blocking serum for 60 minutes at room
temperature. After two 2 minute washes in TBS the secondary antibody (goat anti-
rabbit, 0.5% in 2% blocking serum, Vectastain) was added and slides were incubated
for 60 minutes at room temperature. ABC reagent was made according to the
manufacturer's instruction (2 drops A and 2 drops B in 2.5 ml TBS) and left to stand
at room temperature for 30 minutes. Excess secondary antibody was removed by
washing in TBS for 2 minutes and ABC reagent was added to the slides and incubated
for 30 minutes at room temperature. Excess ABC reagent was removed by washing in
TBS for 2 minutes. NovaRed (Vector Labs) was used according to the manufacturer's
instructions to develop the stain. This was followed by two washes of 2 minutes in
dEhO. Slides were counterstained with hematoxylin (Vector Labs)(l minute) and
washed twice in TBS for 2 minutes. Slides were dehydrated by two washes in 100%
ethanol for two minutes, and then cleared by placing in xylene for 2 minutes. Slides
were mounted using Vectamount Permanent Mounting Medium.
2.9 Statistical Analysis
All data were analysed using Graphpad Prism software (Graphpad, San Diego, CA).
Real time data were assessed for statistical significance using the non-parametric
Mann-Whitney test or the Student's t test in Mimtab.
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Appendix
A.1 Oligonucleotides Utilised in the Study
A.1.1 Primers Used for PCR and Real Time PCR








5'-GCG CGG ATC CGA CAC CTG GAG
AAG ATG ATG ATA TTC-3'
5'-CGC GGA ATT CGG TTC TAG AAA







5'-CCA GCC TGT ACT GIT GCC CCT-3'







5'-GTG GCA TCC ATG AAA CTA CA-3'
5'-GTA CTC CTG CTT GCT GAT CC-3'
62 Murine (3-actin
272bp product








5'-TGG CAC TCA AAC TTG GTT GTG G-
3'






5'-CAC CTG AGA TCA AGT CTA-3'





5'-GGC ACA TTT GCT GCA GAA CCC
AG-3'







5'-CGT TGA CAT CCG TAA AGA CC-3'
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A.1.2 Oligonucleotides Utilised Not Including PCR Primers
Name Sequence Modifications
Bamlinker 5'-CGC GGA TCC GCG-3' 5' phosphate
Kpnlinker 5'-GGG TAC CC-3' 5' phosphate
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■=£> = For.vardSequencing Primer
JLm = Reverse Sequencing Primer
Appendix 2.2 pCR®4-TOPO
LqcZu initiation cooon




CACACAGGAA ACAGCTATGA CCATGATTAC GCCAAGC7CA GAATTAACCC TCACTAAAGG
GTGTGTCCTT TG7CGA7AC7 GGTACTAATG CGG77CGAG7 CTTAATTGGG AGTGA'iGTCC





EooR I Mot I
AGGGC GAATTCGc'cG
TCCCG CTTAACCGCC
Ml 3 rowata ( 20) phminfl site
Comments for pCR®4-T0P0®
3956 nucleotides
lac promoter region: bases 2-216
CAP binding site: bases 95-132
RNA polymerase binding site: bases 133-178
Lac repressor binding site: bases 179-199
Start of transcription: base 179
M13 Reverse priming site: bases 205-221
LacZu-ccdB gene fusion: bases 217-810
LacZu portion of fusion: bases 217-497
ccc/B portion of fusion: bases 508-810
T3 priming site: bases 243-262
TOPO® Cloning site: bases 294-295
T7 priming site: bases 328-347
M13 Forward (-20) priming site: bases 355-370
Kanamycin promoter: bases 1021-1070
Kanamycin resistance gene: bases 1159-1953
Ampicillin (to/a) resistance gene: bases 2203-3063 (c)
Ampicillin (to/a) promoter: bases 3064-3160 (c)
pUC origin: bases 3161-3834
(c) = complementary strand
Appendix 2.3 pST76k_SrE
Sstl Asd Pad Fsel
tgagctaactcacattaattgcgttgcgcgaattcgagctcggc 'gcgccttaat taaggccgg cc
ACTCGATTGAGTGTAATTAACGCAACGCGCTTAAGCfrCGAGCCGCGC|3GAAT[faattcc)3gccgg















Appendix 2.4 pBluescript SK-
fl {-) origin 24-330
|j-galactosidase "-fragment 463-816
multiple cloning site 653-760
lac promoter 8 1 7-938
pUC origin 11 58-1 825




pBluescript SK (+/-) Multiple Cloning Site Region
(sequence shown 601-826)
T7 Promoter Kpn I
Apa I
bcoOlOV I






7* — : ►M13 -20 primer binding sile 17 pnmer binding site KS pnmer binding site...
Bspl06 I Not I
Cla I Hind III bcoR V bcoK I Pst I Sma I BamH I Spe I Xba I I bag I BstX I Sac II Sac I
I I I I I I I I I I I I I I
...AT^GATAAGCTTGATATCGAATTCCTGCAGCCCGGGG^ATCCACTAGTTCTAGAGCGGCCGCCACCGCGGTGGAGCTCCA.
...ICS pnmer binding site SK primer binding site
T3 Promoter | -gal »'-frogmont
^ 1 ^ 1
...GCTTTTGTTCCCTTTAGTGAGGGTTAATTTCGAGCTTGGCGTAATCATGGTCATAGCTGTTTCC
^ I 3 pnmor binding site ^ I 3 Reverse pnmer binding site
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0.5% (w/v) yeast extract
1% (w/v) NaCl
1 x LB broth, 1.5% (w/v) bacto-
agar
1 x LB broth, 20 mM glucose, 20
mM MgCL
3 M NaCl, 300 mM sodium
citrate (pH 7.0)
150 mM NaCl, 2.5 mM KC1, 10




1% (w/v) NaCl, 0.025% (w/v)
KC1, 0.4% (w/v) Tris (pH 7.4)
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A.4 Commercial Suppliers of Reagents and Equipment Used in this
Study
ABgene, ABgene UK (Head Office, ABgene House, Blenheim Road, Epsom, KT19
9AP, UK. www.abgene.com
Ambion Inc., Ambion (Europe) Ltd., Ermine Business Park, Spitfire Close,
Huntingdon, Cambridgeshire, PE29 6XY, UK. www.ambion.com
Amersham, Amerhsal Place, Little Chalfont, Buckinghamshire, HP7 9NA, UK
www.amershambiosciences.com
B & K Universal, Grimston, Aldbrough, Hull HU11 4QE, UK, www.bku.com
BioRad Laboratories Ltd., BioRad House, Maylands Avenue, Hemel Hempstead,
Hertfordshire, HP2 7TD, UK www.bio-rad.com
Corbett Research, 14 Hilly Street, Mortlake, Sydney, Australia, NSW 2137
www.corbettlifcscicnce.com
Flowgen, Wilford Industrial Estate, Ruddington Lane, Wilford, Nottingham, NG11
7EP, UK www.flowgen.co.uk
Invitrogen Ltd., 3 Fountain Drive, Inchinnan Business Park, Paisley, PA4 9RF, UK
www.invitrogen.com
Merck BDH, Boulevard Industrial Park, Padge Road, Beeston, Nottingham, NG9
2JR, UK www.merckbiosciences.co.iik
MWG Biotech (UK) Ltd., Anzignerstr. 7a, 85540 Ebersberg, Germany
www.mwgbiotech.com
New England Biolabs (NEB), 240 County Road, Ipswich, MA 01938-2723, USA
ww/w.neb.com
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Nunc, Kamstrupvej 90, Postbox 280, DK-4000, Roskilde, Denmark.
www,nuncbrand.com
Promega UK, Chilworth Science Park, Southampton, SOI6 7NS, UK
www.promega.com
QIAGEN Ltd., Boundary Court, Gatwick Road, Crawley, West Sussex, RH10 9AX,
UK www.qiagen.com
Roche, Bell Lane, Lewes, East Sussex, BN7 1LG, UK
www, roche-applied-science.com
Sigma, Sigma-Aldrich Company Ltd., Dorset, England, UK www.sigmaaldrich.com
Stratagene, 11011 N. Torrey Pines Road, La Jolla, CA 92037, USA
www.stratagene.com
Thermohybaid, Action Court, Ashford Road, Ashford, Middlesex, TW15 1XB, UK
www, thermohybaid.com
Vector Laboratories, Ltd., 3 Accent Park, Bakewell Road, Orton Southgate,
Peterborough, PE2 6XS, UK www, vectorlabs.com
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Chapter 3: Investigation of genes
important for viral persistence in the
lung
3.1 Background to the Study
3.2 Using Viral Load to Measure the Contribution
of Particular Genes to Viral Persistence in the
Lung
3.3 Experimental Protocol
3.4 Investigation of Viral Genes with a Role




3.1 Background to the Study
The lung has been identified as a site of persistence for a number of herpesviruses.
MCMV is able to establish a persistent infection in the lungs, and recurrence of the
virus in this location is associated with development of interstitial pneumonia
(Balthesen et al., 1993; Kurz et al., 1999; reviewed by Reddehase el cil, 2002).
CMV, EBV, HHV-7 and HHV-8 have all been implicated in development of
idiopathic pulmonary fibrosis (Tang et al., 2003; Stewart et al., 1999). The
association of clinical disease with herpesvirus persistence in this organ makes the
lung an important area for study. Identification of key viral genes required for
persistence may allow for development of vaccination and/or treatment strategies.
MHV-68 has been shown to establish a long-term infection of the lung. Following
intranasal inoculation with the virus laboratory mice initially develop an acute
infection in the lung which is cleared by approximately 10-12 days post-infection. A
persistent infection is then established in the lung that can still be detected as late as
12 months post-infection and possibly beyond (Stewart et al., 1998). This study
further showed that in the absence of B cells viral DNA was still maintained in the
lungs at late time points post-infection. Using a combination of in situ hybridisation
and staining for viral lytic gene products, the cell type identified as harbouring the
virus in this situation was the epithelial cell. This technique did not exclude the
possibility that other cell types such as macrophages or dendritic cells were able to
harbour latent virus.
A later study by Flano et al. (2003) used FACS to separate the different populations
of lung cells, and subsequently the frequency of cells harbouring virus within each
population was determined by a limiting dilution PCR assay. This method showed
that at 3 months post-infection only the B cell population had a significant pool of
MHV-68 infected cells (1/17917), while all other populations (macrophages, dendritic
cells and null (including epithelial] cells) had frequencies lower than 1 in 2 x 105
cells. This study did not investigate the effect of anti-viral treatment on viral




Both studies agree that the presence of virus at late time points is consistent with
latent rather than chronic lytic infection. This was demonstrated by Stewart et al.
(1998) by demonstration of the continued presence of viral DNA in the lungs of pMT
mice following treatment w ith 4"-S-EtdU. and following treatment only episomal (and
not linear) forms of the genome were detectable, indicating a latent infection.
However, both wild-type and p.MT untreated mice have both linear and episomal
forms of the genome at late time points, indicating that ongoing lytic infection or
reactivation may be a normal feature of MHV-68 infection in the lung. Preformed
infectious virus was similarly detected by Flano et al. (2003), albeit at extremely low
levels (<100 PFU/tissue) and not in every mouse studied. These studies did not
determine whether viral load in the lung was reduced following anti-viral treatment,
which would indicate whether viral replication is required to maintain normal viral
load in this organ.
3.1.1 Viral Genes with a Potential Role in Persistence in the Lung
The majority of studies on viral genes involved in establishment and maintenance of
MHV-68 latency have focused on the spleen, and several genes have been identified
as important in these processes. These include M2. M4 and ORF72.
M2 is a B cell associated antigen implicated in control of viral expansion in spleen
lymphocytes. Disruption of the gene results in high levels of persistence at later time
points (up to d70 post-infection studied) (Macrae et al., 2003; Jacoby et al.. 2002).
M4 plays a role during establishment of latency in the spleen. During acute-phase
latency (14-21 days post-infection) the absence of the M4 gene product results in a
10-100-fold reduction in the number of genome positive spleen cells (Townsley et al.,
2004), although by d42 viral levels are equivalent in both wild-type and M4-knockout
viruses (Evans et al., 2006).
ORF72 (v-cyclin) is required for efficient reactivation from latency (van Dyk et al.,
2000). V-cyclin interacts with cellular cdks to drive cell cycle progression in order to




Immune evasion may also play a role in maintenance of a persistent infection, and
several viral genes are known to be involved in this process. These genes include M3,
K3 and ORF4.
The M3 gene product is a secreted chemokine binding protein, able to block binding
of host chemokines to cell surface receptors. Previous studies utilising a virus with
M3 disrupted by insertion of a LacZ cassette showed a disruption in establishment of
latency in the spleen, w ith a decline in latent load due to immune clearance of the
virus (Bridgeman et al., 2001). However these results were not reproduced on
infection with an M3.stop virus, where establishment and reactivation from splenic
latency occurred as for wild-type virus (van Berkel el al.. 2002).
K3 is able to bind to and downregulate surface MHC class 1 expression and so
prevents or reduces CTL recognition of infected cells. Following infection with a K3-
deficient virus establishment of normal latent load is impaired and long-term (up to
180 days post-infection) viral load appears lower than in wild-type-infected mice (but
this difference is not statistically significantly different) (Stevenson el al., 2002).
ORF4 (Regulator of Complement Activation. RCA) inhibits complement C3
activation in both the classical and alternative pathways (Kapadia et al., 1999)
Complement plays a role in regulation of viral latency, and in its absence a higher
frequency of reactivation is observed in the spleen and PECs. The RCA protein is also
required for efficient persistent replication in IFNyR-/- mice (Kapadia et al., 2002).
Loss of the left-hand end of the genome of MHV-68 (incorporating genes Ml, M2.
M3. M4 and 8 vtRNAs) has given rise to the naturally occurring deletion mutant
MHV-76. The virus replicates at lower levels and is cleared more rapidly from the
lung, and establishes latency in the spleen at lower levels than wild-type virus
(Macrae et al., 2001; Clambey et al., 2002).
Amongst the studies on viral persistence in the lung one paper identifies a gene
transcribed at late time points post-infection in the lung. Mil is an anti-apoptotic Bcl-
2 homologue, and transcripts of this gene can be detected in the lungs at 10 months
post-infection, suggesting an important role for this gene in long-term persistence
(Roy et al., 2000). This gene has also been implicated in reactivation from latency in
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the spleen, but this function has not been investigated in the lung (Gangappa et al.,
2002).
3.1.2 The Host Immune Response and its Role in Viral Persistence
Interactions between the host immune response and the virus may also play a role in
determining the level of virus persistence Type I interferon has previously been
shown to play a role in clearance of the virus from the lung, with IFN-a/p R^~ mice
harbouring infectious virus in the lung up to 21 days post-infection (Dutia et al,
1999). Reactivation of latent virus from spleen and peritoneal cells in these mice is
enhanced, demonstrating a role for type 1 interferon in control of latent infection
(Barton et al, 2005).
Type II interferon is important for control of both latent and persistent replication.
Treatment of latently infected PECs in vitro with IFNy reduces the frequency of cells
that reactivate virus (Steed et al., 2006). In the absence of IFNy pre-formed (i.e. lytic)
virus can be detected up to d42 post-infection in peritoneal cells but not in die spleen.
Similarly, reactivation from latency in the PECs is enhanced in IFN-y7" mice (Tibbetts
et al, 2002), and in vivo depletion of IFN-y in wild-type mice also increases the
frequency ofcells that reactivate virus (Steed et al, 2006).
In the absence of the immune response involved in control of persistence or latency in
the lung, levels of persistence (and hence viral load) may be altered.
3.2 Using Viral Load to Measure the Contribution of Particular Genes to
Viral Persistence in the Lung
The above genes were selected for further study into their involvement in
establishment or maintenance of a persistent infection in the lung. Real time PCR was
used to quantify viral load in the lungs at late time points post-infection to see if the
absence of any of these genes affected this measure. Figure 3.1 shows the MHV-68
mutants used in the study.
3.2.1 Background to Real Time PCR
Real time PCR is an established method for the quantification of viral load in vivo
(reviewed by Niesters). Several different strategies can be employed to detect PCR
amplification in real time, all of which utilise the production of a fluorescent signal
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MIA - Ml deletion mutation
2023 3282
1170 bp deletion with a 190 bp insertion.
Unpublished data, see results chapter 4 for further
details
76(RAM2) - M2 frameshift mutation
4031 4337 4627
4bp deletion causing frameshif!
Macrae ct al. 2003
yHV68-M3.stop - M3 stop mutation
6060 7176 7277
Van Berkel et al. 2002
M4Stop - M4 stop mutation
3 in-frame translational stop codons
Geere et al. 2006




Kapadia et al, 2002
AK3TET - K3 insertion mutation
24733 25335
FRT site plus 165bp plasmid sequence
Stevenson el al, 2002






Ml. .M2 ,M3 M4 . ORF4
I I'
Deletion of Ml, M2. M3. M4 and vtRNAs 1-8
Van Dyk et al, 2000 Macrae ct al, 2001
Figure 3.1a - Mutant viruses used in the initial study. Genes with a potential role in latency
or immune evasion were identified and the corresponding mutant viruses were obtained. The figure
shows the name, specific mutation and origin of each virus used. Thanks to B.M. Dutia, A.I.
Macrae, P.G. Stevenson and H. W. Virgin IV for the kind gift of these viruses.
3 in-frame translational stop codons
& a frameshift mutation
TK Kan' - Thymidine kinase deletion mutant 27- STOP - ORF27 stop mutant
32879 34810 45329 45480 46090
FRT site plus 165bp plasmid sequence, minus
150bp of viral genome
Coleman et al, 2003
Stop codons in all reading frames
May et al, 2005a
FS73 - ORF73 frameshift mutation
103927 104379 104868
5bp insertion causing frameshift
Fowler et al, 2003
Figure 3.1b - Mutant viruses used during investigation of the role of lytic genes during
long term persistence in the lung. Genes with a role during acute infection in the lung were
identified and the corresponding mutant viruses were obtained. The figure shows the name, specific
mutation and origin of each virus used. Thanks to P.G. Stevenson and S. Efstathiou for the kind gift of
these viruses.
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once a PCR product is formed (reviewed by Bustm, 2005; Mackay et al., 2002).
Hydrolysis probes (e.g. the TaqManIM system) utilise the 5"-nuclease activity of the
DNA polymerase to hydrolyse a probe bound to the target amplicon. This releases a
fluorescent reporter dye previously quenched by a second fluorescent dye located at
the 3" end of the probe and allows detection of amplified product. Hybridisation
probes require two separate probes to bind to the target sequence in a head-to-tail
arrangement. One probe will carry the donor fluorophore (usually fluorescein) and the
other an acceptor fluorophore. Binding brings the tyvo probes into close proximity,
allowing fluorescence resonance energy transfer from donor to acceptor and resulting
in emission of red fluorescent light. Molecular beacons utilise a third strategy.
Hy bridisation probes are generated that form a stem-and-loop structure, w ith the loop
complementary' to the target sequence. In solution the stem structure maintains a
fluorescent reporter dve in close proximity to a quencher molecule located at the other
end of the probe. When bound to the target the stem-loop structure separates and the
quencher and reporter are distant enough that the reporter signal can be delected.
These methods are highly specific and sensitive but are also expensive. A
significantly less expensive method uses sequence non-specific DNA-binding
fluorophores. SYBR green I fluoresces when associated with dsDNA yvhich is
exposed to a suitable yvavelength of light. While much cheaper, this method requires
the primers used in the PCR reaction to be highly specific as formation of other
products or primer dimer wi 11 give an over-estimate of the amount of specific product.
3.2.2 Development of a Real Time PCR Assay to Measure Viral Load
An assay yvas developed using the SYBR-green method of detection Primers were
designed and optimised to allow amplification of the target sequence in the absence of
any non-specific product or primer dimer. Primers specific to the ORF50 gene
(RTAmod) yvere selected as fulfilling the above criteria. To generate a standard curve
serial dilutions of plasmid pLXSN with the ORF50 gene cloned in (pLXSN+RTA.
obtained from Dr Bemadelte Dutia) yvere generated. Initially the DNA content of the
plasmid stock was determined by spectrophotometry and the plasmid copy number
determined using the equation given in Materials & Methods section 2.6.1.1.3.
Plasmid pLXSN+RTA had a total size of 7.3kb. giving a single copy of the plasmid a
mass of 4.818 x 106Da.
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Figure 3.2a shows the range of the qPCR platform. The DNA template containing 1 x
1()6 copies per pi (i.e. 5 x 106 copies per reaction) was amplified first, with each
subsequent dilution amplified at intervals of 4 cycles until the DNA template was
diluted by 4 orders of magnitude. Quantitation of the amount of target in the unknown
samples is achieved by measuring C-r (the threshold cycle, or cycle number at which
the fluorescence increases above background level) and using the standard curve to
determine starting copy number. Ct is determined by software analysis and is set at a
point where all curves represent logarithmic growth.
Figure 3.2b shows the specificity of the RTA primers when used to amplify lung
DNA one month post-infection. Melt-curve analysis was used to determine the
specificity of each qPCR. The temperature at which PCR products melt varies over a
large range, and because of length differences non-specific products usually melt at a
lower temperature than desired PCR products. Following qPCR amplification the
mixture was heated from 65°C to 95°C in increments of 0.1 °C. The presence of a
specific PCR product was detected by a sudden loss of fluorescence as the uniform
population of DNA strands melted. Non-specific products such as primer dimer were
detected by irregular decreases in fluorescence. Both plasmid and lung DNA
produced a single peak of the same size, corresponding to the amplification of the
same region of template DNA.
3.2.3 Normalisation of Samples
Normalisation is used to correct sample-to-sample variation. For RT real time PCR
this reduces variation as a result of differences in initial RNA quantity or quality, or as
a result of experimental treatment such as reverse transcription. Real time PCR results
are usually normalised against a control gene that may also act as a positive control
for the reaction. The ideal housekeeping gene (or genes) for this process has been
investigated and reviewed many times and is often controversial (see chapter 5 for
further discussion). However this debate is not an issue when normalising samples for
DNA rather than cDNA levels. Any cellular gene or region of DNA present
consistently in all cell types can be used as a template. Normalisation of DNA
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Figure 3.2a - qPCR platform for the RTA assay using 10-fold dilutions of the
pLXSN+RTA plasmid. Reactions containing 5 x 106 copies of the plasmid are amplified first
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Figure 3.2b - Melt curve analysis of pLXSN+RTA and DNA from infected lung samples 1
month post-infection. PCR reactions are heated from 65°C-95°C in increments of 0. l°C. The presence
af a single peak at approximately 87°C indicates a single specific PCR product is produced in reactions
containing either plasmid or lung DNA as template.
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The P-actin gene was selected as the normalisation gene because this assay had
already been developed and optimised for use in real-time PCR by Clive McKimmie
(PhD thesis. 2005). Standards for this reaction were made using uninfected mouse
lung DNA as a template, p-actin 1 primers were used to amplify the target region by
PCR to generate a fragment of 272 bp. PCR samples were run on a 1% agarose-TAE
gel and visualised using a long wave UV transilluminator. The band was excised and
DNA extracted using a QIAquick Gel Extraction kit and resuspended in 30 pi Buffer
AE. Serial 10-fold dilutions were made using Buffer AE down to 1/10.000.000.
For the qPCR reaction the p-actin 2 primers (which are internal to the region
amplified by the p-actin 1 set) w ere used, with the platform shown in figure 3.3a The
sensitivity of this reaction extends from a 1/1000 dilution of the P actin-1 template
down to 1/10,000,000. As before melt curve analysis was used to determine the
specificity of the qPCR reaction (shown in figure 3.3b).
Quantification for the P-actin PCR is relative - the absolute copy number in each of
the standard dilution series is not determined, and hence the copy number for
unknown samples is a value relative to the standard dilutions, not an absolute value.
As this assay is used only to confirm that levels of P-actin are similar in all samples
an absolute value is not necessary.
3.3 Experimental Protocol
A previous study showed that BALB/c mice show greater levels of MHV-68 gene
expression and higher viral titres in the lung during acute infection compared to
C57BL/6 mice (Weinberg el a/., 2004). This corresponds to our own results - an
initial study involving infection of C57BL/6 mice failed to produce useful data
because at later time points the level of viral DNA in the lungs fell below the limit of
detection of our assay. BALB/c mice were used in all subsequent experiments
because their increased susceptibility to infection meant the viral load in the lungs at
late time points was above the limit of detection of the assay, and therefore it was
likely any difference in phenotype would be more easily detected.
Female BALB/c mice aged 5-6 weeks were infected intranasallv with 4 x 103 PFU of
virus. For each of 3 time points (1,3 and 6 months post-infection) three mice per time
point per virus were infected. Mice were thoroughly perfused with SPBS and the
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amplified template. Reactions containing 1/100 dilution of the P actin-1 template (marked A) are
amplified first, with subsequent 10-fold dilutions amplified at intervals of 4 cycles to a 1/100,000,000
dilution of the template (marked B).
Figure 3.3b - Melt curve analysis of p actin qPCR using p actin-1-amplified product or
infected lung DNA 1 month post-infection as template. PCR reactions are heated from 65°C-
95°C in increments of 0.1°C. The presence of a single peak at approximately 87°C indicates a single
specific PCR product is produced in reactions containing either P actin-1 PCR product or lung DNA as
template.
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lungs were removed. DNA was extracted using the protocol for an entire lung detailed
in section 2.1.2.2 of Materials and Methods. This method ensures that there is less
chance of error due to sampling effect that could occur when using the standard
Qiagen DNeasy protocol and extracting DNA from only 25 mg of lung tissue.
Initially the viral load in all samples was quantified using the RTA real time assay.
Comparison of samples between different real time runs is not advisable as
differences in mastermix composition and threshold level may introduce error into the
results. To overcome this each real time run contained all three wild-type MHV-68-
infected samples as well as the mutant virus under investigation. All samples and
standard dilutions were run in triplicate to increase the accuracy of the results. The
mean viral load for each sample was calculated from the replicates. Quantification of
P-actin for each sample was carried out using the P-actin real time PCR. Samples and
standards were run in duplicate. RTA levels were then normalised to the level of P-
actin using the method given previously (Materials and Methods section 2.6.3).
3.3.1 Initial Results
Figure 3.4 shows the melt curve analyses for RTA real-time reactions using 6 month
samples. At l and 3 months post-infection a single product is detected. However
when amplifying DNA from the 6 month lungs levels of viral DNA in some samples
were too low to be detected by the RTA assay and non-specific amplification was
observed. Viral load in the 6 month samples were therefore quantified using a more
sensitive qPCR assay that uses primer set M4RT (primer sequences shown in
Appendix 1.2). The lowest copy number that can be accurately measured by this assay
is 101 copies/pl (compared to 102 for the RTA assay). Figure 3.5 shows the platform
and the melt curve analysis for the 6 month samples using the M4 assay. A single
peak at 84°C can be seen in the melt curv e, indicating specific amplification of the M4
gene. The M4RT primers bind to a region of the M4 gene distal to the mutation in the
M4.stop virus and therefore viral load can still be measured in mice infected with this
virus. In MHV-76 the region these primers bind to is absent so it was not possible to
measure viral load in MHV-76-infected mice.
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Figure 3.4 - Melt curve analysis of an RTA qPCR using either pLXSN+RTA or DNA
from infected lung 6 months post-infection. Curves contain a peak at approximately 87°C
(marked A) which corresponds to amplification of the pLXSN+RTA template, ranging from 5 x 106
to 5 x 102 copies per reaction. The majority of the 6 month infected lung samples show more than
one peak (the most obvious are marked B), indicating non-specific amplification of template DNA.
Quantification of viral load in these samples is not possible because the dsDNA present does not
correspond to the specific RTA-amplified region of the viral genome.
Fluoiescence
Figure 3.5a - qPCR platform for the M4 assay using 10-fold dilutions of the M4
plasmid. Reactions containing 5 x 107 copies of the plasmid (marked A) are amplified first, with
subsequent 10-fold dilutions amplified at intervals of 4 cycles to a minimum of 5 x 101 copies
(marked B).
Figure 3.5b - Melt curve analysis of the M4 assay using either M4 plasmid or lung
DNA 6 months post-infection. The presence of a single peak at approximately 83°C indicates a
single specific PCR product is produced in reactions containing either plasmid or lung DNA as
template. The non-specific amplification seen previously when amplifying the same template lung
DNA does not occur when using the M4RT primer set.
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Figure 3.6 shows normalised viral load results for all viruses at all time points
investigated. At some time points there may appear to be differences in viral load
between mutant- and wild-type-infected mice (of note are the ORF72-infected mice at
3 and 6 months post-infectioa and the Ml 1-infected mice at 6 months post-infection).
However statistical analysis was carried out using the non-parametric Mann-Whitney
test and at no time point did any of the viruses studied show any significant difference
to the wild-type virus.
During the course of the experiment a virus w ith a potential role in immune evasion
(and hence with a possible role in persistence in the lung) became available. The role
of Ml during MHV-68 infection is discussed in detail in chapter 4 and has previously
been implicated in reactivation in the spleen (Clambey et a/., 2000). Our data also
indicates a potential role during acute infection of the lung. As before 3 mice per time
point were infected intranasally with 4 x 103 PFU of MIA virus, with the same
number of mice infected with wild-type MHV-68 for comparison. At 3 weeks post¬
infection one mouse infected with MHV-68 died of causes unrelated to viral infection.
One month post-infection 3 mice infected with MIA and 2 mice infected with wt virus
were sacrificed and lung viral load quantified using the RTA assay as before.
Prior to the 3-month time point, results became available for the 6-month time point
for all other viruses. The small sample sizes had made statistical analysis difficult and
it was decided in the case of the MIA experiment to omit the 3 month time point in
favour of a larger sample group at the 6 month time point. The viral load in mice 6
months post-infection was determined as before using the M4 assay.
Results for the MIA experiment are also shown in figure 3.6. Statistical analysis using
the Mann-Whitney test showed no significant difference at the 1 and 6 month time
points between the MIA and wild-type viruses. The increased sample size did
however allow for greater confidence in the results.
3.3.2 Investigation of the Role of Type I and Type II Interferons in Long
Term Persistence in the Lung
A single 6-month time point was selected. Previous studies had not shown any
difference in viral load at the intermediate time points of 1- and 3-months post¬












































































































































Figure 3.6 - Viral load in the lungs at 1-, 3- and 6-months post-intranasal infection
with 4 x 105 PFU of the stated mutant virus. Viral load is quantified using real time PCR
DNA was extracted from infected lungs and 100 ng used per PCR reaction. At 1- and 3-months post¬
infection primers specific to the RTA gene were used to amplify viral DNA in infected lungs. At 6
months the more sensitive M4 assay was used. Samples were subsequently normalised to the amount
of P-actin in the sample (previously determined by a separate qPCR reaction using P-actin-specific
primers) . The line labelled A is the limit of detection using the RTA assay; the line labelled B is the
limit of detection using the M4 assay.
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Previous data has shown that IFN-a/p R " mice (Muller et ah, 1994) are highly
susceptible to infection with MHV-68, with 80% mortality following intranasal
infection with 4 x 10" PFU of virus. Infection with 4 x 103 PFU results in 50%
mortality before d!3, with mice surviving past this point remaining in good health
(Dutiae/ al., 1999).
IFN-a/p R IFNyR " and control 129 SV/EV mice were infected intranasally at 5-6
weeks of age with 4 x 10" PFU of wild-type MHV-68. 12 IFN-a/p R and 6 each of
the IFNyR" and 129 SV/EV mice were infected, with the expectation that -50% of
the IFN-a/p R mice would die before the 6 month time point was reached. By 6
months post-infection 8/12 IFN-a/p R mice were dead, a figure slightly higher than
previously stated, and likely to result from the small sample group used in this
experiment All IFNyR"" and 129 mice survived. At 6 months mice were perfused and
sacrificed as before, and lung viral load was quantified using the M4 assay.
Results for this experiment are shown in figure 3.7 At 6 months post-infection viral
load for IFNyR"" mice infected with MHV-68 is higher than for wt mice similarly
infected, although this difference is not statistically significant. Average viral load in
the lungs of IFN-a/p R " mice is higher than for both IFNyR" " and w1 mice, although
again this is not a statistically significant difference.
3.4 Investigation of Viral Genes with a Role during Lytic Replication in
the Lung
Genes were previously selected on the evidence of their involvement in immune
evasion or establishment and/or maintenance of latency, factors thought likely to be
key in viral persistence in the lung. However given that the genes appeared to have no
effect on viral load at late time points post-infection it was decided to investigate
several other candidates. Two genes had previously been identified as playing a role
during lytic infection in the lung, and the corresponding mutant viruses were obtained
from Dr. Philip Stevenson at the University of Cambridge. The thymidine kinase (TK"
) virus is severely impaired in lytic replication in the lungs but by one month post¬
infection normal levels of splenic latency have been established. The ORF27 gene
encodes a glycoprotein (gp48) required for intercellular viral spread. Mutation of this
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Figure 3.7 - Viral load in the lungs of wild-type 129, IFNyR"'" or IFNapR"7" mice at 6
months post-intranasal infection with 4 x 103 PFU of wild-type MHV-68. As before, viral
load was quantified using the M4 real time PCR assay to quantify viral copy number in 100 ng
template DNA. Samples were normalised to the amount of P actin in the sample. The dashed line
denotes the limit of detection of the assay.
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viruses, with a deficit in lytic replication in the lungs compared to wild-type virus but
not as extreme as that observed for the TK- virus. Similarly there is a reduction in the
initial amount of latent virus in the spleen but this is resolved by one month post¬
infection.
To determine if latency plays any role in maintenance of persistent lung infection an
ORF73-deficient virus was obtained from Dr. Stacey Efstathiou at the University of
Cambridge. ORF73 is involved in episome maintenance, and the absence of this gene
in MHV-68 results in complete failure to establish latency in the spleen (Fowler 2003,
Moorman 2(X)3).
3.4.1 Experimental Protocol
Initially the ORF73 virus (shown in figure 3.lb) was used to set up an experiment as
before with time points at l, 3 and 6 months post-infection and 3 mice per virus per
timepoinl Wild-type MHV-68 virus was also used to infect mice as a control. Mice
were infected with 4 x K)5 PFU of virus intranasally. By 7 days post-infection all
mice infected with the ORF73 virus w ere dead, and w ere disposed of before autopsies
were possible. All mice infected with wild-type MHV-68 survived and appeared
healthy at d 10 but were culled at this point as they were no longer required. Previous
studies using the ORF73 virus involved intranasal infection at I x 1()4 PFU and did
not report any unexpected deaths (Fow ler el al2003).
To test the hypothesis that lytic replication may be important for viral persistence in
the lung BALB/c mice were infected with the TK, ORF27, ORF73 or wild-type virus
(virus mutants shown in figure lb). Mice were infected with l x 104 PFU intranasally
to avoid any of the complications seen previously when infecting with a higher dose.
Owing to time constraints a single time point at 2.5 months was chosen. 6 mice per
virus were used to aid statistical analysis. One mouse infected with ORF73 died at l
month post-infection of causes unrelated to viral infection. At 2.5 months post¬
infection lungs were harvested and assayed as before using the M4 real time assay.




Figure 3.8 shows the normalised results for the TK, ORF27 and ORF73 viruses
compared to the wild-type MHV-68 control. Statistical analysis using the non-
parametric Mann-Whitney test shows viral load in mice infected with the TK virus is
significantly different to mice infected with the wild-type virus (p<0.0051), as is the
ORF73 virus (p<0.0225), but no significant difference was observed on infection with
the ORF27 virus.
To determine if normal latent infection was established in the spleen following
infection with viruses that had altered viral load in the lungs the viral load of spleens
from the TK, ORF27, ORF73 and wild-type MHV-68-infected mice were quantified
using real time PCR. DNA was extracted using the standard protocol for the Qiagen
DNeasy kit (Materials & Methods section 2.1.2.1) and viral load quantified as before
usmg the M4 real time assay. In all cases the viral load fell below the limit of
detection of the assay and hence viral load could not be quantified using this
technique (data not shown).
3.5 Discussion
Prior to 1998 the lung was not considered an important site for MFTV-68 persistence
Stew art el al. (1998) first demonstrated persistence of the virus in the lung at late time
points post-infection, and using pMT (B cell-deficient) mice demonstrated persistence
in the absence of B cells. In both wild-type and pMT mice episomal and linear forms
of the genome were found, indicating a non-B cell type was able to harbour latent
virus. This alternative cell type was identified by in situ hybridisation as the lung
epithelial cell.
Since 1998 debate has continued about the cell type harbouring latent virus in the
lung, w ith evidence presented by Flano el al. (2003) that the B cell is the predominant
site of latency at late time points with little or no contribution from epithelial cells.
However, while the focus has centred on the site of persistence of the virus, little
attention has been paid to the possibility that latent infection is not the only means of
maintaining the virus in the lungs. Evidence exists in other herpesviruses that there is
the potential for chronic lytic infection existing below the detection limit of infectivity







































































Figure 3.8 - Viral load in the lungs at 2.5 months post-intranasal infection with 1 x 104
PFU of the stated mutant virus. As before, viral load was quantified using the M4 real time
PCR assay to quantify viral copy number in 100 ng template DNA. Samples were normalised to the
amount of P actin in the sample. The dashed line denotes the limit of detection of the assay. Mutant
virus samples marked * have viral load significantly different to mice infected with wild-type virus
(as determined using the non-parametric Mann-Whitney test).
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but debate continues as to whether this is a true latent infection or if low level
persistence is occurring (reviewed by Reddehause el al., 2(X)2). Previous studies on
long-term MHV-68 infection in the lung cannot discount the possibility of a chronic
infection occurring alongside latency.
In our study we assessed the contribution of both lytic and latent genes in maintaining
a long-term infection of the lung to determine the likelihood of chronic versus latent
infection.
M2 is a latently expressed gene that functions in a tissue-specific manner - it is
required for establishment of normal levels of latency in the spleen but not in the
peritoneal exudate cells (Jacoby el al., 2002). Similar to the PECs. the absence of the
M2 gene did not result in any alteration in viral load in the lung. M2 is required for
colonisation of splenic follicles and exiting of infected germinal centre B cells into the
memory B cell compartment (Simas el al., 2004), and this process may not be
necessary for maintenance of viral load in the lung.
In the absence of the M3 gene no effect is seen on viral load at late time points in the
lung. No previous role has been identified for M3 during latency, either in vitro
(Husain el al., 1999; Martinez-Guzman el al., 2003) or in vivo (van Berkel el al.
2(X)2). A single in vitro study has shown the presence of an RTA-responsive element
in the M3 promoter region which could link M3 transcription to the latent-lytic switch
(Martinez-Guzman el al., 2003) but no obvious role in reactivation has been shown in
vivo. Vaccination with an M3-containing construct protects during lytic infection in
the lung but has no effect on latent infection, suggesting M3 is expressed only during
the lytic cycle or in a very limited number of latently infected cells (Obar el al.,
2(X)4). There may still be a role for genes involved solely in lytic replication in
maintenance of viral persistence - preformed infectious virus can still be detected at
late time points post-infection (Flano el al., 2003), suggesting the possibility of
ongoing chronic lytic replication or reactivation from latency. However at this point




Despite a clear role for M4 in establishment of latency in the spleen again there is no
obv ious role in maintenance of infection in the lung. While levels of long-term splenic
latency are independent of M4, differences in viral load are still apparent at 1 month
post-infection (Townsley etal, 2004). This difference was not replicated in the lungs,
with viral load unaffected by the loss of M4 at 1-, 3- and 6-months post-infection.
M4 has been shown to act in a tissue-specific manner, with no requirement for the
gene in establishment of latency in the PECs (Evans et cil, 2006). Similarly there
appears to be no role in establishment or maintenance of latency in the lung. This may
be due to the tissue-specific requirements mentioned above, or alternatively viral
persistence in the lung may not depend on latent infection to the same extent as in the
spleen. Interestingly minor effects have been noticed during acute infection of the
lung. Infection with MHV76inM4 (MHV-76 with the complete M4 gene inserted into
the left-hand end) causes higher viral titres on days 1-3 compared to both MHV-76
and MHV-68 (Townsley et ciL). Higher viral lung titres are reported on d9 following
infection with an M4.stop mutant (Evans et at.) but this result has not been replicated
following infection with a very similar M4.stop mutant (Geere et a!., 2006). If any
small differences do exist these do not appear to have any impact on long-term viral
load in the lungs.
Complement is known to play a role in regulation of several aspects of B cell biology
(Ochsenbein et n/., 1999; Carroll & Fischer, 1997). As lung B cells are one of the
suggested sites of MHV-68 persistence the interaction between complement and B
cells may impact viral persistence. A previous role for the MHV-68 RCA (Regulator
of Complement Activation) gene during v iral persistence has been demonstrated in
the spleens of IFNyR"mice. However in wild-type mice the lack of a role for RCA
during latency in the spleen is mirrored by the absence of an obvious role for the gene
during persistence in the lung. Complement (but not the RCA gene) has been shown
to affect viral latency in both the spleen and PECs, and while our studies have not
investigated the effect of complement deficiency on persistence in the lung we




Many viruses use avoidance of MHC class I antigen presentation as a mechanism to
subvert the immune response. Herpesviruses, poxviruses and retroviruses all encode
proteins capable of targeting MHC class I molecules for degradation (reviewed by
Furman and Ploegh, 2002), acting at different points in the MHC biosynthesis and
antigen presentation pathway to prevent viral antigen presentation at the cell surface.
While the mechanism of KSHV genes K3 and K5 action have been studied in detail in
vitro (Loren/.o el al., 2002; Hewitt el al., 2002; reviewed by Fruh et ciL, 2002) little is
known about its role in vivo. The presence of a close homologue in the MHV-68
genome, K3, allows study of the role of K3 in vivo, and we have focussed on the role
of K3 in maintenance of viral load in the lungs.
While infection with a K3-deficient virus results in a lack of expansion of latently
infected cells in germinal centres and ultimately a reduction in viral load in the spleen
the same effect is not observed in the lung. At no time point studied was the viral load
statistically significantly different between mice infected with wild-type or K3-
deficient viruses.
Interestingly Stevenson et al. (2002) report a slight elevation of viral lung titres in Re¬
infected mice at days 8-10 post-infection, although the virus is subsequently cleared
with normal kinetics by d 15. While not statistically significant, at 1 month post¬
infection viral load in mice infected with the K3 virus is elevated compared to wild-
Pipe. This brings into question the validity of results where such a small sample group
is used, and the only way to confirm if the mild enhancement during acute lung
infection has any impact on long-term load would be to repeat the experiment using a
much larger sample group.
In the case of the M11 gene, high levels of transcription in the lung but not the spleen
at 10 months post-infection would indicate an important role for this gene during
persistence in the lung (Roy et al., 2000). At 1 and 3 months post-infection there is no
obvious difference in viral load in mice infected with wild-type or M11 -deficient
virus. However at 6 months there is an indication that viral load is reduced in the
Ml 1-infected mice compared to the wild-tvpe-infected mice, although owing to the
small sample group this is not statistically significant.
Previous studies have shown that the Ml 1-deficient virus is able to establish latency
in the spleen and PECs at normal levels (as measured by viral load). The phenotype
observed for the Mil.stop virus is a reactivation deficit in PECs (Gangappa et al.,
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2002). Therefore it is possible that while the Mil virus can establish latency at
normal levels, reactivation in the lungs may be impaired in the absence of the gene. If
the deficit observed at 6 months can be reproduced in a larger sample group this
would indicate reactivation is important for maintenance of viral load at late time
points.
An alternative role has been demonstrated for the Ml 1 gene in maintenance of
persistent (not latent) infection of IFNyR " mice. These mice characteristically show
persistent replication, with large vessel vasculitis and premature death (Week el al.
1997; Dal Canto el al., 2000). The Ml l.stop virus is attenuated in these mice, with
decreased incidence of artentic lesions and a threefold greater survival rate
(Gangappa el al., 2002). This study involved i.p. infection so effects in the lung were
not investigated. However if persistent replication is important for maintenance of
viral load, intranasal infection of IFNyR" mice with the Ml l.stop virus may show
differences compared to infection with wild-type virus. This would be an interesting
study to undertake but time constraints did not permit it.
The viral cvclin gene has been shown to play a key role in reactivation from latency
(Van Dyk el al., 2000; Van Dyk el al. 2003). At 6 months post-infection mice
infected with a v-cyclin-deficient virus show normal viral load in both splenocytes
and PECs but show impairment in viral reactivation (Van Dyk el al., 2003). At all
time points studied viral load in the lungs was not statistically significant different in
mice infected with v-cyclin or wild-type virus. However at both 3 and 6 months post¬
infection there appears to be a trend towards a reduction in viral load in the v-cyclin
infected mice. Owing to the small sample sizes it is impossible to tell if this apparent
reduction in viral load is a true difference or merely a result of the sample size.
Several possibilities arise as a result of the lack of clarity in the results. If the
difference observed at 6 months post-infection is a true reduction in viral load through
loss of v-cyclin this would suggest reactivation from latency is important in
maintenance of viral load at late time points. Alternatively if the difference at 6
months is merely a result of sample variation and viral load in the v-cyclin-infected
mice is in fact the same as in wild-type-infected mice this would indicate reactivation
is not important for maintenance in the lung.
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Viral reactivation is involved in maintenance of viral load in MuMT mice. Mice
infected with the v-cyclin-deficient virus establish latency at similar levels to wild-
type infected mice but by 6 months post-infection viral load in the spleen is relatively
lower (Van Dyk et al., 2003). Reactivation and reseeding in these mice is key to
maintenance of viral load in the spleen, and may also be much more important in the
lungs of immunocompetent mice than previously thought.
The results for the Ml 1 and v-cyclin viruses together suggest a possible requirement
for reactivation in maintenance of viral load in the lung at late time points. However
these experiments w ill have to be repeated with greater numbers of mice to test this
hypothesis.
MHV-76 replicates to lower levels, is cleared more rapidly and shows an earlier and
larger immune response in the lungs compared than that seen following infection with
MHV-68. 5 months post-infection viral DNA can only be detected in the lungs of 1/4
mice, compared to 4/4 in the spleen (Macrae et al., 2001). This failure to detect viral
DNA in the lungs suggested a potential defect in long-term persistence. However al 1-
and 3-months post-infection there is no obvious difference in viral load as measured
by real-time PCR. The assay used by Macrae was sensitive to 1-10 copies of the viral
genome in 1 pg DNA, which is considerably more sensitive than the 500 copies per
100 ng used in the RTA real-time assay.
Given the lack of a significant change in viral load between 3- and 6-months post¬
infection in mice infected with the individual M1-M4 mutants it seems unlikely that a
significant difference in viral load would be detected at 6 months post-infection for
mice infected with MHV-/6. Unfortunately this was not tested owing to sensitivity
problems with the RTA assay below 500 copies/lOOng template DNA. The absence of
the M4 gene meant the more sensitive M4 assay could not be used, and the cost of
developing a real time assay for gene outside the deleted region is too large for use at
one time point in one set of samples.
Previous studies involving Ml have involved disruption of Ml with a LacZ cassette,
a method that may result in distorted phenotvpes (Jacoby et al., 2002). The phenotvpe
reported for the Ml .LacZ virus was a deficiency in reactivation, a phenotvpe common
in viruses carrying the LacZ cassette. Our more recent studies indicate loss of M 1
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results in a disruption in the acute phase of latency, characterised by the absence of
splenomegaly and a reduction in the number of latently infected cells in the spleen at
dl4. In the lung our data indicates Ml controls acute infection in the lung, and
following deletion of the gene higher viral titres and delay ed clearance from the lung
are observed. However despite differences during acute infection of the lung and
acute phase latency in the spleen, there is no alteration in long term persistence at 1-
or 6-months post-infection.
Of the genes previously show n to be important for latency in the spleen, none showed
the same requirement in the lung. This suggests a different gene expression
programme is required for maintenance of latency in the lung, or that latency is not a
key feature of viral persistence.
To determine if lytic replication in the lung has any effect on long-term viral load the
TK" and ORF27-deficient viruses were used to inoculate mice. At the same time the
ORF73-deficient virus also became available
At the single time point tested the TK virus showed a significantly reduced viral load
compared to wild-type virus. This was a very surprising result as prev ious studies in
the lung have focussed on the role of latency during long-term infection, and the TK"
deficient virus is able to establish latency in the spleen at normal levels by 1 month
post-infection (Coleman et ai, 2003) Two possible conclusions can be drawn from
these results: either a certain level of lytic replication is required to establish normal
latent levels of virus, or lytic replication is largely responsible for maintaining viral
load in the lungs and latency is a relatively insignificant part of this process.
In the case of herpes simplex virus TK" viruses have been used to demonstrate that
impaired lytic infection results in a reduction in the number of neurons earn ing the
latent viral genome and also in a fewer copies of the latent genome per infected cell
(Slobedman et al., 1994; Thompson & Sawlell, 2(X)0). However these experiments
did not measure if latent load increased to wild-type lev els at later time points, as is
the case for TK" MHV-68 levels in the spleen.
Vaccination with MHV-68 lytic cycle proteins produces a similar effect to infection
with a TK" virus. The initial lytic infection in the lung is substantially reduced
following vaccination, and establishment of latent infection in the spleen is similarly
impaired, although by 1 month post-infection levels in the spleen are comparable to
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non-vaccinated mice. Vaccination with a latent epitope (M2) caused no deficit during
initial lytic replication in the lung, and while initial levels of latency in the spleen
were reduced long-term latency was established at normal levels (Woodland et al.,
2001). Use of lytic epitope vaccination could be used to further test our hypothesis
that normal lytic replication in the lung is necessary' for establishment of normal long-
term viral load.
The ORF27-deficient virus is deficient in intercellular viral spread (May et al., 2005a;
2005b). Following intranasal infection the virus shows reduced lytic replication in the
lung, although not to the same extent as the TK" virus. In contrast to the TK" virus this
initial deficit does not affect long-term viral load. This suggests two possibilities:
there is a threshold level of initial lytic replication required for normal establishment
of latency, with the TK" virus falling below this level and the ORF27 virus above it;
or the different mechanisms in which the two viruses are deficient affect
establishment of latency differently. The ORF27 virus shows no growth deficit in
vitro following high M.O.I, infection, while low M.O.I, resulted in impaired growth in
BHK-21 cells. If single-cycle replication can result in establishment of latency there
would be no expectation of a deficit in establishment of latency by the ORF27 virus.
Either of the above possibilities may explain the lack of a role for ORF27 in long term
persistence in the lung.
The KSHV ORF73 homologue (LANA) has been shown to have multiple functions
(reviewed by Viejo-Borbolla & Schulz, 2003), including segregation of episomes to
progeny cells during cell division, repression of RTA promoter activity and control of
cell cycle progression. The ORF73 of HVS is similarly involved in targeting and
inactivation of cell cycle control proteins (Borah et al., 2004). In the case of MHV-68
the ORF73 gene sequence analysis would suggest functional similarities to the KSHV
protein this awaits confirmation. However the MHV-68 gene has been shown
essential for establishment of latency in the spleen following intranasal inoculation
(Fowler et al., 2003).
Use of the ORF73-deficient virus helps determine if latency is a requirement for viral
persistence in the lung. Mice infected with the ORF73 virus had reduced viral load 2.5
months post-infection compared to infection with wild-type virus, indicating a
requirement for latency during long-term infection. This would suggest that in the
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case of the TK" infected mice a certain level of lytic replication is required in order to
seed a sufficient number of latently infected cells, although it does not entirely
eliminate the possibility of ongoing chronic lytic replication assisting in maintenance
of viral load.
In order to confirm that latency in the spleen had been established at normal levels by
the TK" and ORF27 viruses and failed in the case of the ORF73 virus, real-time PCR
was used to quantify viral load in the spleens. However all spleens including those
infected with wild-type virus fell below the 50 copy limit of detection. Given that
lOOng of template DNA corresponds to DNA from approximately 347,222 cells (data
from Jackson Laboratories, www.informatics.jax.org), and the number of infected
cells is approximately 1/1,000,000; it is not surprising that detection of viral DNA is
problematic. Early attempts to use nested PCR to enhance the sensitivity of
quantification were unsuccessful as this process introduced a large degree of variation
into the replicates, indicating the nested reaction did not occur uniformly in all
samples and therefore potentially distorting results (data not shown). A better option
would have been to use a reactivation assay, or to develop an assay where more than
lOOng template DNA can be used.
While indicating a significant role for latency in maintenance of viral load, we have
not eliminated the possibility that ongoing lytic replication is a factor. As mentioned
previously, Stewart el al. (1998) investigated the effect of inhibiting viral replication
by treatment with 4"-S-EtdU, but did not measure the impact of treatment on viral
load. A reduction in viral load following anti-viral treatment would indicate viral
replication (whether from reactivation or chronic lytic infection) is an important factor
in long-term persistence in the lung. An ongoing lytic infection would also help to
explain the importance of the TK gene in maintenance of viral load. This w ould be an
interesting experiment, but time constraints did not permit it to be carried out.
Mice deficient in the type I interferon response show 100- to 1000-fold higher viral
titres during acute infection of the lung. Our previous work has shown that a lytic
replication deficiency results in a reduction in the viral load in the lung at late time
points post-infection. An obvious hypothesis might therefore be that enhanced lytic
replication may lead to establishment of latency at higher levels and hence increase
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viral load at late time points. This was not the case however for the Ml virus, and
similarly in IFN-a/p R mice this does not appear to happen. The initially high lytic
titres do not result in a higher viral load at 6 months post-infection. This is mirrored
by the situation in the spleen, where IFN-a/p R mice eventually establish latency at
normal levels despite the presence of virus considerably earlier and at 10-fold higher
levels compared to wild-type mice.
Depletion of interferon in wild-type mice following resolution of acute infection
results in increased reactivation in the PECs, showing that interferon continues to play
a role after acute infection. Barton et al. (2005) have shown that type I interferon is
important in control of virus reactivation during the early phase of virus latency but is
dispensable at later time points. If the same is true in the lung potential differences
during early latency may not have been detected by measuring a single time point at 6
months post-infection.
Type II interferon is not involved in viral clearance from the lung during acute
infection - mice deficient in the ty pe II interferon response are able to clear the virus
from the lungs. Our studies show IFNyR mice are able to maintain long-term
infection of the lung at similar levels to wild-type mice, indicating that IFNy does not
have an obvious role during acute or long-term infection of the lung.
Interferon-y has previously been implicated in control of reactivation in the PECs but
not in the spleen. Reactivation has not been definitively shown to be important for
maintenance of infection in the lung, but our initial experiments suggest that it
appears likely to be involved. The lack of a role for interferon-y in control of
reactiv ation in the spleen suggests other host mechanisms must be in place to control
this process, and these mechanisms may also be functioning in the lung.
Our results would suggest a model whereby an initial level of lytic replication during
acute infection is required to seed latent infection at normal levels in the lung. Once
latent infection is established, viral load can initially be maintained in the absence of
any reactivation. However at later time points (from 3 months post-infection)




In conclusion we have identified that initial levels of lytic infection may play an
important role in establishing sufficient levels of latency to maintain viral load at late
time points. Reactivation may play a role in maintenance of viral load but further
studies are required to determine if this is the case. With the exception of ORF73,
genes identified as necessary, for establishment and maintenance of viral load in the
spleen did not show the same effect in the lung. We still have not conclusively ruled
out the presence of an ongoing chronic infection in the lung, but have demonstrated
that establishment of latency is necessary for maintenance of normal viral load.
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4.1 Background to the Study
The left end of the MHV-68 genome has been an area of considerable interest for
some time. This part of the genome contains four open reading frames (M1-M4) and 8
viral tRNA-like molecules which are unique to MHV-68. While these genes are
dispensable for replication in vitro, several have been shown to play an important role
in MHV-68 pathogenesis in vivo.
Of the four unique genes Ml is the least investigated Initial sequence analysis
identified this gene as a potential serpin homologue (Bowden el al1997). Serpins
(serine proteinase inhibitors) have multiple regulatory functions in vivo (reviewed by
Potempa et al., 1994) but are also found in the poxvirus family of viruses. Poxvirus
serpins have been shown to inhibit apoptosis (Brooks et al., 1995; Macen et al. 1996),
a function which may allow infection of a wider range of cells (Moon et al., 1999).
Viral serpins are also involved in regulation of inflammation (Ray et al., 1992).
Several previous attempts have been made to investigate the role of M1 using M 1
deletion viruses. The V2 (Simas et al., 1998) and LHAgfp (Dutia et al., 2004) viruses
have deleted part or the entire M1 gene and replaced it with a reporter gene (LacZ or
GFP) under CMV promoter control. These viruses both lack several of the tRNA-like
molecules found at the left-hand end of the genome The Ml LacZ virus generated by
Clambev et al. (2000) has 480bp of the Ml gene and 131 bp of upstream sequence
replaced bv an expression cassette containing LacZ under the CMV immediate-early
promoter.
There are problems associated with disruption of MHV-68 genes with large
expression cassettes, and Clambey et al. (20(H)) did note that an M1 deletion virus
(M1A511) without an expression cassette had a slightly different phenotype to the
Ml .LacZ virus. Previous changes in phenotype attributed to the loss of M1 were later
shown to be a result of the LacZ insertion rather than any change in M1.
4.2 Generation of M1A and M1 ARev Viruses
4.2.1 Generation of the M1A Virus
Previous work in our lab produced a virus with a large deletion in the Ml region This
virus lacks l 170 bp of the Ml gene, corresponding to genome co-ordinates 2022-
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3193. This removes the majority of the Ml ORF. which is located at genome co¬
ordinates 2023-3283. During the BAC mutagenesis procedure, 190 bp of sequence
was also introduced into this region, consisting of M13 sequence and an FRT site.
4.2.2 Generation of the M1 ARev Virus
To confirm that any change in phenotype observed following infection with the MIA
virus was due to the targeted mutation and not a distal mutation in the MHV-68
genome, a marker rescue virus (MlARev) was constructed in which the Ml ORF
sequences were restored in MI A.
As the MIA virus was created by mutagenesis of the MHV-68 BAC (Adler et al
2000) the revertant was generated using the two-step replacement procedure
previously described for BAC-denved viruses (Borst et al., 1999; Messerle et al.,
1997; O'Connor et al., 1989). The process is illustrated in figure 4.1.
The Hind E fragment of the MHV-68 genome cloned into pUC13 (Efstathiou et al.,
1990) was used as a template to repair the lesion in the Ml gene. This fragment
incorporates the first 6.1 kb of the left-hand end of the genome including the complete
Ml gene plus flanking sequences.
The shuttle plasmid pST76k SrE contains a limited number of restriction
endonuclease sites within the multiple cloning site. As none of the sites present were
also found at the termini of the Hind E fragment it was necessary to add linker
sequences to the ends of Hind E to allow cloning into one of the restriction sites.
Initially a sample of pUC 13+Hind E was remov ed from a glycerol stock previously
fro/en at -80°C and spread on an agar plate containing ampicillin. Following
overnight incubation at 37°C a single colony was isolated and grown overnight in LB
containing ampicillin. Following enzymatic digestion with Hmdlll the sample was
run on a 1% agarose gel and the 6. lkb fragment corresponding to Hind E was gel
extracted using a Qiagen Qiaquick Gel Extraction Kit. Nucleotides were then added to
the restriction termini of the Hind E fragment using T4 polymerase to create blunt
ends. The blunt-ended Hind E DNA was then purified using phenolxhloroform to
remove any contaminating T4 polymerase.
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figure 4.1 BAC Mutagenesis Procedure in E. coli DH10B cells (adapted from O'Connor et al, 1989)
i. Formation/selection of cointegrates
lSacB
MIA BAC pST76k_SrE J
Transfection of the shuttle plasmid pST76k SrE,
(Materials & Methods section A.2.3) containing the
corrected copy of Ml into K. coli containing the MIA
BAC allows homologous recombination mediated by
rccA to occur.
2. Resolution of cointegrates
After incubation at 43°C individual colonies
are streaked onto plates containing
chloramphenicol and incubated at 30°C. RecA
is active at this temperature, allowing
resolution of cointegrates.
A
The shuttle plasmid replicates most
efficiently at 30°C so incubation of
transfected cells is carried out at at this
temperature. RecA is active at this
temperature so recombination can occur.
Growth on kanamycin- and
chloramphenicol-containing agar plates
selects for cells containing both the MIA
BAC and the shuttle plasmid.
After 24-28 hours plates are moved to
43°C- this prevents replication of the
shuttle plasmid and only cells containing
cointegrates will form colonies.
Resolved cointegrates are selected by incubation on
plates containing chloramphenicol and 5% sucrose.
Plates are incubated for 24-48 hours at 30°C.
r \
Confirmation of kanamycin sensitivity is
achieved by plating colonies in parallel on
kanamycin and chloramphenicol plates.
This can be checked by restriction enzyme
mapping or PCR analysis.
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BamHI linkers (sequence given in Materials & Methods section A. 1.2) were added to
the blunt ends using T4 DNA ligase. The Hind E fragment was then digested using
BamHI. and PCR-purified using the Qiagen QIAquick kit to remove any unattached
linkers.
pST76k_SrE was also digested using BamHI and treated with calf intestinal
phosphatase (CIP) to prevent self-annealing. The Hind E fragment and pST76k_SrE
were then ligated overnight using T4 DNA ligase. This DNA was electroporated into
electrocompetent DH10B cells. Bacteria were spread on agar plates containing
kanamycin to select for the presence of recombinant plasmids and incubated
overnight at 30°C.
This protocol was attempted numerous times but at no point were any recombinant
plasmids formed. A similar strategy using Kpn linkers (Materials and Methods section
A.1.2) in place of BamHI was attempted (with pST76k_SrE digested with Kpnl) with
similarly poor results. A third strategy involving the blunt ending of the Hind E
fragment (and no linkers added) followed by ligation into the Smal site of
pST76k SrE also did not work.
To test if addition of BamHI linkers to the Hind E fragment was occurring
successfully it was decided to attempt cloning of the Hind E/BamHI fragment into
another plasmid containing a BamHI site in the multiple cloning site. pBluescript SK-
was digested with BamHI and incubated overnight at 17°C with the Hind E/BamHI
fragment in the presence of T4 DNA ligase. Following electroporation into DH10B
cells bacteria were spread on plates containing ampicillin and incubated overnight at
37°C. Many colonies were formed, and individual colonies were used to inoculate 5
ml LB containing ampicillin. After overnight incubation at 37°C plasmid DNA was
extracted from cultures using a Qiagen Miniprep kit. DNA was digested using BamHI
and run on a 1% gel. Figure 4.2 shows the presence of a 3 kb and a 6.1 kb band,
corresponding to the 3 kb plasmid fragment and the 6.1 kb Hind E fragment.
Having determined that BamHI linkers could successfully be added to Hind E to
allow cloning into pST76k_SrE, the ligation of Hind E to the shuttle plasmid was






Figure 4.2 The HindE fragment of MHV-68 was successfully cloned into pBluescript. Following
blunt-ending of the HindE fragment and subsequent addition of BamHl linkers, HindE was cloned
into the BamHl site of pBluescript. Individual bacterial colonies were grown overnight in LB and
plasmid DNA extracted. Following plasmid digestion with BamHl, fragments were run on a 1% gel
and stained with ethidium bromide. The presence of a 3.1 kb band and (corresponding to the
pBluescript plasmid) and 6.1 kb band (corresponding to the HindE fragment) indicated the successful
cloning of HindE into pBluescript. Digests from two independent colonies are shown (marked 1 and
2). Band sizes were determined relative to a 2 log ladder (marked M) (NEB).
M 1 2 3 4 5 - M
igure 4.3 HindE (including the Ml gene) was successfully cloned into pST76k_SrE. The presence of
indE in pST76k_SrE was confirmed by by PCR using primers specific for the gene (bdgene4 and
(15'race) which give a product of 340 bp. 5 separate colonies are shown above (numbered 1-5), as well
; a negative control (-). Band sizes were determined relative to a 1 kb+ ladder (marked M) (NEB).
Chapter Four Results
(Hind E) to vector (pST76k_SrE), different ratios were used, from 1:1 up to 6:1. After
numerous attempts the original 3:1 ratio produced colonies containing recombinant
pST76k_Sre with Hind E. PCR using primers specific to the Ml gene confirmed the
presence of the Ml gene in the plasmid (shown in figure 4.3).
From this point onwards the protocol proceeded as demonstrated in figure 4.1.
Briefly, the pST76k_SrE+Hind E was electroporated into DH10B cells containing the
MIA BAC. DHlOBs containing both the BAC and the shuttle vector were selected by
plating in the presence of kanamycin and chloramphenicol. After incubation at 30°C
to allow formation of cointegrates, selected colonies were replated at 43°C where the
shuttle cannot replicate and only cells containing a cointegrate will form colonies.
Colonies growing at 43°C were replated at 30°C to allow resolution of cointegrates -
the bacterial recA is active at this temperature. As the resulting colonies were likely to
be a mixture of either resolved BACs or cointegrates, cointegrates were selected
against by plating at 30°C in the presence of 5% sucrose. Confirmation of kanamycin
sensitivity was achieved by plating colonies in parallel on kanamycin and
chloramphenicol plates.
Individual colonies were selected and grown overnight in 5 ml LB containing
chloramphenicol. Colonies known to contain PHA3 (wild-type BAC) and MIMbac
(the MIA BAC) were also grown to allow for comparison. BAC DNA was extracted
using the Sigma BAC DNA kit and eluled into a final volume of 15 pi.
Infectious MlARev virus was thai reconstituted from BAC DNA. BAC vector
sequences must be removed from the virus prior to use in vivo as failure to remove
these sequences results in attenuation of the virus (Adler et al., 2001). As the vector
sequence is flanked by loxP sites, passaging the virus through Cre 3T3 cells
expressing Cre recombinase results in excision of the BAC vector DNA. As the vector
sequence contains glp under control of the CMV IE promoter it is possible to
differentiate between viral plaques which have excised the vector sequence
(colourless) and those which have not (greenXAdler et al., 2000). Following isolation
of MlARev virus lacking BAC vector DNA, viral stocks were grown and titrated.
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Confirmation of the reintroduction of the complete Ml gene into the MlARev
genome was achieved using southern blotting.
To make the radioactive probe for the Ml gene HindE in pUC13 was digested with
Hindlll and the resulting fragments run on a 1 % agarose gel. The band corresponding
to HindE (6.1 kb) was isolated and the DNA extracted using the Qiagen QIAquick gel
extraction kit. This DNA was then radiolabeled with (a-32P)dCTP according to the
protocol given in Materials & Methods 2.2.10.4-5.
BHK-21 cells were infected with MIA, MlARev or PHA4 (wild-type MHV-68)
viruses according to the protocol given in 2.2.10.1. Viral DNA was extracted from the
BHK-21s and digested with EcoRV. In the case of PHA4 and MlARev digestion with
this enzyme was predicted to produce fragments of 6216 bp and 2901 bp, while
digestion of MIA was expected to produce bands of 4774, 2901, 444 and 20 bp (as
shown in figure 4.4). After separation of the DNA fragments by electrophoresis the
DNA was transferred to nylon membrane and probed with the radiolabelled HindE
fragment.
Figure 4.4c shows the southern blot of EcoRV-digested MIA, MlARev and PHA4
DNA. As predicted, both PHA4 and MlARev show an identical restriction fragment
pattern, with bands of the predicted size. MIA shows the predicted alteration, with a
reduction in size of the 6216 bp band to 4774 bp, and a new band at 444 bp (the
predicted band at 20 bp was not visible). The band at 2901 bp is still present in MIA.
4.3 In Vitro Characterisation of the M1A and MlARev Viruses
4.3.1 M1A and MlARev Replicate Equivalently to PHA4 In Vitro
Previous studies involving viruses with a deficiency in the Ml gene have not
indicated any requirement for Ml during in vitro growth (Clambey et al, 2000; Simas
et al, 1998; Dutia et al, 2004). Analysis of single and multiple rounds of replication in
BHK-21 cells demonstrated that all viruses replicated equivalently, confirming Ml is
dispensable for in vitro replication and does not affect cell-to-cell spread. One- and
multi-step growth curves are shown in Figure 4.5.
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Confirmation of the reintroduction of the complete Ml gene into the MlARev
genome was achieved using southern blotting.
To make the radioactive probe for the Ml gene Hind E in pUC13 was digested with
Hindll 1 and the resulting fragments run on a 1 % agarose gel. The band corresponding
to Hind E (6.1 kb) was isolated and the DNA extracted using the Qiagen QIAquick
gel extraction kit. This DNA was then radiolabeled with (a-32p)dCTP according to
the protocol given in Materials & Methods 2.2.10.4-5.
BHK-21 cells were infected with MIA. MlARev or PHA4 (wild-type MHV-68)
viruses according to the protocol given in 2.2.10.1. Viral DNA was extracted from the
BHK-21s and digested with EcoRV. In the case of PHA4 and MlARev digestion with
this enzyme was predicted to produce fragments of 6216 bp and 2901 bp. while
digestion of Ml A was expected to produce bands of 4774, 2901, 444 and 20 bp (as
shown in figure 4.4). After separation of the DNA fragments by electrophoresis the
DNA was transferred to nylon membrane and probed with the radiolabeled Hind E
fragment.
Figure 4.4c shows the Southern blot of EcoRV-digested MIA, MlARev and PHA4
DNA. As predicted, both PHA4 and MlARev show an identical restriction fragment
pattern, with bands of the predicted size. M1A shows the predicted alteration, with a
reduction in size of the 6216 bp band to 4774 bp, and a new band at 444 bp (the
predicted band at 20 bp was not visible). The band at 2901 bp is still present in MIA.
4.3 In Vitro Characterisation of the M1A and MlARev Viruses
4.3.1 M1A and MlARev Replicate Equivalently to PHA4 In Vitro
Previous studies involving viruses with a deficiency in the Ml gene have not
indicated any requirement for Ml during in vitro growth (Clambey et a/., 2000; Simas
el a!., 1998; Dutia et al., 2004). Analysis of single and multiple rounds of replication
in BHK-21 cells demonstrated that all viruses replicated equivalently. confirming Ml
is dispensable for in vitro replication and does not affect cell-to-cell spread. One- and






































Figure 4.4a & b Construction and confirmation of the genome structure of MIA and MlARev.
(A) Structure of the region encoding Ml. The diagram shows the site of the deletion in MIA, the
restriction fragments generated by digestion with EcoRV (RV) and the position of the probe used
for the Southern Blot analysis. (B) The MIA insertion. A 193 bp insert containing two EcoRV sites
(RV) replaces genome co-ordinates 2022-3193.




Figure 4.4c Southern Blotting shows the deletion of approximately 1 kb in the HindE region of the
MIA virus and the subsequent restoration of this region in the MlARev virus. Viral DNA was
extracted from BHK-21 cells infected with MIA, MlARev or PHA4. DNA was digested with EcoRV, and
the fragments were separated by gel electrophoresis and subsequently transferred by southern blotting to a
nylon membrane. Probing with (a-32p)dCTP-labelled HindE revealed identical band patterns for the
- MlARev (lane 2) and PHA4 (lane 1) DNA, with two bands (2901 bp and 6216 bp) observed as predicted.
The MIA virus (lane 3) retained the 2901 bp band, showed a reduction in size of the 6216 bp fragment to
4774 bp, and contained two further bands of 444 bp and 20 bp (not visible) as predicted by the deletion of



















4.5 The MIA virus replicates with the same kinetics as wild-type and revertant viruses in vitro.
BHK-21 cells were infected with 5 p.f.u. per cell (one-step, a) or 0.05 p.f.u. per cell (multi-step, b)
and harvested at specific time points post-infection. Infected cells were lysed by freeze-thawing and
virus titres were determined on BHK-21 cell monolayers. All infections and titrations were carried
out in duplicate. The data represent the mean±SD.
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4.4 In Vivo Characterisation of the M1A and M1 ARev Viruses
4.4.1 Infection with M1A Results in Increased Lung Titres Following
Intranasal Infection
Previous studies investigating the role of M l have focussed primarily on the spleen.
Following intranasal infection with MHV-76, a reduction is seen in viral titres
compared to infection with MHV-68. and MHV-76 is cleared more rapidly from the
lung (Macrae et al., 2001). This phenotvpe has not been attributed to the individual
action of genes M2. M3 or M4. or the viral tRNA-like molecules (Macrae et al., 2(X)3;
Jacoby et al., 2002; van Berkel et al.. 2002; Evans et al., 2006; Geere et al., 2006; A.
Cliffe, 2(X)5). This suggests a potential role for Ml in modulating infection in the
lung. To test this hypothesis female BALB/c mice aged 5-6 weeks were infected
intranasallv with 4 x IO3 PFU of MIA, Ml ARev or PHA4. 4 mice were infected per
virus per time point. At the appropriate time mice were sacrificed by CO2
asphyxiation and the lungs and spleen removed
Lung titres were determined using plaque assays according to the protocol given in
Materials & Methods section 2.7.6.2. Time points assayed were 3, 5, 8 and 10 days
post-infection. As shown in Figure 4.6, MIA infection results in significantly elevated
lung titres at days 5 (p<0.05), 8 (p<0.005) and 10 (p<0.01) days post-infection
compared to both Ml ARev and PHA4, although not at day 3.
These findings suggest that Ml is important during productive infection with MHV-
68. Prev ious data (figure 3.6) indicates that the initial elevation in lung tilres does not
affect long-term levels of viral persistence in the lung, and the role for Ml in the lung
appears to be limited to the acute phase of infection.
4.4.2 M1 Plays a Role in Stimulation of Lymphoid Cell Proliferation
Clambey et al. (2000) identified a role for Ml in reactivation from latency in the
PECs following intraperitoneal infection. No statistically significant difference was
observed in the spleen, although the frequency of reactivation was slightly higher for
Ml LacZ at late time points.
To determine if differences in reactivation were reproduced following infection with
MIA and also if intranasal infection affected establishment, maintenance or













0 3 6 9 12
Days Post-Infection
Figure 4.6 The MIA virus replicates to higher titres in the lung. BALB/c mice were infected
intranasally with 4 x 105 PFU of either the MIA, MIARev or PHA4. Lungs were harvested at
various times post-infection and virus titres were determined on BHK-21 cell monlayers. The data
shown represent the mean+SD for 4 mice. A significant difference was observed between MIA and
both MIARev and PHA4 at days 5, 8 and 10 post-infection (P<0.05, Students's /-test).
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of either MIA, MlARev or PHA4. Spleens were removed at specific time points post¬
infection and weighed.
Mice infected with M1 ARev or PHA4 showed increasing spleen mass from day 5 to a
peak at d 15, with mass returning to an approximately normal level by d22 (shown in
figure 4.7a). This rise and fall in spleen mass is mirrored by the number of
splenocytes - again there is 6-7- fold rise in number from d5 to d 15 followed by
subsequent return to normal levels (figure 4.7b).
Changes in spleen mass failed to occur following infection with MIA, with
proliferation of lymphocytes severely impaired and showing only a two-fold rise in
numbers. This is similar to the deficit observed following infection with MHV-76,
where splenocyte numbers fail to rise to the same levels as seen on infection with
MHV-68 (Macrae et al., 2001). This phenotype has not been observed in MHV-68
mutants lacking M2 (Macrae et al., 2003). M3 (Van Berkel et al., 2002), M4 (Geere
et al., 2006) or the tRNA-like molecules (A. Cliffe. 2005). This aspect of the MHV-
76 phenotype is therefore likely to be solely due to the actions of the Ml gene.
Levels of latent virus in the spleen were to be measured by the ex-vivo reactivation
assay (Materials & Methods section 2.7.6.3). However owing to an unfortunate
infection in the BHK-21 cells the only lime point at which the assay was performed
was at dl5. Figure 4.8 shows the results for this single time point. Despite the
comparativ ely low splenocyte numbers there are a greater number of infective centres
(i.e. cells reactivating latent virus) in MlA-infected spleens compared to MlARev- or
PHA4-infected spleens (p<0.05). This suggests either a higher number of infected
cells in the spleens of M1 A-infected mice, or an equivalent or reduced number of cells
reactivating virus at an increased level. To determine what process was driving the
increased levels of infective centres quantitative PCR was used to determine the viral
load in the spleens of Ml A- and control-infected mice.
4.4.3 Quantification of Viral Load in the Spleens of M1A-, MlARev- and
PHA4-infected Mice
Splenocytes previously stored at -80°C (excess remaining from the ex-vivo
reactiv ation assay) were used to quantify lev els of viral DNA in the spleen during the
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Figure 4.7 Ml is necessary for lymphocyte expansion and the corresponding increase in spleen
mass. BALB/c mice were infected with 4 x 105 p.f.u MIA, MIARev or PHA4. At various times post¬
infection spleens were removed and weighed (a) and the number of splenocytes counted (b). The data
shown represent the mean±SD A significant difference was seen between MIA and the control
viruses (MIARev and PHA4) in spleen mass at dlO (p<0.01) and d 15 (p<0.005), with the MIA virus
failing to show any increase in mass at these time points. This corresponds to a failure of the MIA
virus to drive lymphocyte expansion, with a significant difference in splenocyte number between




















Figure 4.8 At dl5 deletion of Ml results in increased reactivation from latency. BALB/c mice
were infected intranasally with 4 x 105 p.f.u of either MIA or control (MlARev or PHA4) viruses.
Each data point represents 4 mice. Mice were sacrificed 15 days post-infection. The MIA virus shows
a significant increase in the number of infective centres at dl 5 compared to control viruses (p<0.01,
Student's /-test).
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and PHA4-infected samples were studied. No differences have been observed in vitro
or in vivo between the MlARev and PHA4 viruses so only 4/8 of the available
samples were used for quantification of viral load to reduce costs.
DNA was extracted from splenocvtes using the Qiagen DNeasv kit. DNA was
quantified and 100 ng template DNA was used in the M4 real-time PCR assay to
quantify viral load. As before (see chapter 3) viral load was normalised to the levels
of P-actin DNA in the samples to correct for any variation in quantity or quality of the
template DNA Figure 4.9 shows the results for this experiment. At dlO both MIA
and control (MlARev or PHA4) infected samples show similar viral loads. However
at dl5 mice infected with the MIA virus show an approximately 5-fold reduction in
virus levels compared to controls. By dl9 post-infection the viral load is again
equivalent in the MIA- and control-infected samples.
Results from these experiments indicate that there appears to be a failure of the MIA
virus to drive lymphocyte expansion, resulting in a lack of increase in spleen mass.
Viral DNA load is significantly reduced on dl4 compared to wild-type virus, which
may or may not be as a result of the absence of lymphocyte expansion. Levels of
reactivating virus are significantly higher following infection with MIA, indicating
that control of reactivation is impaired. While the frequency of infected splenocytes is
equivalent in M1A-, MlARev- and PHA4-infected mice, the frequency of reactivation
of virus in MlA-infected mice is approximately 5-fold higher. The real time PCR
assay cannot determine whether a reduction in viral load is a result of few er infected
cells, or if the number of infected cells remains constant and the viral copy per cell is
reduced. A reduction in viral copy number per cell would account for the similar
frequencies of infected splenocytes observed in M1A-, MlARev- and PHA4-infected
mice despite the apparent differences in viral load.
In order to confirm the results observed above and to determine if enhanced
reactivation of the MIA virus is observed at times other than dl4, the experiment was
repeated.
Female BALB/c mice were infected as before with either MIA or MlARev viruses
(PHA4 was omitted as the results were expected to match those of MlARev). Mice























Figure 4.9 Deletion of Ml results in failure to establish normal viral load at dl5. DNA was extracted
from the spleens of the mice used in the previous experiment (figures 4.9-10) and viral load was
quantified using real time PCR. At dl5 viral load in mice infected with MIA was significantly reduced
(pO.OOOl, Student's /-test).
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for levels of reactivating virus and for quantification of viral load. However for
unclear reasons a number of mice succumbed to the virus several days after infection.
While the mice were infected at the same age as in the previous experiment, there is a
possibility" the mice used in the repeat experiment were smaller, and this reduction in
size in some way increased susceptibility to viral infection.
Figure 4.10 shows the survival curve for mice infected with either MIA or Ml ARev.
All mice infected with MIA survived, while 8/12 mice infected with Ml ARev died
between 9 and 13 days post-infection. This indicates the Ml virus is attenuated in vivo
compared to the wild-type virus
Owing to the deaths of the MlARev-infected mice the experiment continued with
only 2 Ml ARev-infected mice per time point, and only dlO and dl5 investigated.
However, the extremely small sample sizes coupled with the likelihood that a number
of mice were presenting with clinical symptoms at the point of sacrifice made
repetition of the previous experiments difficult. While a number of experiments were
attempted (shown in figures 4.11-4.13) the results were likely to have been skewed by
the inclusion of sick mice at the time points investigated. As such, the results obtained
previously were not reproduced in this second experiment and it was not possible to
validate our findings.
4.5 Discussion
These data show a distinct role for the Ml gene in the pathogenesis of MHV-68.
Preliminary results indicate a role for M1 during acute infection of the lung, as w ell as
confirming a previously identified role during virus reactivation in the spleen.
Our data show loss of Ml results in a significant increase in viral titres at early time
points in the lung and delayed clearance. No previous studies involving M1 -deficient
viruses (Clambey et a/., 2000; Simas et al., 1998; Dutiae/al, 2004) have investigated
viral replication in the lung and this is the first indication of a role in this organ.
Infection of mice with the deletion mutant MHV-76 which lacks Ml as well as M2.
M3, M4 and 8 vtRNA-like molecules does not result in the elevated lung titres
observed following infection with MIA (Macrae et al., 2001). In fact MHV-76
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Figure 4.10 The MIA virus is attenuated in vivo compared to the wild-type revertant virus MIA
Rev. BALB/c mice aged 5-6 weeks were infected intranasally with 4 x 105 p.f.u. of either MIA or
MIARev virus. The Kaplan-Meier analysis shows the deaths of 8/12 MlARev-infected mice between 9
















































Figure 4.11 MIA fails to cause an increase in spleen mass at dl5 but this does not correlate with
a failure to cause lymphocyte expansion. As shown previously in figure 4.9a the control virus
(MIARev) shows a peak in spleen mass at d 15, while the MIA virus fails to stimulate this peak (a).
However the previous difference between viruses at d 10 is not seen, possibly due to the ill-health of
the MIA Rev mice at this point. Unlike the previous experiment the peak in spleen mass in the
MIARev virus is not accompanied by a peak in splenocyte numbers (b). Data points for the MIA virus
correspond to 4 mice; data points for the MIARev virus correspond to 2 mice. Data were analysed
using the Student's /-test.
101_l , T T ,
8 10 12 14 16
Days Post-Infection
Figure 4.12 Deletion of Ml results in increased reactivation from latency. Spleens taken previously
from BALB/c mice (see figure 4.14) were assayed for the level of reactivating virus. At dlO the MIA
virus shows a significantly higher level of reactivating virus compared to the MlARev virus (p<0.05,












Figure 4.13 Spleen viral load is below the limit of detection following intranasal infection with
either MIA or MIA Rev. Female BALB/c mice aged 5-6 weeks were infected intranasally with 4 x 105
p.f.u. of either MIA or MIARev. Owing to the deaths of a number of MlARev-infected mice, 4 mice per
time point were used for MlA-infected mice and 2 mice per time point for MlARev-infected mice. The
majority of samples fall below the limit of detection of the assay (indicated by the line A) making
accurate comparison of viral load between the two viruses difficult.
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along with earlier clearance from the lung, a direct contrast to the MIA virus. This
suggests another part of the left-hand end of the genome is also involved in
maintaining normal viral titres in the lung. Mutation of any of the other unique genes
or the tRNAs individually does not affect lung titres (Jacob}- et al., 2002; van Berkel
et al., 2002; Bridgeman et al., 2001; Evans et al., 2005; Geere et al., 2006; A Clilfe,
personal communication). This suggests a combination of genes and/or tRNAs in the
unique region are responsible for normal viral titres in the lung, and the combined loss
results in the reduction in lung titres in MHV-76 that are not observed in any single
unique gene mutant
Previous studies have shown Ml plays a role in viral reactivation. Clambev et al.
(2000) found 1/3 PECs reactivating virus following infection with Ml.LacZ
compared to 1/15 following infection with wild-type virus at 6 weeks post-infection.
At this time point spleen cells demonstrated a small increase in frequency of
reactivation compared to wild-type virus. Our initial experiment demonstrated a 5-
fold increase in the frequency of spleen cells reactivating virus at d 15. Whether this
difference was maintained at other time points remains to be determined - it is
possible by 6 weeks post-infection similar results to those obtained by Clambey et al.
may be reproduced.
Data from the first experiment showed that a peak in spleen mass was linked to
increased number of splenocytes in MlARev- or PHA4-infected mice, a common
characteristic of MHV-68 infection (Sunil-Chandra et al., 1992a; Sunil-Chandra et al,
1992b). Following infection with MIA, neither of these features were observed.
Spleen mass and lymphocyte expansion following infection with Ml-deficient viruses
has previously been studied by Dutia et al. (2004) using the V2 virus that lacks Ml
and vtRNAs 1 and 2 (Simas et al., 1998). This study showed that following infection
of wild-type 129 SV/EV mice with V2, spleen numbers at dl 3 are lower than in mice
infected with wild-type virus. However, spleen cell numbers in V2-infected mice
continue to rise from d 13 until at least d29 (the last time point investigated). In this
study splenomegaly appears delayed rather than abolished, and it is possible that in
the BALB/c mice this phenomenon is repeated, albeit with a longer initial delay.
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MHV-76 infection also fails to cause splenomegaly (Macrae el al., 2001; Clambey et
al., 2002), a characteristic not attributed to any other of the unique genes. This
suggests this aspect of the MHV-76 phenotype is due to the loss of Ml from the viral
genome.
In the case of the second experiment a large number of MlARev-infected mice died,
leading to the conclusion that the MIA virus was relatively attenuated. This
attenuation was also noted by Clambey following infection of C.B-17 SCID and
IFNyR-deficient mice with the Ml.LacZ virus. The most likely explanation for the
deaths of the MlARev-infected mice was a reduction in size compared to the previous
experiment
The repeat experiment produced a number of confusing results, a problem
compounded by the small sample sizes in the MlARev-infected group owing to the
deaths.
At dlO spleen masses and splenocyte numbers were marginally lower in MlARev-
infected mice compared to MIA, most likely because the MlARev-infected mice were
terminally ill at this point. At this time point MIA was able to reactivate virus at
higher levels. By dl5 spleen masses of MlARev-infected mice had increased to a
level higher than that of MlA-infected mice, reproducing results from the previous
experiment. However this was not linked to a significantly higher level of splenocytes
in MlARev-infected mice, which either suggests spleen mass is not directly related to
splenocyte number, or that the splenocytes were miscounted. There is a possibility
that spleen mass is influenced by factors independent of cell number, such as fluid
content. However the second option appears more likely as it is not clear how spleen
mass could increase in the absence of either an increased number or a massively
increased size of cells, and an increased size of cells was not observed.
Reactivation at d 15 is equivalent for both viruses, and it is not possible to tie this to
any difference in viral load because almost all samples measured fell below the limit
of detection of the real time assay.
This experiment was useful in that it confirmed Clambey's previous findings that Ml -
deficient viruses are attenuated in vivo, but owing to the extremely small sample sizes




Previous sequence analysis indicated sequence homology of the Ml gene to the
poxvirus serine proteinase inhibitor (serpin) SPI-1 gene (Virgin et al., 1997), although
Ml lacks clear homology to the functionally important hinge domain and reactive site
loop of the poxvirus serpins (Bow den el al., 1997). As mentioned previously, the role
of the poxvirus SPI-1 gene appears to be inhibition of apoptosis (Brooks el al., 1995;
Moon et al., 1999). A role in inhibition of apoptosis has not yet been demonstrated for
Ml, although the presence of another anti-apoptolic gene in the MHV-68 genome has
been widely documented. The Ml 1 gene is a bcl-2 homologue that is able to inhibit
Fas- and TNF-induced apoptosis (Wang et al., 1999; Roy et al., 2000) and is required
for efficient reactivation from latency (Gangappa et al., 2002). However, the
properties of Ml-deficient viruses do not mirror the properties of M11-deficient
viruses, which suggests that if Ml is an inhibitor of apoptosis it is acting at a different
point during infection to the known anti-apoptotic Ml 1 gene.
Further sequence analysis has demonstrated similarities between the Ml and M3
genes of MHV-68 (van Berkel et al., 1999). The M3 gene shows no significant
homology to the poxvirus SPI-I gene, and functions as a secreted chemokine binding
protein to modulate the host immune system (van Berkel et al., 1999; Parry et al.,
2000; van Berkel et al., 2000;). Structural analysis of M3 and Ml have shown that Ml
and M3 may share folding features, but that the M3 chemokine contact residues are
rarely conserved in Ml, indicating that an unrelated function for Ml is likely
(Alexander et al., 2002).
This study also indicates that the M4 gene of MHV-68 may share folding features
with both M3 and Ml, indicating a possible relationship between Ml and M4. The
function of the M4 gene of MHV-68 is also yet to be elucidated; however, it encodes
a secreted glycoprotein required for establishment of normal viral load during acute
phase latency (Evans et al., 2006; Geere et al., 2006). This defect in viral load during
acute phase latency mirrors our findings following in vivo infection with the Ml
deletion virus. However, despite some similarities disruption of M4 does not produce
an identical phenotype in vivo to disruption of Ml (Evans et al., 2006; Geere el al.,
2006; Clambey et al., 2000). This indicates that while possibly related, the functions
of these two genes are not redundant.
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One of the key features following deletion of Ml is the enhanced reactivation from
latency in the spleen. This is a phenomenon also observed in B cell-deficient mice
(Week el al, 1999). It is tempting to speculate that in the absence of Ml an
interaction with B cells fails to occur, and as a result B cells in immunocompetent
mice fail to control reactivation.
In conclusion our preliminary results confirm findings previously shown. M1 appears
to play a role in virus reactivation in lymphoid tissue, and loss of Ml from the virus
genome results in attenuation as determined by reduced virulence in young or small
mice. Our results also show a number of previously unidentified characteristics of an
Ml-deficient virus, including an increase in lung titres during acute infection, and a
failure to drive splenomegaly. These data are only preliminary, however due to time
constraints it was not possible to repeat all experiments to confirm the results. While
structural similarities appear between the Ml gene and the other MHV-68 unique
genes M3 and M4, the functions of these genes do not appear to be redundant,
indicating a unique function for the Ml gene during acute infection of the lung and
establishment of latency in the spleen.
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Chapter 5: In Vivo Characterisation of
the M4ln1 Virus
5.1 Background to the Study
5.2 Generation of the M4ln1 and M4ln1Rev
Viruses




5.1 Background to the Study
The left end of the MHV-68 genome has long been known to play a role in
pathogenesis of the \irus (Nash et a!., 2001). The region contains four unique genes
and eight viral tRNA-like molecules, all of which have been studied to investigate
their roles during infection.
As well as the coding DNA sequence, an amount of apparently non-coding DNA is
contained within the left end of the genome. This includes a 1.2 kb region located
between the M3 and M4 genes. Little is known about the importance of this region in
v iral pathogenesis, but it is conserved in the naturally occurring deletion mutant
MHV-72. This virus is similar to the MHV-76 virus, but while MHV-76 is lacking the
first 9.5 kb of the left end of the genome, MHV-72 misses only the first 7 kb. As a
result, while MHV-76 lacks genes M1-M4 and the vtRNAs, MHV-72 still carries the
complete M4 gene as well as sequences upstream of this gene. The presence of an
extra 2.5 kb of sequence in the MHV-72 genome results in a slightly altered
phenotype compared to MHV-76. Mice infected with MHV-72 are prone to
development of tumours at late time points post-infection, a characteristic not
associated with MHV-76 infection (Oda et aI., 2005). This suggests that M4 and/or
the upstream sequences may play a role in tumorigenesis.
5.2 Generation of the M4ln1 and M4fn1Rev Viruses
Tire M4 gene has been a focus of interest for some time. Initial studies identified the
start of the M4 gene at genome co-ordinate 8409 bp (Virgin et a!., 1997). To
investigate the role of M4 during MHV-68 infection, an M4 mutant virus was
generated using the MHV-68 BAC system developed by Adler et al. (2000). Shuttle
recombination (method from Wagner & Kos/inovvski. 2004) was used to insert a
19bp region of DNA containing 3 in-frame stop codons into the start of the M4 gene
at genomic co-ordinate 8409. The aim was to prevent translation of the M4 gene, and
this virus was known as the M4Inl virus. To confirm that anv change in phenotype
observed following infection with the M4Inl virus was due to the targeted mutation
and not a distal mutation in the MHV-68 genome, a marker rescue virus (M4InlRev)
was constructed in which the w ild-type M4 sequences were restored in M4Inl (Geere,
2004).
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Prior to characterisation of the M4Inl virus, studies on the M4 gene revealed the start
codon was in fact located at genomic co-ordinate 8526 (Townsley el al, 2004). This
indicated that the mutation had been introduced into an apparently non-coding region
of the genome betw een the M3 and M4 genes.
However despite the location of the mutation in an intergenic region, the M4Inl virus
show ed an altered phenotype following intranasal infection of IFNyR"" mice. Of note
w ere the lungs of these mice at 12 days post-infection, w here a substantial increase in
pathologv was observed in M4Inl-infected mice compared to MHV-68-infected mice.
The initial in vivo study of this virus w as limited to a small group of mice at a limited
number of time points (Geere. 2004).
To further characterise the M4Inl virus we conducted a number of in vivo studies to
determine how the mutation altered pathogenesis of the virus.
5.3 In Vivo Characterisation of the M4ln1 Virus
5.3.1 Intranasal Infection of Wild-Type 129 SV/EV Mice Results in
Increased Viral Lung Titres at Early Time Points Post-Infection.
Previous observations suggested the M41nl virus resulted in an altered phenotvpe in
the lung following intranasal infection of IFNyR" mice. To investigate if this
phenotvpe occurs in conjunction with an alteration in viral levels in the lung 3-4
month old IFNyR"" and w ild-type 129 mice were infected intranasally with 4 \ 105
p.f.u. of either M4Inl or control viruses (M4InlRev or PHA4) At various time points
post-infection mice were sacrificed and organs were removed and stored at 80°C
until required Infectious virus was determined by plaque assay (Materials & Methods
section 2.7.6.2) and the results are shown in Figure 5.1. At 3 days post-infection the
virus litre is significantly higher in 129 mice infected with M4Inl compared to 129
mice infected with either of the control viruses (M4Inl Rev or PHA4). No significant
difference was observed following inoculation of IFNyR"" mice with M4!nl or
control v i Rises.
Townsley el a! (2004) found that following insertion of the M4 gene into the MHV-
76 genome elevated lung titres were observed 1 day post-infection relative to MHV-
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7igure 5.1 The M4Inl Virus causes increased lung titres at early time points in wild-type 129
nice but not in IFNyR_/ mice. 3-4 month old mice were infected intranasally with 4 x 105 p.f.u. of
either M4Inl or a control virus (50% of mice infected with M4InlRev and 50% with PHA4). At 3
lays post-infection 129 mice infected with M4Inl showed significantly increased viral titres in the
iung compared to mice infected with the control viruses (p=0.04, Student's /-test). This difference was
not observed following intranasal infection of IFNyRmice. At all other time points no significant
difference was observed between mice infected with M4Inl or control viruses. Each data point
represents four mice. The limit of detection of the assay is labelled A.
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speculation that the mutation upstream of the M4 gene may be resulting in a similar
phenotype in the M4In 1 virus, potentially due to upregulation of the M4 gene.
5.3.2 M4in1 is Attenuated In Vivo Following infection of Juvenile IFNyR'
Mice
The M4 phenotype is most obvious in the spleen, with a 10-100-fold deficit in viral
load observed during acute phase latency (Evans et al., 2006; Geere el al., 2006). This
deficit is observed between days 14 and 17, and is resolved by d42. To test if viral
load in the spleen was altered at these time points both wild-type 129 and IFNyR""
mice were infected intranasally with 4x10 p.f.u. of either M4Inl or M4InlRev (no
study has indicated a difference between M4InlRev and PHA4. so PHA4 was not
included for cost reasons). The previous in vivo study had involved infection of mice
aged 3-4 months, but owing to time constraints mice were subsequently infected at 5
w eeks of age. The aim w as to quantify viral load at the time points 15, 20 and 40 days
post-infection, with 4 mice per virus per time point However there was an
unexpected consequence of infecting IFNyR" " mice at a younger age. At 12 days post¬
infection 8/12 IFNyR"" mice infected with M4InlRev died (shown in Figure 5.2).
M4Inl-infected IFNyR"" mice all survived until d40, as did the remaining 4
M4In 1 Rev-infected mice. All 129 mice survived regardless of the virus they were
infected with.
It is not entirely surprising that infection of immunocompromised mice at such a
young age resulted in premature death for many of the mice. Howev er, interestingly
none of the mice infected w ith M4In! succumbed to infection despite being in all
respects identical to the mice infected with M4InlRev. This suggests that M41n! is
attenuated in vivo, indicated by the reduced mortality of these mice compared to wild-
type infected mice.
5.3.3 investigation of M4!n1 Pathogenesis in Juvenile Mice
In order to carry out previously planned experiments and also to repeat previous
experiments to verify results, 6 week old IFNyR"'" and 129 mice were infected
























figure 5.2 M4Inl is attenuated following intranasal infection of juvenile IFNyR_/" mice. 5 week old
FNyR"/" mice were infected intranasally with 4 x 105 p.f.u. of either M4Inl or M4InlRev viruses. 12
nice per virus were infected in total. By dl2 8/12 mice infected with M4InlRev had died from
nfection. All mice infected with M4Inl survived. The remaining mice remained healthy until d40,
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figure 5.3 M4Inl is attenuated following intranasal infection of 6 week old IFNyRmice. 6 week
>ld IFNyR"" mice were infected intranasally with 4 x 105 p.f.u. of either M4Inl or M4InlRev viruses,
letween days 9 and 13 6/32 mice succumbed to infection. Unexpectedly 2/32 mice infected with






During the course of the experiment IFNyR" mice infected with M4Inl Rev again
began to fall ill and die as a result of infection. Between days 9 and 13, 6/32 mice
infected with the revertant virus died (shown in figure 5.3). This 19% death rate is a
significant reduction on the previous figure of 67% for 5 week old mice but still
suggests that the remaining immune system in these mice is not developed enough at
6 w eeks old to control MHV-68 infection.
2/32 mice infected with M4Inl succumbed to infection, although at later time points
than M4Inl Rev-infected mice. This was an unexpected result because in the previous
experiment involving younger mice no deaths were observed in this group. However
the percentage of deaths w as still greatly reduced compared to M4Inl Rev-infected
mice, leading to the conclusion that M4Inl is attenuated in IFNyR"" mice up to 6
weeks of age
Despite the deaths of mice in both groups there were still sufficient numbers
remaining to earn' out the majority of planned experiments, albeit with reduced
numbers at certain time points. To further investigate if the M4Inl virus showed
elevated titres at very early time points in the lung, infected mice were sacrificed at I,
3, 6, 9 and 13 days post-infection and the lungs removed. Viral titres were determined
as before using a plaque assaw Figure 5.4 shows the results for this experiment.
Unlike the previous results (figure 5.1) no difference was seen in M4Inl and
M4InlRev viral titres in either 129 or IFNyR" mice at very early time points post¬
infection (dl or d3). However at d9 IFNyR"" mice infected with M4InlRev show
significantly higher titres than M4In!-infected mice. This time point corresponds to
the onset of death in this particular group of mice and indicates that an inability to
control infection was causing death By d 13 virus was cleared by M4Inl Rev-infected
mice, indicating that mice still alive at this time point were able to recover from
infection. In contrast, M4Inl-infected IFNyR"" mice had not completely cleared the
virus from the lungs by d 13. A number of mice from this group went on to die shortly
after this time point, suggesting that some mice w ere unable to control infection. It is
not known if this is coupled to a lack of clearance of the virus from the lung.
At no time point were differences observed in 129 mice infected with either M4Inl or
M4InlRev. This contrasts with the previous experiment where M4Inl infection
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Figure 5.4 The M4Inl Virus is attenuated at d9 relative to wild-type virus in IFNyR"A mice but not
in wild-type 129 mice. 6 week old mice were infected intranasally with 4 x 105 p.f.u. of either M4Inl or
M4InlRev. Unlike the previous experiment no difference in viral titres was seen at very early time points
post-infection in either 129 or IFNyR7" mice, although at d9 IFN yR~/_ mice infected with M4Inl showed
significantly lower titres compared to mice infected with M4InlRev. Each data point represents four
mice. The limit of detection of the assay is labelled A.
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control infection, and this lack of control masks the differences observed following
infection of older mice.
5.3.4 Viral Load in the Spleen is Unaffected by the insertion in the M4ln1
Virus
M4 is essential for establishment of normal latent load in the spleen following
intranasal infection (Townsley et al.. 2004; Evans et a!., 2006; Geere et a!, 2006). To
determine if viral load was affected by the presence of a small insertion upstream of
the M4 start codon, viral load was quantified using real-time PCR. DNA was
extracted from the spleen using a Qiagen DNeasy kit (Materials & Methods section
! .2.1) and real-time PCR was carried out according to the protocol given in Materials
& Methods section 2.6. The M4 assay (using primers distal to the mutation in M4InI)
was used. Normalisation was used to correct for variation in quality and quantity of
template DNA.
Spleen samples from both experiments (infection of 5- or 6-week old mice) were used
for quantification. As shown in figure 5.5, at no time point studied was a difference in
viral load observed between M4Inl and M4InlRev for either IFNyR" or 129 mice.
This indicated that M4 activity was not significantly altered in the spleen and suggests
that the lung phenotype is unlikely to be related to M4. However given that
differences in the lung observed in older mice were not detected following infection
of younger mice, there is a possibility that a difference betw een M4In! and w ild-type
viruses could go undetected in this experiment.
To determine if M4 expression was altered in the M4Inl virus a reverse transcriptase
real-time PCR assay was developed to quantify M4 transcription. Given that previous
results did not indicate any effect of the M4Inl insertion on M4. it was decided to
investigate if M3 was in any way affected. While the M3 gene is much further from
the site of the mutation than M4 there was still the possibility of an effect on M3
expression.























Figure 5.5 Viral load in the spleen is unaffected by the mutation in the M4Inl virus. 6 week old
IFNyR"/" and 129 mice were infected intranasally with 4 x 105 p.f.u. of either M4Inl or M4InlRev. At
various time points up to dl7 post-infection mice were sacrificed and the spleens removed. 5 week old
mice were infected as above and at d40 mice were sacrificed and the spleens were removed. Real-time
PCR was used to quantify viral load. Each data point represents at least 4 mice, with the exception at
dl7 (the point corresponding to IFNyR"7" mice infected with M4InlRev represents only 2 mice). At no
point is the viral load for mice infected with M4Inl different to the control virus for both IFNyR"'" and
129 mice.
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In order to determine if M3 or M4 transcript levels were affected by the presence of
the mutation at genome co-ordinate 8409, real time assays w ere developed for both
genes. The assay w as developed using the SYBR-green method of detection.
For the real time assay primers were designed that fell w ithin the region of the M3 or
the M4 transcript (shown in Materials & Methods appendix 1.2). To generate
standards for absolute quantification plasmids were made containing either the
complete M3 or M4 gene. Initially the gene (either M3 or M4) was amplified by PCR
from viral DNA (see Materials & Methods section 5). PCR products were then cloned
into pCR4®-TOPO® vector and the plasmid copy number per pi was determined by
spectrophotometry. Serial ten fold dilutions were made to generate the standard
dilution series for use in the real time PCR reaction.
Figures 5.6 and 5.7 show the range of quantification of the M3 and M4 assays. In both
cases the DNA template containing 1 x I07 copies per pi (i.e. 5 x 107 copies per
reaction) was amplified first, with each subsequent dilution amplified at inter\als of 4
cycles until the DNA template was diluted by 6 orders of magnitude. Quantitation of
the amount of target in the unknown samples w as achieved as before by measuring C r
and using the standard curve to determine starting copy number. Melt curve analysis
w as used to demonstrate the specificity of the primers.
5.3.5.1 Normalisation of cDNA Samples
The amount of cDNA in a given sample can vary owing to factors such as RNA
degradation, quantity of RNA present in the reverse transcription reaction, and
i taction efficiency during reverse transcription.
To reduce variation RNA was quantified by spectrophotometry pnor to reverse
transcription. Normalisation of samples w as also used to correct for any otherw ise
undetected variation, for example due to degradation of either the RNA or cDNA.
The use of housekeeping gene to normalise input levels of template is a w idely used
practice. Howev er the idea! gene for use in this process is the subject of much debate
(Thellin et a!., 1999; Suzuki et al., 2000; Vandesompele et a2002; reviewed by
Huggett cl al.. 2005). Commonly used genes include p-actin. GAPDH and 18s rRNA
amongst others. Ideally several housekeeping genes are used to normalise the sample
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Figure 5.6 The M3 real time assay platform. The M3 assay can quantify viral load in the range 50 -
50,000,000 copies per 100 ng template DNA (a). Reactions containing 5 x 107 copies are amplified first,
with subsequent 10-fold dilutions amplified at 4-cycle intervals. The PCR reaction is amplifying a single
specific product that melts at 86°C (b).
Figure 5.7 The M4 real time assay platform. The M4 assay can quantify viral load in the range 50 -
50,000,000 copies per 100 ng template DNA (a). Reactions containing 5 x 107 copies are amplified first,
with subsequent 10-fold dilutions amplified at 4-cycle intervals. The PCR reaction is amplifying a single




(Vandesompele et al., 2002), but time and cost made this an unrealistic proposition.
Therefore we selected p-actin as the housekeeping gene for normalisation.
Viral infection of cells often results in host shutoff and hence impairment of
housekeeping gene transcription. This affects the normalisation process as levels of
the normalisation gene are skewed in infected compared to uninfected cells. To
determine how levels of p-actin were affected by MHV-68 infection, BHK-21 cells
were infected with either M41nl or M4InlRev. 2 x 106 cells were infected at 5 p.f.u.
per cell and incubated at 37°C. Mock-infected cells were set up in parallel. 4 samples
were set up for each of the viruses and the uninfected controls. At 1 7 hours post¬
infection RNA was harvested and reverse transcribed. Levels of p-actin were
determined using real time PCR.
At the time point investigated p-actin levels were approximately 100-fold lower in
infected cells compared to uninfected cells, and samples infected at different MOIs
also showed variation in p-actin levels at the time point investigated (data not shown).
However within samples infected at the same MOI, P-actin levels were very similar.
Therefore provided in vitro samples are infected at the same MOI, P-actin levels are
constant between samples and p-actin is a suitable housekeeping gene for
normalisation.
In vivo infections are much more complicated as the level of infection (and hence the
level of p-actin downregulation) shows much more variation between samples.
How ever at 16 days post-intranasal-mfection the level of genome positiv e cells in a
spleen infected with wild-type virus is approximately 1/300 (Evans et al., 2006). At
this frequency P-actin levels are unlikely to be substantially affected by MHV-68
infection, and variation in levels of infection between samples are also unlikely to
alter P-actin lev els significantly. On this basis we decided that P-actin was a suitable
housekeeping gene for normalisation of in vivo samples.
5.3.6 Transcription of M3 and M4 In Vitro are Unaffected by the M4in1
Mutation
BHK-21 cells were infected at a M OT. of 5 with either M4Inl or M4In!Rev and
incubated at 37°C. At v arious time points post-infection cells w ere harvested and the
RNA extracted. RNA was reverse transcribed and the resulting cDNA was used in
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real time PCR assays to quantify the levels of M3 and M4 transcription. Samples were
normalised to the level of p-actin RNA
Figure 5.8 shows the results for this experiment. Samples were taken at 4, 8, 12 and
24 hours post-infection. At no time point studied was any difference detected in M3
or M4 transcription between M4Inl and M4InlRev. This suggests the phenotype
observed following infection with M4Inl is not due to an alteration in transcription of
the neighbouring genes. However to confirm this is the case during in vivo infection
this experiment was repeated using samples taken from infected mice.
5.3.7 M3 and M4 Transcription In Vivo Are Not Affected by the M4ln1
Mutation
Previous study of the M4Inl virus had identified a phenotype in the lung, and
therefore it would seem obvious to start inv estigation of alteration in transcription in
this organ.
To determine if a different phenotype is observed following infection of IFNyR""
mice, both wild type 129 SV/EV and IFNyR"" 6-week old mice were infected
intranasally with 4 x 103 p.f.u. of either M4Inl or M4Inl Rev (these mice were used in
other experiments shown in figures 5.4 and 5.5). At various times post-infection 4
mice per virus were sacrificed. Spleen samples were stored in RNALater to preserve
RNA until it could be extracted. At dl 3 an extra 4 mice per time point were sacrificed
(the lungs from the first four mice being required for the lung titration, figure 5.4) and
the lungs inflated with 10% neutral buffered formalin. This was to allow for
histological sections to be taken as well as RNA to be extracted.
To determine if M3 or M4 levels were altered in the lungs following infection with
M4Inl, the organs were embedded in paraffin and 5 pm sections were cut and placed
onto slides. Sections were then scraped off slides using a clean scalpel blade, and
RNA was extracted using the method given in Materials & Methods section 2.4.2.
However all RNA extracted in this way was degraded, as demonstrated by a failure to
amplify the p-actin gene by PCR following reverse transcription in any samples tested
(data not shown). This failure was most likely due to a delay in processing from
formalin to paraffin (Ben-Ezra el a/., 1991; O'Leary el al., 1994). While a number of
kits are available for optimised extraction of RNA in this way, time constraints did



































































Figure 5.8 The M4Inl mutation does not affect in vitro transcription of M4 or M3. Levels of both
M4 (a) and M3 (b) transcripts following in vitro infection of BHK-21 cells with M4Inl were comparable
to levels in cells infected with M4InlRev at all time points studied (up to 24 hours post-infection).
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therefore not possible to determine if M3 or M4 transcription was altered in the lungs
of M4In 1-infected IFNyR" ~ or 129 mice.
As spleen samples had been preserved in RNAlater, extraction of RNA presented no
problems. Figure 5.9 shows levels of M3 and M4 transcripts in the spleens of IFNyR""
and 129 mice infected with either M41nl or M4Inl Rev. At no time point studied was
a significant difference observed in transcript levels between M4Inl and M4InIRev in
either IFNyR" " or 129 mice.
As the RNA extraction from the lung was unsuccessful it is not possible to
conclusively prove that M3 or M4 transcription is not in some way altered following
infection with M4Inl. Given the lack of an alteration in viral load in the spleen it
appears unlikely the mutation is affecting M4.
5.3.8 M4ln1 Infection Results in Attenuated Pathology in the Lungs of
Both IFNyR7 and Wild-Type 129 Mice
IFNyR"" and 129 mice were infected at 6 weeks of age with 4 x 105 p.f.u. of either
M4Inl or M4Inl Rev. At 13 days post-infection lungs were removed and inflated with
10% neutral buffered formalin. Lungs were embedded in paraffin and 5 pm sections
were cut placed on slides and stained with H & E
At the same time slides previously analysed were obtained for comparison with our
more recent work. The original slides were made from the lungs taken from 3-4
month old mice infected intranasally with 4 x 105 p.f.u. of either M4Inl, M4InlRev or
PHA4. and sacrificed at d 12. Lungs were inflated with formalin and embedded in
paraffin prior to sections being cut and stained with H & E.
Sections were assessed for both the type of pathology present and also scored blind
for severity of pathology. Sections were scored on a scale of 0-4, with 0 indicating no
pathology. 1 for mild pathology, 2 for moderate. 3 for severe and 4 lor extremely-
severe pathology.
In the initial investigation into the pathogenesis of M4InI in vivo, the report suggested
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Figure 5.9 The M4Inl mutation does not affect in vivo transcription of M4 or M3. Levels of both
M4 (a) and M3 (b) transcripts following in vivo infection of IFNyR~/_ or 129 mice with M4Inl were
comparable to levels in IFNyR~/_ or 129 mice infected with M4InlRev at all time points studied (up to 17
days post-infection).
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infected mice. Our subsequent reanalvsis of the slides indicates this may not be the
case.
Figures 5.10 and 5.11 show representative areas of M4Inl-, M4InlRev-, and PHA4-
mfected mice from the original experiment. In IFNyR ~ mice (figure 5.10) infected at
3-4 months old with M4Inl one of the two samples exhibits almost no pathology,
while the other exhibits unusual pathology not found in any other sample -
inflammation is found around the airways and the vasculature, and is predominantly
non-supperative and PMN inflammation. Owing to the sample size of 2 it is difficult
to draw conclusions from this.
In the case of control-infected 3-4 month old mice (2 infected with M4InlRev; 2 with
PHA4) the results are much more consistent. Moderate to extremely severe reactions
are observed in the four mice, with 3 out of 4 rated severe or extremely severe. The
airways for all four mice showr peribronchiolar non-supperative inflammation, and all
mice show non-supperative lymphocyte-dominated vasculitis.
Our later study involving infection of 6 week old IFNyR mice showed similar
results, albeit with younger mice showing greater pathology compared to the
corresponding 3-4 month old samples. The 4 mice infected with M41nl aged 6 weeks
all show the peribronchial non-supperative inflammation and vasculitis observed in
many other samples. However this group showed extensive fibrosis in the
interstitium. a characteristic not obv ious in the corresponding older mice.
In the case of the 6 week old M4InlRev mice the pathology observ ed was similar to
that in the M4Inl-infected mice, but all samples were scored as having extremely
severe pathology. This indicates again that the M4Inl virus has an attenuated
phenolype in vivo.
Surprisingly, the wild type 129 mice recapitulated the phenotype of the M4Inl virus,
a result that had not been detected previously (shown in figure 5.11).
In the case of mice infected aged 3-4 months, all samples showed evidence of
peribronchiolar non-supperativ e inflammation and vasculitis. Again, the M4Inl-
infected mice showed ev idence of a reduction in pathology compared to M4InlRev-
or PHA4-infected mice, but this is a relatively small difference, and the small sample
size does not easily allow for conclusions to be made.
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Figure 5.10 M4Inl shows attenuated pathology following intranasal infection of IFNyR"7" mice.
At 12 or 13 days post-infection lungs were removed from mice infected with either M4Inl, M4InlRev
or PHA4 and fixed with formalin. Samples were embedded in paraffin wax, and 5 pm sections were
cut and stained with H&E. In both mice 6 weeks old (a) or 3-4 months old (c, e) at time of infection
the M4Inl virus shows reduced pathology compared to 6 week old mice infected with M4InlRev (b)
or 3-4 month old mice infected with M4InlRev (d) or PHA4 (f).
Four mice were available per virus for the 6 week old mice, with consistent results within the sample
groups - the M4InlRev-infected mice showed extensive fibrosis and areas of consolidation (marked
C) within the interstitium. Non supperative inflammation was observed around the bronchioles
(marked B) and the vasculature (marked V).
Two mice were available per virus (M4Inl, M4InlRev or PHA4) for the 3-4 month old mice. Results
were consistent for the control-infected viruses, with extensive non supperative vasculitis and
peribronchiolar inflammation. Results were inconsistent for M4Inl-infected mice, with one showing
very little inflammation (e) and one showing a reaction not observed in any other sample, with thick
perivascular cuffs of non supperative and mixed PMN inflammation (c).
(f)
I
Figure 5.11 M4Inl shows attenuated pathology following intranasal infection of wild-type 129
mice. At 12 or 13 days post-infection lungs were removed from mice infected with either M4Inl,
M4InlRev or PHA4 and fixed with formalin. Samples were embedded in paraffin wax, and 5 pm
sections were cut and stained with H&E. In both mice 6 weeks old (a) or 3-4 months old (c) at time of
infection the M4Inl virus shows reduced pathology compared to 6 week old mice infected with
M4InlRev (b) or 3-4 month old mice infected with M4InlRev (d) or PHA4 (e).
Two mice were available per virus for the 6 week old mice, with consistent results within the sample
groups - the M4InlRev-infected mice showed fibrosis and consolidation on a reduced level to that
observed for IFN yR-/- mice infected with the same virus. M4Inl-infected mice showed focal small
areas of inflammation, with very little pathology overall.
Two mice were available per virus (M4Inl, M4InlRev or PHA4) for the 3-4 month old mice.
M4InlRev- and PHA4-infected mice showed similar results (d,e), with moderate non supperative
inflammation around the bronchioles and vasculature. M4Inl-infected mice showed the same type of






In the case of the mice infected at 6 weeks, sections from only 2 mice per virus were
available. All mice showed mild penobronchiolar non-supperative inflammation and
vasculitis, although as before the M4Inl -infected mice appeared to have less severe
pathology . Again, owing to the small sample size it is difficult to draw conclusions
from these results.
Figure 5.12 shows the scores for both the IFNyR ~ andl29 mice infected with M4Inl,
M4InlRev or PHA4. In the case of the IFNyR mice large variation was observed
within all sample groups The 3-4 month old mice appear to exhibit a reduction in
pathology compared to the 6-week old mice, possibly because the increased age at
time of infection gives more time for development of the remaining aspects of the
immune system. It appears that in the case of both the 3-4 month and the 6-week old
mice the M4InlRev and PHA4 viruses exhibit a greater level of pathology . There is
no statistical difference between the M4Inl virus and the control viruses: however the
small sample sizes make any analysis extremely difficult.
For wild type 129 mice infected with M4Inl, M4InlRev or PHA4, the results are
similar - again, the M4InlRev- and PHA4-infected mice show on average higher
levels of pathology compared to the M4In 1-infected mice However, again the very
small sample groups make any statistical analysis difficult, and while this evidence is
suggestive of attenuation of the M4Inl virus in the lung, it is not conclusive.
5.3.9 Investigation of Novel Transcripts in the Region of the M4ln1
Mutation
Following infection of BHK-21 and OMK cells with MHV-68, Dutia et al. (2004)
identified a number of novel transcripts that are detectable with a probe spanning part
of the left end of the genome (nt 106-1517). These include 4.3 kb and 3.2 kb
transcripts present in low abundance in the mRNA fraction. Introduction of mutations
into the left hand end of the genome in the region of the vtRNAs and Ml can result in
the disruption of these transcripts and the presence of alternative sized RNA
molecules, potentially as a result of aberrant processing.
To determine if these transcripts are disrupted by the mutation in the M4Inl virus

























Figure 5.12 The M4Inl virus causes attenuated pathology in the lungs following infection of both
IFNyR-/- and 129 mice. Mice aged 3-4 months or 6 weeks old were infected intransally with either
M4Inl, M4InlRev or PHA4 (samples labelled "control" consist of 2 M4InlRev- and 2 PHA4-infected
mice). At 12-13 days post-infection lungs were removed and sections prepared that were stained with
H&E. Sections were then scored blind for the severity of pathology. For both IFNyR-/- (a) and 129 (b)
mice the M4Inl virus showed attenuated pathology in both mature and juvenile mice.
Chapter Five Results
MHV-68 (g2.4) or PHA4. Uninfected control cells were set up in parallel. OMK cells
were used because these appear to produce higher levels of the unidentified transcripts
(B Dutia, personal communication). Cells were incubated overnight before the RNA
was harvested and prepared for Northern blotting according to the method given in
chapter 2 section 4.5. The blot was probed using pEH1.4 (Dutia el al., 1999),
corresponding to genome co-ordinates 106-1517. Despite washing the blot under
increasingly stringent conditions it was impossible to remove large amounts of non¬
specific hybridisation and therefore the unique transcripts could not be detected. It
was not possible to determine if these transcripts had been altered by the presence of
the M4Inl mutation.
5.4 Discussion
Previous studies on the pathological features of MHV-68 controlled by the left end
have focussed on the clearly defined open reading frames. We have shown that
mutation in a presumed non-coding region can alter the pathogenesis of MHV-68.
This region does not appear to control transcription levels of neighbouring genes and
yet is capable of substantially altering pathology in the lung. The phenotype observed
does not correspond to any phenotype previously observed in any of the other unique
genes of MHV-68. It is possible that the mutation has disrupted one of the more
recently identified transcripts in this region but our studies were unable to determine
if this is the case.
The role of the region at genomic co-ordinate 8409 seems to primarily affect
pathology in the lung at around 12-13 days post-infection. The M4Inl mutation
results in attenuation of pathology at this time point, although this difference is less
apparent by d20 and no difference is observed by d40 (previous unpublished study by
B. Gangadharan following infection of 3-4 month old mice with M4Inl, M4InlRev or
PHA4, data not shown). This suggests the role for the region around co-ordinate 8409
is limited to the acute phase of the infection.
Following infection of 3-4 month old mice, increased viral titres are detected in
M4Inl-infected 129 mice at d3. By d5, no significant difference is detectable between
M4Inl- and control-infected 129 mice. However, M4Inl is cleared by d9, while wild-
type controls are not completely cleared until d!2. While not shown in this
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experiment to be statistically significantly different, this phenotvpe would appear to
be reiterated in IFNyR" mice. This suggests that M4Inl may have initial replication
advantage, which is followed by more rapid clearance from the lung.
Similar results have been obtained previously following infection of BALB/c mice
aged 4-5 weeks (B. Dutia, unpublished data). Intranasal infection with M4Inl
produces higher viral titres at dl compared to infection with M41nlRev, indicating an
initial replication advantage. Unlike in the 129 mice, there are no obvious differences
in viral titres by d3, and both M4Inl and M4InlRev are cleared by dlO. This could be
due to a difference in the host response as a result of strain differences, however as
this experiment has not been repeated it is difficult to draw conclusions on this
apparent difference.
The pathology observed in the lungs of M4Inl-infected mice aged 3-4 months is less
severe than that observed in the control-infected mice at d 12 in both IFNyR" " and 129
mice. However, differences between 129 mice infected with M4Inl or a control virus
are small, and repetition of this experiment using a larger sample group is necessary
to determine ifM4Inl is attenuated in the lungs of these mice.
The repetition of this experiment using juvenile mice produced results that are
difficult to interpret. The high viral titres in M4Inl Rev-infected IFNyR" " mice at d9 is
most likely due to the use of extremely sick mice at this time point rather than a true
difference between M4Inl and M4InlRev. The lack of clearance of M4Inl from the
lungs of IFNyR"" mice at dl3 is again most likely a feature of the onset of severe
disease rather than a true difference between M4Inl and M4InlRev. However, it is
worth noting that the onset of disease in M4Inl-infected IFNyR" " mice was delayed
compared to M4InlRev-infected mice, which would indicate that M4Inl is attenuated
compared to wild-type virus. M4Inl-infected IFNyR"*" mice show onset of severe
illness later than M4Inl Rev-infected mice, and fewer M4Inl-infected mice die, again
indicating that M41nl is attenuated in vivo.
As before, the limited sample sizes for 129 mice infected at 6 weeks old does not
allow for any firm conclusions to be drawn. While our initial results suggest that
M4Inl is also attenuated in the lungs of these mice further studies are required to
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demonstrate that the phenotype observed in the IFNyR" " mice is also present in wild-
type 129 mice.
The attenuated lung pathology at dl3 coupled with earlier viral clearance from the
lung in M4Inl-infected mice would suggest the mutation could have altered an
immune evasion/modulation gene. Owing to the proximity of the mutation to the
known immune evasion gene M3, this gene would appear a likely candidate for
potential upregulation. All previous studies investigating the role of M3 in the lung
have determined that disruption of the gene does not affect viral replication (van
Berkel et al., 2002; Bridgeman et al., 2001); however these studies have not
investigated if lung pathology is altered. Therefore there is a possibility that alteration
in M3 transcription may result in a change in lung pathology without affecting viral
replicatioa Our results in the spleen do not support the suggestion that the M4Inl
mutation is altering M3 transcription in any way; however we were unable to
ascertain if this was the case in the lung. This leaves an alteration in M3 transcription
in the lung a possible explanation for the M4Inl phenotype. There is evidence that
viral transcription in the lung is regulated differently to transcription in the spleen at
late time points post-infection (Roy et al., 2000; Wakeling et al., 2001). It is therefore
possible that the M4Inl mutation is able to affect transcription in the lung at earlier
time points without affecting it in the spleen, and we were not able to investigate viral
transcription in the lung.
Another explanation for the altered lung pathology seen on infection of M4Inl relates
to the existence of as-yet uncharacterised transcripts in the region of this mutation.
There are two transcripts identified in vitro by Dutia et al. (2004) of 4.3 kb and 3.2 kb
that span this region and are present in the mRNA fractioa Our attempts to isolate
these transcripts from OMK cells infected with M4Inl or control viruses were
unsuccessful; however it would be interesting to determine if either of the transcripts
were disrupted by the presence of the M4Inl mutation. Results suggest that the
mutation disrupts an immunomodulatory function of the virus, based on the alteration
of lung pathology and the lack of any affect on viral replication. If either or both of
these transcripts are shown to be disrupted or altered in the M4Inl virus, this would
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suggest a potential function for them. However at present this is speculative as
disruption to the transcripts has not been demonstrated in the M4Inl virus.
M4Inl is able to traffic normally to the spleen and establishes infection at equivalent
levels to wild-type MHV-68. The latest time point studied was 40 days post-infection,
and at this later time point the M4Inl mutation had no effect on viral load. Previous
studies have not indicated that this mutation affects reactivation in the spleen in any
way (B. Dutia, unpublished data), and spleen sections from dl3-d40 show no
differences in IFNyR " and 129 mice infected with M4Inl, M4InlRev or PHA4 (B.
Gangadharan, unpublished data). It would therefore appear that the effects of the
M4Inl mutation are limited to the acute infection of the lung.
Several naturally occurring deletion mutants of MHV-68 have been isolated,
including MHV-72. This virus lacks genes Ml, M2 and M3, and also the tRNA-like
molecules. The development of tumours at late time points post-infection in mice
infected with this virus may be attributed to the presence of a 2.5 kb region present in
MHV-72 but absent in MHV-76 (Oda et al, 2005). This 2.5 kb region includes the
M4 gene and the upstream region including the area of the M4Inl mutation.
A study where the M4 gene was inserted into the left-hand end of the MHV-76
genome did not investigate the long-term effects of the addition M4 to the MHV-76
genome (Townsley el al., 2004). Therefore it is not possible to determine at this point
whether the tumorigenic phenotype observed following infection with MHV-72 is
attributable to either M4 or the upstream sequences. Our studies using the M4Inl
virus did not investigate tumorigenesis at late time points, although this may also have
provided some insight into the role of the M3-M4 intergenic region in the
development of tumours following viral infection.
In conclusion we have identified a region of the MHV-68 genome that contributes to
pathology in the lung at early time points. This region may contain as yet
uncharacterised transcripts that are altered by the mutation carried by the M4Inl
virus. Further studies are required to determine if this is the case, or if the mutation in






Developing a greater understanding of MHV-68 pathogenesis allows insights into the
mechanisms used by other clinically important herpesviruses. In particular, MHV-68
persistence in the lung may be relevant to at least one human syndrome. Idiopathic
pulmonary fibrosis (IPF) is characterised by progressive fibrosis in the lung in
association with varying degrees of inflammation (Katzenstein et al., 1998). A
number of different drug regimes have been investigated as potential treatment for
this syndrome, but at present there is no conclusive evidence that any of these
methods are effective, and many of these treatments are associated with significant
side effects. At present lung transplantation is the only therapy shown to increase
long-term survival in IPF patients; however the availability of such transplants limits
the number of patients that can receive this treatment (reviewed by Walter el al.,
2006).
The underlying cause of IPF is unknown. However several studies have demonstrated
the presence of herpesvirus DNA in the lungs of a significant percentage of IPF
patients (Stewart el al., 1999b), with up to 97% of patients identified as having one or
more herpesviruses in the lung in one study (Tang et al., 2003). Most commonly
associated with IPF are CMV, EBV, HHV-7 and HHV-8. Interestingly, a syndrome
extremely similar to IPF can be reproduced in mouse lungs following infection with
MHV-68 This syndrome is seen following infection of mice treated with bleomycin
(Lok el al., 2002), or following infection of IFNyR"" mice (Mora et al., 2005), but in
not following infection of untreated or immunocompetent mice. This indicates that
herpesvirus infection alone is not sufficient to drive the IPF-like syndrome observed
following MHV-68 infection, but in association with injury to the lung tissue or
immunosuppression lung fibrosis can develop.
As a potential factor in the development of TPF, investigation of herpesvirus infection
of the lung is increasingly important. The murine IFNyR"7" model shows that MHV-68
infection can produce a syndrome with striking similarities to human IPF. Therefore
study of MHV-68 in the lung may allow7 further understanding of disease onset and
progression, particularly in the early stages of the disease where clinical symptoms
may not yet be apparent. Our study has identified a number of viral factors that affect
herpesvirus persistence in the lung, and may provide potentially targets for treatment
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in the future. The viral thymidine kinase gene is common to all herpesviruses, and in
the MHV-68 model the loss of this gene significantly reduces long-term viral load.
The MHV-68 ORF73 gene has a similar effect on levels of viral persistence at late
time points, and has a homologue in KSHV, a possible causative agent of TPF.
Our study also shows that reactivation from latency may be important for
maintenance of viral load during long-term lung infection. Experiments involving the
Mil - and ORF72-deficient viruses need to be repeated with larger sample groups to
improve statistical analysis. Reactivation from latency is enhanced in mice deficient
in the type II interferon response (Steed et al., 2006), and therefore may be an
important factor in the development of the IPF-like disease in IFNyR"" mice.
Despite the increasing evidence that the presence of a herpesvirus in the lung is
associated with IPF, there does not appear to be any investigation into the effect of
anti-viral treatment on TPF progression. This would be an interesting experiment to
carry out in the IFNyR"" mouse model of lung fibrosis, to determine if disease
outcome is affected by this treatment. IFNv-lb has been investigated as a treatment
for IPF, as the downregulation of TGF-p by type II interferon may prevent TGF-P-
driven fibroblast proliferation and collagen synthesis. While this treatment has shown
some promise in clinical trials, the effects appear to be limited to indiv iduals in the
early stages of disease, and the small sample sizes available for trials do not allow
easy analysis of the effectiveness of treatment. This is an experiment that could easily
be repeated in the mouse model to overcome the problem of small sample sizes.
While HCMV has been suggested as a causative agent of IPF, this has not been
investigated in the murine CMV model. As with the gamma-2-herpesvirus MHV-68,
the lungs have been shown to be a major reservoir of MCMV (Balthesen et al., 1993;
Kurz et al., 1997), but whether this virus is able to induce fibrosis in the lungs of
IFNyR"" mice is unknown. This experiment might provide further clues as to the
potential involvement of CMV in development of IPF.
As well as identification of viral genes common to a number of herpesviruses that
play a role during infection of the lung, we have also identified a factor in the unique
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region of the MHV-68 genome involved in acute infection of the lung. The
introduction of a mutation at genome co-ordinate 8409 in an apparently non-coding
region of the genome surprisingly alters the viral phenotype in the lung around dl 3
post-infection. Introduction of 19 bp containing 3 in-frame stop codons in this region
results in less severe pathology in the lungs of mice infected with this mutant virus,
and reduced mortality in juvenile mice compared to infection with wild-type virus.
Initial investigations ofneighbouring genes revealed no deficit in transcription in vitro
or in vivo in the spleen. However the observed phenoty pe was in the lung and we
were unable to determine if either M3 or M4 transcription were affected by the M4Inl
mutation in this organ. As mentioned previously, there are several examples of MHV-
68 genes that are regulated differently in the lung and the spleen.
The identification of two previously unidentified transcripts by Dutia el al. (2004) in
the region of the mutation provides a possible explanation for the attenuated
phenotype observed in the lungs of M4Inl-infected mice. The position of these
transcripts would suggest the possibility of overlapping genes, a feature observed in
the genomes of other members of the herpesvirus family (e.g. HSV-1 yi34.5 and
ORFs P and O) (Roizman & Pellet, 2001). While we were unable to demonstrate the
presence of the transcripts, or their disruption as a result of the mutation in the M4Inl
virus, this is still a possible explanation for the observed phenotype. Repetition of
experiments to investigate the presence of these transcripts following in vitro
infection with M4In1 should resolve this question. In the event that one or both of the
transcripts are altered in the M4Inl virus, the next stage of investigation would
involve more exact characterisation of these transcripts.
An alternative possibility is that the introduction of the mutation at 8409 bp is
affecting the activity of genes outside the immediate region. At present there are no
examples in the MHV-68 genome of promoter or enhancer regions acting at a
significant distance to the target gene; however that does not mean this is not possible.
Use of real-time PCR has allowed investigation of the neighbouring M3 and M4
genes, and the same technique could be applied to determine if the M4Inl mutation is
affecting transcription of other MHV-68 genes. As the M4Tnl phenotype is most
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obvious in the lung, investigation of transcription in this organ would be more likely
to highlight any differences between the M4Inl and wild-type viruses. Genes with a
potential role in the lung include Ml (see chapter 4), M4 (Evans et al., 2006;
Townsley et al., 2004) and K3 (Stevenson et al., 2002). Given that the M4Inl
phenotype appears to affect lung pathology without significant changes in viral
replication, a gene or genes involved in modulation of the host immune response
would appear most likely to produce the altered phenoty pe.
As well as apparently untranscribed regions involved in viral pathology, the left end
of the MHV-68 genome also contains a number of defined ORFs whose function has
not yet been fully defined. Of the four ORFs in this region the Ml gene is the least
investigated, and elucidation of its role during infection may provide further insights
into viral pathogenesis.
Despite early indications that the Ml gene was a homologue of the poxvirus serpin
SPT-1, a gene with known anti-apoplotic properties, the functional regions of the
serpin are absent in Ml (Virgin et al., 1997; Bowden et al., 1997). While the anti-
apoptotic properties of Ml have not been investigated, it appears that despite a
possible common origin to SPI-1, Ml has evolved an alternative function, or at least a
function independent of the hinge domain and reactive site loop of the serpin gene.
Initial results indicate an important role for Ml during acute infection of the lung. In
the absence of the Ml gene, viral litres are significantly elevated at al! time points
studied, and the virus is cleared more slowly. While a number of genes have been
identified whose absence decreases viral replication during acute infection (including
ORF54 [Song et al., 2005], ORF21 [Coleman et al., 2003] and ORF27 [May et al.,
2005a]), no other MHV-68 gene has been identified whose absence results in
increased viral replication. This suggests a novel function for Ml in control of viral
replication in the lung, acting to prevent excess replication in this organ. Reduction or
inhibition of replication may result in fewer targets for the immune response and
hence aid viral persistence and possible spread to other organs. Studies are ongoing in




Ml also appears to play a substantial role in the spleen. Loss of the gene results in a
severe splenomegaly deficit in association with a failure to increase the number of
splenocytes. During acute phase latency viral load is reduced, and yet ex vivo
reactivation from latency is elevated. A reduction in viral load in the spleen during
acute phase latency is a observed following disruption of the M4 gene (Evans et al.,
2006; Geere et al., 2006), indicating that control of viral load in the spleen is
attributable to more than one viral factor. The secreted glycoprotein M4 shares
structural properties with the Ml protein, indicating a possible link between the
properties of these two genes (Alexander et al., 2002). However, the enhanced
reactivation from latency has only been demonstrated in Ml-deficient viruses
(Clambey et al., 2000), demonstrating that Ml and M4 are not functionally redundant.
Our preliminary results confirm the findings by Clambey et al., and indicate that the
normal role of Ml in the spleen involves reduction or inhibition of reactivation.
Whether this occurs by controlling the host cell environment to maintain the virus in a
quiescent state, or by inhibiting viral factors that drive reactivation remains to be
investigated. Ongoing studies in our laboratory to determine the crystal structure of
Ml may provide further information as to the potential binding sites of this protein
and hence determine its interactions with other proteins.
The inability of the Ml A virus to drive splenomegaly may indicate a role for this gene
in driving host cell proliferation. A number of viral genes are known homologues of
host cell cycle proteins (e.g. v-cyclin) but no homology to host cell cycle proteins has
been demonstrated for Ml. This would suggest Ml may drive cell cycle progression
by an as-yel undiscovered mechanism, or that Ml is able to activate other viral factors
that are able to drive splenomegaly. Again, further studies into the structure of Ml
may provide insight into Ml interactions w ith other proteins.
Previous structural and sequence analysis have demonstrated similarities between the
Ml and M3 genes of MHV-68 (van Berkel et al., 1999; Alexander et al., 2002). The
secreted M3 protein is a broad spectrum chemokine binding protein, and is able to
disrupt in vitro chemotaxis of lymphocytes (Jensen et al., 2003). However, despite
apparent similarities between the two genes, M3 has no obvious role during acute
infection in the lung, or in establishment of or reactivation from latency, properties
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that are key features of the Ml gene. Ml also lacks residues important in mediating
M3 interaction with chemokines, indicating that this aspect of the M3 protein is not
also possessed by Ml. Therefore it appears unlikely that Ml and M3 are in an)' way
functionally redundant.
It is therefore clear that further studies are required to investigate the different areas of
MHV-68 pathogenesis investigated in this thesis. While a number of genes involved
in long term persistence in the lung have been identified, repetition of these
experiments are necessary to confirm results. The left end of the MHV-68 genome is
important in viral pathogenesis, but contains a number of regions whose function
remains to be defined. These include both defined ORFs and apparently non-coding
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